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2Abstract
Trials for comparing I treatments with a control are considered, where the aim is to identify
one treatment (if at least one exists) which is better than control. Tests are developed
which use all of the data simultaneously, rather than combining separate tests of a single
arm versus control.
The null hypothesis H0 : ∆i ≤ 0 is tested against H1 : ∆i > 0 for at least one i, where
∆i represents the scaled difference in response between treatment i and the control, i =
1, . . . , I, and, if rejected, the best treatment is selected. A likelihood ratio test (LRT)
is developed using order restricted inference, a family of tests is defined and it is shown
that the LRT and Dunnett-type tests are members of this family. Tests are compared by
simulation, both under normality and for binary data, an exact test being developed for
the latter case.
The LRT compares favourably with other tests in terms of power and a simple loss function.
Proportions of subjects on the control close to (
√
I−1)/(I−1) are found to maximise the
power and minimise the expected loss.
Two-stage adaptive designs for comparing two experimental arms with a control are de-
veloped, in which the trial is stopped early if the difference between the best treatment
and the control is less than C1; otherwise, it continues, with one arm if one experimental
treatment is better than the other by at least C2, or with both arms otherwise. Values
of the constants C1 and C2 are compared and the adaptive design is found to be more
powerful than the fixed design.
The new tests can make a contribution to improving the analysis of multi-arm clinical
trials and further research in their application is recommended.
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Chapter 1
Introduction
1.1 Background
A clinical trial is a randomized experiment on humans for the assessment of one or more
treatment regimes for a disease or condition. Clinical trials are widely used in the develop-
ment of drugs before licensing and for the assessment of licensed drugs or other treatments
when one treatment is to be selected for use.
The entire process of a drug’s development goes through several stages. After it has
been studied on animals and cell cultures in pre-clinical investigations, a drug undergoes
toxicological, pharmacological and safe dose selection and then testing for efficacy and
confirmation of efficacy. Clinical trials in drug development are usually classified as phase
I, phase II or phase III, depending on whether the primary aim is the assessment of
toxicity, finding efficacy and the most effective dose, or comparison with the best standard
treatment. Phase IV is a post-marketing, rather than an experimental phase, and is used to
check for long-term safety issues. However, in practice these divisions may become blurred.
For example, when phase II studies are randomized, patient entry can be continued on a
control and at least one experimental arm, which leads to a phase II/III study.
In so-called pragmatic trials, one or more potentially improved interventions, perhaps of
quite different types, might be tested against current practice, in order to decide whether
this practice should be changed. The treatments might be drugs which are already on the
market, other types of medical procedure, or even such things as educational interventions.
In this project our main concern is phase III or II/III trials, or pragmatic trials, with
efficacy as a primary response. A treatment has to be selected and evidence is needed to
16
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show that it is indeed effective by comparing it to a control treatment in a randomized
trial.
Clinical trials have been in extensive use for the last four or five decades and statistical
methods are used for all types of trials. Different methods and designs have been developed
based on the specific demands of different types of trial. New methodological developments
in statistical inference are constantly needed to meet the demands of new types of trial.
Historically, most clinical trials have involved comparing two arms. Therefore widely
developed methods are available for such comparisons. Increasingly, the number of arms
is being extended to three or more. However this has been less common than comparing
two treatment arms and consequently the methodology is much less developed.
In this thesis, we develop and evaluate methodologies for situations in which more than
one experimental treatment is compared with a common control and the objectives of the
trial are to establish efficacy of at least one experimental treatment and to select the best
treatment. We demonstrate the importance of correctly defining the null hypothesis to
meet these objectives and develop appropriate testing procedures. We provide a set of
tools for selecting the best treatment where several treatments with a common control are
compared, including large sample tests, small sample tests for binary responses, methods
for finding suitable sample sizes and allocations and an introduction to sequential adaptive
designs.
In the rest of this chapter we briefly discuss some of the background to the work in this
thesis. In section 1.2 we describe the methodology which is available in trials with two
arms and more than two arms in which the objective is to test for superiority of one or
more treatments over a control. Examples of multi-arm trials, which will be used later in
the thesis, are introduced. Some of the methodology of hypothesis testing which we will
use is described in section 1.3. Design issues in clinical trials which will be used later in
the thesis are mentioned in section 1.4, before the aims of the thesis are clarified in section
1.5.
1.2 Clinical trials
1.2.1 Trials with two arms
Two-arm trials for testing superiority have been in use for many years, especially in phase
III, and widely developed statistical methods are available. Another possible objective of a
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two-arm trial is to demonstrate the equivalence of two arms, but this will not be discussed
further in this thesis. In a two arm trial for superiority an experimental arm is typically
compared with a standard (or placebo) control arm. In comparing two treatments there is
a single comparison between treatments and hypothesis testing is simple and unambiguous.
If ∆ is a difference between treatments, a simple null hypothesis of the form H0 : ∆ = 0
might be tested against the two-sided alternative H1 : ∆ 6= 0.
Often, interest centres on whether or not the experimental treatment is better than the
control, with no practical importance attaching to whether it is worse or simply no better.
Then the simple null hypothesis H0 : ∆ = 0 or a composite null hypothesis of the form
H0 : ∆ ≤ 0 against the alternative H1 : ∆ > 0, lead to identical uniformly most powerful
tests for Normally distributed data, and identical approximate tests more generally, e.g.
chi-squared test, Z-test or t-test depending on the nature of the response. Because the
tests are equivalent, there is little or no discussion of which null hypothesis should be
used in clinical trials when the alternative hypothesis is one-sided. The only errors in
two-arm trials are of type I or type II. Standard methods are available in any statistical
text book. Other types of trial are intended to show equivalence, or non-inferiority, of a
new treatment, compared with a standard control.
1.2.2 Trials with three or more arms
Multi-arm trials are used for several different purposes. For example, in dose-finding
studies, several doses could be used to find the maximum tolerable dose. Alternatively,
interest could be in comparing the high dose with the medium dose and the medium dose
with the low dose. Three arm trials for assessing non-inferiority of a new treatment can
include an active control, usually the standard treatment, and a placebo along with an
experimental arm in the so-called gold-standard design (Pigeot et al., 2007; Kieser and
Friede, 2007). Non-inferiority trials to compare two new treatments with a control could
also be run. The null hypothesis in this case might be that both new treatments are
inferior to the control and the alternative is that at least one of the new treatments is
not inferior to the control, where inferior is taken to mean a difference less than some
pre-specified amount. These hypotheses are quite similar to those we will discuss in this
thesis and this will be addressed briefly in Chapter 2, although this is not the main aim
here. An equivalence trial would be similar, but two-sided, so will not be discussed further
in this thesis.
Trials with more than two arms can have a number of possible treatment structures.
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However, the treatment structure alone does not imply which comparisons should be
tested. For example, in a three arm trial, the following treatment structures can arise for
drugs A and B:
1. A, B and A+B;
2. A, B and standard (or placebo);
3. high dose of A, medium dose of A and low dose of A.
In different trials, different questions will arise, e.g. in 1 it might be desired to test for
superiority of the combination against each of the mono-therapies.
Here we consider trials in which it is desired to test two or more experimental treatments
against a control and, if efficacy is established for at least one, to select the best one.
Instead of running several separate small trials it is more efficient, in terms of time and
costs, to run one big trial with a common control and two or more experimental arms.
Any of the different structures listed above can lead to an interest in comparing two
experimental arms with a common control. All that is required is that two of the arms
are experimental and one is a standard treatment or placebo, which is to be used as a
control. For 1 and 3, any of the arms can be the control group, depending on the practical
application.
Examples of Three arm trials
We introduce three trials which will be referred to later in the thesis. These all involve
comparing two experimental treatments with a control, although there is one of each of
the structures listed above.
1. The ATAC trial (The ATAC Trialists’ Group, 2002), compared different adjuvant
treatments for breast cancer, namely tamoxifen, anastrozole and a combination of
anastrozole plus tamoxifen. The aim of the trial was to see whether anastrozole
alone or anastrozole in combination with tamoxifen was better than tamoxifen alone
(the standard treatment at the time). The two drugs work differently but both
affect the estrogen response of the tumour, so there was no a priori reason to expect
the combination treatment to be at least as good as the individual therapies and
it is important to allow the direct comparison of the two mono-therapies. In the
event, the treatments were antagonistic and the combined arm did worse that the
CHAPTER 1. INTRODUCTION 20
anastrozole alone arm. We now know that it is indeed the case that addition of
tamoxifen (which can act as a mild estrogen) reduces the efficacy of anastrozole
(which prevents the production of estrogen from fat). Had the trial tested only
the combination against each of the individual therapies, which is quite typically
of interest in combination drug trials, it would not have shown a significant result
and a class of dugs (aromatase inhibitors) that have considerably improved the
treatment of breast cancer might not have been licensed. This example shows the
importance of testing the appropriate hypothesis for the clinical question of interest
and not automatically assuming that a particular treatment structure should lead
to a particular test.
2. The DASH trial (Appel et al., 1997) compared the effects on blood pressure of
three dietary patterns, namely a control diet representing a typical American diet, a
diet high in fruit and vegetables and a “combination” diet high in fruit, vegetables
and low-fat dairy products. Although the published analysis considered two-sided
tests of all pairwise comparisons, it is not desirable that one might fail to make
a recommendation because the combination diet is no better than the fruit and
vegetable diet, even though the fruit and vegetable diet is better than the control.
From a public health perspective one wants to know whether there is convincing
evidence (a significant result) that a change of diet will be beneficial and, if so, we
make a recommendation as to what change should be made.
3. The MORE trial (Cummings et al., 1999) compared two doses of raloxifene with a
placebo for efficacy in breast cancer prevention in post-menopausal women. The aim
was to establish evidence that raloxifene was efficacious (through a hypothesis test)
and, if it was, to recommend one of the doses. It is not critical whether the high
dose is significantly better than the low dose and it is not necessary to model the
dose-response relationship. In fact, several studies have failed to find a dose-response
relationship. We would certainly not want to fail to reject the null hypothesis if the
low dose was as good as or better than the high dose. In the original trial it was
found that the low dose was better than the control, but the high dose was no better
than the low dose.
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1.3 Hypothesis testing
1.3.1 Fundamental concepts
Hypothesis testing is very widely used in analysing the data from clinical trials and in
other applications. While in many application areas more emphasis is placed on estima-
tion, in clinical trials regulatory requirements and the very large amounts spent on drug
development require an objective methodology for evaluating new treatments and it has
become common practice to require that an experimental treatment shows a statistically
significant improvement over the control in order to be considered efficacious. Although
other approaches, such as Bayesian decision theory, have begun to be influential, they are
still less commonly used in practice. In this thesis, we will assume that a hypothesis test
will be used as the main criterion of efficacy.
The fundamental idea of hypothesis testing is to state the possible values of one or more
parameters θ ∈ Θ, i.e. specify the model, and then define a null hypothesis, usually denoted
H0, which restricts the parameter space to θ ∈ Θ0 ⊂ Θ. The alternative hypothesis,
usually denoted H1, is that the parameters lie within the set given by the model, but
outside those given by the null hypothesis, i.e. θ ∈ Θ \ Θ0. We might have a fully
parametric model or study population parameters without fully specifying the population
distribution. A hypothesis is said to be simple if it completely specifies the parameters of
the model, i.e. Θ0 consists of a single point. Otherwise, it is said to be composite. For
example, as mentioned in the previous section, the model might be that the difference
in response between an experimental and a control treatment is measured by ∆. Then
H0 : ∆ = 0 is a simple null hypothesis, H0 : ∆ ≤ 0 is a composite null hypothesis,
H1 : ∆ = 3.5 is a simple alternative hypothesis (though this is rarely used except for
power calculations) and H1 : ∆ > 0 is a composite alternative hypothesis.
The distinction between simple and composite null hypotheses, with a one-sided alterna-
tive, is important for the work presented here. Although with two arms there is generally
no practical difference, an important point to note for the work described in this thesis is
that, if the null hypothesis is H0 : ∆ = 0 and the alternative is H1 : ∆ > 0, then H0
⋃
H1
defines a model which does not allow the possibility of the experimental treatment being
worse than the control. Although this might sometimes be reasonable, usually it is not
and, many authors use H0 : ∆ = 0 when they really mean H0 : ∆ ≤ 0. Although it makes
no real difference with two arms, the distinction is crucial for the work on multi-arm trials
reported in this thesis, since the natural extensions of these different null hypotheses to
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more than two arms lead to different likelihood ratio test statistics.
It is very common to use hypothesis tests to compare two treatments. A test of H0 : ∆ = 0
against H1 : ∆ 6= 0 is called a two-sided test, whereas a test of H0 : ∆ = 0 or H0 : ∆ ≤ 0
against H1 : ∆ > 0 is called a one-sided test, i.e. the distinction is on the basis of the
alternative hypothesis. In comparing more than two treatments, we will likewise refer to a
two-sided alternative as one defined by two-sided inequalities, while a one-sided alternative
will be defined by one-sided inequalities, i.e. “greater than” or “less than” relationships.
Note that this should not be confused with the number of tails of a reference distribution
the test statistic is compared with, e.g. in analysis of variance, the F test is used for a
two-sided alternative, although we use only one tail of the F distribution.
Let y be the response data, assumed to be a realisation of a random variable Y. A test
is a rule of the form: reject H0 if and only if Y ∈ R, for some set R known as the
rejection region. Rejecting H0 when it is true is known as a type-I error, while failing to
reject H0 when it is false is known as a type-II error. Let γ(θ) be the probability that
H0 is rejected. The size of a test, α, is the maximum probability of a type I error, i.e.
α = maxθ∈Θ0 γ(θ). The power of a test is 1 − β(θ) = γ(θ) for θ ∈ Θ \Θ0. A size α
test is said to be uniformly most powerful (UMP) if it is at least as powerful as any other
size α test for all θ ∈ Θ \Θ0. When no UMP test exists, or is known, different methods
can be used, but a very common procedure is to use a likelihood ratio test. This rejects
H0 for large values of the test statistic λ = log
{
L(
ˆθ;Y)
L(
˜θ;Y)
}
, where θˆ = arg maxθ∈Θ L(θ; Y)
and θ˜ = arg maxθ∈Θ0 L(θ; Y).
For testing a single comparison between two treatments against a one sided alternative,
if normality is assumed, a Z-test is the UMP test (and also the LRT) whether the null
hypothesis is the simple one of equality, or the compound one of inequality. For the two-
sided alternative, there is no UMP test and it is common to use the LRT, which is again
the Z-test. For more than two-arms, to test the null distribution of equality against the
two-sided alternative, no UMP exists and we usually use a global χ2 test, which is the
LRT. For comparing several arms with a control, with a one-sided alternative, again there
is no known UMP. This is related to the fact that different types of differences between
the treatments can lead to H1 being true, e.g. all treatments being better than control, or
only one.
Correctly rejecting H0 when it is false, but for the wrong reason is sometimes known as a
type-III error. This is most commonly used to describe the rejection of a null hypothesis
in favour of a two-sided alternative, when the wrong directional decision is made, e.g. it is
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concluded that treatment 2 is better than treatment 1 when, in fact, the reverse is true.
In practical terms a type-III error is as bad as a type-I error and so the size of the test
should be defined to be the maximum probability of a type-I error or a type-III error.
This corrected size will be discussed in Section 3.5.
1.3.2 Multiple comparison procedures
The most natural statistical approach to comparing more than one experimental arm with
a control would be to compare each experimental arm individually to the control based on
a test of significance (Pocock, 1983, p.229). This introduces the problem of multiple testing
and the standard solution is to adjust the significance level of each test in order to control
the overall significance level, i.e. the probability of rejecting at least one null hypothesis if
they are all true, which is known as controlling the family-wise or experiment-wise type
I error rate in the weak sense. The family-wise error rate is said to be controlled in the
strong sense if the probability of rejecting at least one false null hypothesis is no greater
than the significance level, irrespective of how many null hypotheses are actually true.
Generally, in this thesis, the discussion of family-wise error rates will refer to controlling
them in the weak sense. However, the corrected size used Section 3.5 controls the family-
wise error rate more strongly than in the weak sense, but less strongly than in the strong
sense. The probability of rejecting at least one true null hypothesis may be greater than
the significance level, but the probability of rejecting at least one true null hypothesis and
selecting a treatment which is no better than the control, is no greater than the significance
level. There are several ways in which multiple testing can arise, for example comparing
multiple end points, sequential analysis or others. A recent review of multiple testing is
given by Dmitrienko et al. (2010). Comparing several treatment means is a particular
type of multiple comparison and comparisons of means with a control is a particular type
of this.
By testing more than one such hypothesis, where each test is carried out at level α, the
probability of rejecting at least one null hypothesis when they are all true is greater than α.
Therefore, to control the overall type I error rate, it is important to make an adjustment
for multiple testing, i.e. each test is carried out at a smaller significance level to ensure
that the family-wise error rate is α. The most commonly used correction is the classical
Bonferroni correction. The Bonferroni correction is simple and so is widely used. However
it is too conservative, especially when the test statistics are correlated. In comparing
several treatments with a common control correlations arise, so the Bonferroni correction
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can be extremely conservative. A number of methods have been developed to improve the
Bonferroni correction (Simes, 1986; Hommel, 2001).
Hochberg and Tamhane (1987), Hsu (1996) and Dmitrienko et al. (2010) discuss the
different types of multiple comparisons that can arise from comparing several means, such
as comparing all pairs, comparing each treatment with the best and comparing several
experimental treatments with the control, which is the case we are interested in. The
most widely used method is that of Dunnett (1955), which compares all experimental
treatments to the control. Dunnett’s procedure includes a one-sided method if a larger
treatment effect than control is sought and it is required to find out which new treatments
are better than the control. Originally expressed as simultaneous confidence intervals,
Dunnett’s method is easily used for hypothesis testing. Each treatment is compared to
the control using a one-sided Z-test (or more generally t-test), with the significance level
of each test adjusted by some amount to achieve a familywise error rate of α. Calculation
of the appropriate significance level of each individual test is not a trivial problem and we
will review some of the research in this direction in Chapter 3.
Following Dunnett there have been other developments in this area. Much of it is based
on closed testing procedures for logically related hypotheses, in which decisions to accept
or reject hypotheses must not contradict each other. For example, if the null hypothesis
H0 : µ0 = µ1 = µ2 is rejected, then at least one of the null hypotheses H0 : µ0 = µ1 and
H0 : µ0 = µ2 must be rejected. In the context of multiple comparisons with a control,
step-down and step-up procedures have been defined. In a step-down procedure, e.g.
Holm (1979), the overall null hypothesis is tested first. If it is accepted, then all individual
comparisons with the control are accepted. If the overall null hypothesis is rejected, then
the treatment with the largest observed difference is declared to be different from the
control and then a test is performed comparing all other treatments with the control
and so on. A step-up procedure, e.g. Hochberg (1988), starts by testing the individual
treatment with the smallest observed difference against the control. If it is rejected, then
all treatments are declared to be different from the control, while if it is accepted, it
steps up to the treatment with the next smallest observed difference, and so on. Since
in this thesis, our concern is with the overall null hypothesis, rather than the individual
treatment comparisons, step-down procedures just reduce to Dunnett’s test, or whichever
other test is used for the overall hypothesis. Step-up procedures can lead to new tests, but
our interest is only in whether at least one of the individual null hypotheses is rejected.
There is a lot of discussion and controversy about multiple comparison methods in the
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literature, including several views being expressed that they have no place in the inter-
pretation of data (Mead, 1988). In this thesis, however, we will not actually use multiple
comparisons per se. Rather, we use them indirectly to obtain an overall hypothesis test,
so that the family-wise error rate is exactly the significance level we require and there is
no controversy about this. Note also, however, that this means that we are using these
procedures for a blunter task than they were intended for, so that they might not be the
most appropriate tool. Nevertheless, this approach is by far the most commonly used,
perhaps the only one used, in practice when comparing several treatments with a common
control.
1.3.3 Order restricted inference
In most regression models we make a strong assumption of a linear (or other) regression
function and the parameters are estimated by maximum likelihood or least squares. If no
assumption were made regarding the relationship between the response variable Y and
the explanatory variable X, then at a point X = x, the estimate of E(Y ) will be the mean
of all responses at X = x. The former gives a smooth line, whereas the latter leads to an
unconstrained pattern. Between these two extremes, if the researcher has knowledge that
the true regression function has a particular ordering then this information can be used
to select a regression function. For example in a comparison of three sample means, if it
is known that treatment 1 is bigger than treatment 2, which is bigger than treatment 3,
then we can make an order restriction and assert this. Such a complete specification is
known as a simple order. For I experimental treatments and a control, the general form
is µ0 ≤ µ1 ≤ µ2 ≤ . . . ≤ µI , where µi is the mean from treatment i, i ∈ {1, . . . , I}. Taking
the order restriction into account we can increase the efficiency of analysis by reducing the
expected error, given that the assumed order actually holds.
Any incomplete specification is known as a partial order. For example, if we are comparing
several treatments with a control or standard group and we use the information that all
treatment means are at least as large as the control mean, this is a type of partial order
known as the simple tree order, i.e. µ0 ≤ µi ∀i. Note that the simple tree order µ0 ≥ µi ∀i
is dealt with in an equivalent manner and throughout this thesis, we will assume that a
high response is desirable. There are other complex relations that are partial orders, e.g.
a matrix order such as µ1 ≤ µ2 ≤ µ4 and µ1 ≤ µ3 ≤ µ4, but in this thesis we will use only
the simple tree order. Detailed texts on order restricted inference, covering testing and
estimation for many types of order restriction, are those of Barlow et al. (1972), Robertson
CHAPTER 1. INTRODUCTION 26
et al. (1988) and Silvapulle and Sen (2005).
The set of fitted values which minimise the residual sum of squares, subject to obeying
the specified order, is known as the isotonic regression. Isotonic regression leads to a
wide range of constrained optimization problems, but all the partial orders we discuss in
this thesis can be fitted using the pool adjacent violators algorithm (PAVA) (Robertson
et al., 1988). If the sample means fail to obey the order restriction imposed, we pool
observations which violate the order sequentially until the order restrictions are obeyed.
Isotonic regression is most often used when there is prior knowledge that the treatments
must obey some order restriction. An R (R Development Core Team, 2009) function
isoreg is available to find the isotonic regression estimators for a simple order, with equal
sample sizes in each group, but more general R functions or other software do not seem to
be available and we will not make use of this function.
To illustrate the PAVA algorithm, consider a simple tree order, µi ≥ µ0, i ∈ {1, 2, 3},
where the sample means turn out to be 10, 9, 12, 6 for i = 0, 1, 2, 3 and the sample size in
each group is equal. Groups 1 and 3 both violate the order restriction by having smaller
means than the control and we start by pooling the worst violator (group 3) with the
control. This gives a pooled mean of Y¯03 = 8. Now group 1 no longer violates the order
restriction, so that the group 1 and 2 means do not require any pooling. The isotonic
regression estimates are µˆ0 = 8, µˆ1 = 9, µˆ2 = 12, and µˆ3 = 8.
Robertson et al. (1988) showed that, for any one-parameter exponential family, as well
as for normally distributed data with unknown variance, the isotonic regression estimates
are also the maximum likelihood estimates. Therefore MLEs for the simple order, simple
tree order and many other partial orders can be obtained from the PAVA algorithm for a
wide range of distributional assumptions.
The MLEs can be used to obtain LRT statistics. For example, the null hypothesis of
equality of the means H0 : µ0 = µ1 = µ2 = · · · = µI can be tested under an order restricted
model µi ≥ µ0, ∀i. The LRT for this has been developed and extensively studied (Barlow
et al., 1972; Robertson et al., 1988). Because of the restricted model under H0 having the
parameters on the boundary of the parameter space, it does not satisfy the conditions to be
asymptotically χ2 distributed. In fact, it can be shown to be a mixture of χ2 distributions,
but with unknown mixing probabilities (Robertson et al., 1988). Approximating these
probabilities has been the focus of considerable research. This test is sometimes called the
χ¯2 test.
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In this thesis we will use a simple tree order to define the null hypothesis, but we are
not assuming an order restricted model. This leads to a LRT which has been much less
studied, although the general form was given by Mukerjee et al. (1985) and Robertson
et al. (1988). Again, it does not have a standard distribution and we will approximate its
null distribution using simulations.
1.3.4 Exact conditional test
When the responses are binary, large sample tests based on normal approximations are
used and, asymptotically, have the same properties as the normal theory tests described
above. When the sample sizes are small, however, the approximations are not good enough
and these tests are unreliable. For small samples, exact conditional tests are often used
instead. Fisher’s exact test, for example, compares two treatments to test the null hy-
pothesis of equality against a two-sided alternative. If the control has y0 successes, out
of n0 patients, and treatment 1 has y1 successes out of n1 patients, then we condition on
the total number of successes y0 + y1 and can calculate the probability of r0 successes on
the control, given this total and n0 + n1, for all possible values r0. This is simply the
hypergeometric probability
P (Y0 = r0, Y1 = y0 + y1 − r0|Y0 + Y1 = y0 + y1) =
 n0
r0
 n1
y0 + y1 − r0

 n0 + n1
y0 + y1
 .
Tests can then be carried out by calculating these probabilities for extreme differences
between the success rates on the different treatments. Extensions of Fisher’s exact test
to multiple treatments are also commonly used - see for example Armitage et al. (2002)
for details. Williams (1988) developed a one-sided exact conditional test by assuming an
order restricted model - see also Silvapulle and Sen (2005). However, to the best of our
knowledge, no one-sided test of this type has been developed which does not restrict the
model to having an order restriction.
1.4 Design issues in clinical trials
Most of the work in this thesis addresses issues of hypothesis testing in multi-arm clinical
trials, but we will also discuss some issues in the design of trials which are going to be
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analysed using these tests. Clearly, trials should be designed in order that the analysis is
as informative as possible.
In most clinical trials, the main design questions relate to power - see, for example, Ar-
mitage et al. (2002). These can either be expressed by calculating the power for a particular
sample size, or more commonly by calculating the sample size required to achieve a partic-
ular power. We will use the former to compare the properties of different procedures, but
will also show how to calculate the latter for practical applications. An extra complication
that arises in multi-arm trials, which is straightforward in two-arm trials, at least with
one-sided tests, is that of selection of the best treatment.
The power represents the probability that H0 is correctly rejected when it is false and
is a function of the parameters, but we could correctly reject H0 but then recommend
a suboptimal treatment, or even one which is worse than control, i.e. we could make a
type-III error. Studying power is therefore not enough and some authors (e.g. Horn and
Vollandt (1998)) have previously considered various adjusted powers which take account of
the probability of incorrect selection as well. However, even this seems insufficient, because
we should take account of the impact of incorrect selection, as well as its probability,
through some loss function (or utility function). Although loss functions are widely used
in Bayesian analysis (see, for example, Lee (2004)), they can equally well be used in
evaluating the effect of different testing and estimation methods for frequentist inference,
although this is uncommon.
In two-arm trials, unless costs dictate otherwise, we would usually aim to allocate equal
numbers of patients to the experimental treatment and the control. In comparing several
experimental treatments with a control, it is less obvious that we should allocate equal
numbers to each treatment. The special status of the control might suggest that it should
be given to more patients. However, unless practical limitations dictate otherwise, we
should aim for equal numbers of patients on each experimental arm. Thus, an additional
design question arises in multi-arm trials, namely the proportion of patients to be allocated
to the control. In practice, however, it will sometimes be regarded as administratively, or
ethically, necessary to aim for equal allocation to all arms including the control, so we will
also place considerable emphasis on this case.
Two further questions are whether the trial is to be of a fixed size, or sequentially designed
with a possibility of early stopping, and whether the allocation is fixed at the outset, or
adaptively designed with one or more interim analyses. Sequential design (Whitehead,
1997; Jennison and Turnbull, 2003) has received considerable attention recently, moti-
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vated by the possibility of reducing the cost of clinical trials by stopping early, either
because enough evidence has been accumulated to reject the null hypothesis in favour of
an experimental treatment, or because it becomes clear that there is almost no chance of
the null hypothesis being rejected (futility). As mentioned above, the repeated testing in-
volved in sequential analysis is a type of multiple testing problem and considerable research
efforts are continuing in finding suitable adjustments for repeated testing, as described in
the books by Whitehead (1997) and Jennison and Turnbull (2003).
Adaptive design is much less commonly used in later phase clinical trials, although a
number of methods for adapting the allocation have been suggested in order to expose
fewer subjects to inferior treatments. This is done, for example, by biasing the allocation to
give a higher probability of each patient being allocated to the treatment which currently
seems best, in so-called biased coin designs - see, for example, Pocock (1983), Bauer (1989)
or Atkinson et al. (2007). There seems to be more scope for adaptive design, however,
in multi-arm trials, since dropping treatments after interim analyses is akin to stopping
early for futility in the case of two-arm trials and is really quite different from the adaptive
allocations which have been suggested for two-arm trials. In this thesis we will consider
two-stage adaptive designs for multi-arm trials, where treatments can be dropped at the
interim analysis.
1.5 Aims of the thesis
The setting for this thesis is comparing several experimental treatments against a control
in clinical trials. We assume that a single hypothesis test will be carried out to establish
whether at least one treatment is better than the control. When the null hypothesis is
rejected, the treatment with the best estimated response will be recommended, without
further hypothesis tests. There is no prior assumption that experimental treatments are
no worse than the control, so that an order restriction is defined by our null hypothesis,
but the assumed model does not have any order restriction. The main focus of interest is
three arm trials with a common control, but some general results for testing in multi-arm
trials will be introduced.
The aims of this thesis are to develop and evaluate methods for addressing this problem
based on likelihood ratio tests. We also compare them with other methods and consider
how best they can be applied in clinical trials. Ultimately, the aim is to improve decision
making in clinical trials and to allow them to be run more efficiently.
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In Chapter 2, the notation used throughout this thesis is defined, the models and hypothe-
ses we consider are stated and a likelihood ratio test is defined along with several other
procedures. In Chapter 3, the properties of these test statistics are compared, particularly
with reference to power and expected loss, with the emphasis on three-arm trials. Design
issues in three-arm trials, especially the optimal allocation of patients to treatments, but
also sample size calculations, are discussed in Chapter 4. In Chapter 5, the performance of
the large sample approximations for binary data are assessed and an exact conditional test
for small samples, based on the likelihood ratio test statistic, is developed and its prop-
erties studied. In Chapter 6, a few adaptive sequential designs, based on likelihood ratio
test statistics and single contrasts, are developed and their properties assessed, although
there is much more work to be done in this area. Finally, in Chapter 7, some conclusions
are drawn and some suggestions for further work are made.
Chapter 2
Model and test procedures
Comparing more than two treatments is less common than comparing two treatments and
consequently the statistical methodology is much less well developed. In this chapter, we
look at several tests, some obtained by combining one dimensional tests, some which are
based on likelihood ratio test statistics and others which are based on single contrasts.
As mentioned in Chapter 1, comparing two (or more) treatment regimes with a control can
be considered as a type of multiple testing of the individual comparisons against the control
and several authors have addressed the problem in this light. Many trials have compared
several treatments with a control and, in this case, several authors have suggested using
the famous procedure of Dunnett (1955), or modifications of it (Hsu, 1996). The main
aim of these methods is to deal with the problem of adjusting significance levels of the
individual tests to control the overall type-I error rate. However, the individual tests,
which these methods are intended for, are not directly of interest in the applications we
consider. Our aim is to establish that at least one of the new treatments is efficacious
and to select the best treatment. It is not of primary interest to identify all efficacious
treatments.
Other authors (Mukerjee et al., 1987; Tang and Lin, 1997; Peddada et al., 2006; Zhao,
2007) have addressed the problem more directly by using the methods of order restricted
inference (Barlow et al., 1972; Robertson et al., 1988; Silvapulle and Sen, 2005). In this
work a single hypothesis test is carried out and so there is no issue regarding the significance
level or p-value, except that calculating it might be complicated. Much of the order
restricted inference literature is devoted to likelihood based methods for the null hypothesis
of equality of all the treatments against a one-sided alternative. Unlike in two-arm trials,
this gives a different likelihood ratio test from the null hypothesis that no treatment is
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better than the control and it implicitly assumes some prior knowledge about the ordering
of treatments, i.e. that the experimental arms are at least as good as the control. This
might be appropriate in some circumstances but not for the applications considered in this
thesis. More generally, it has been noted (Mukerjee et al., 1987) that methods based on
order restricted inference are little used in clinical trials, probably due to lack of awareness
of their existence.
In this chapter we define our model, the hypotheses we will test and several test statistics.
The model and the notation we use throughout this thesis are defined in Section 2.1. The
rationale for using a different null hypothesis from that tested by many of the procedures
available in the literature is discussed in Section 2.2. The test statistics being considered
are defined in Section 2.3 and the rationales for the test statistics used are discussed.
Important relationships between the test statistics are derived, with the detailed proofs
being given in the appendix to this chapter in Section 2.5. The relevant literature is
reviewed as appropriate in each of these Sections. Finally, some conclusions are drawn in
Section 2.4
2.1 Model and notation
We consider a trial with I experimental arms and a common “control”. Here the control
can be a standard therapy, not necessarily “no therapy” (or placebo). Let N be the
total number of subjects in all arms and assume that N is large. We present results
for the case where there are ni = δN subjects in each experimental arm and we let
n0 = (1 − Iδ)N be the number of subjects in the control arm. Let Zi for i = 1, . . . , I
be a normalised statistic comparing treatment arm i with the control. For example, Zi
could be the standardised difference between the mean responses for continuous data, the
log odds ratio for binary data, or the log hazard ratio for survival data. Since we have
large samples, it follows, as usual, that Z = (Z1, . . . , ZI)
′ is multivariate normal with
V ar(Zi) = 1 and ρ = Cov(Zi, Zj) = δ/{1 − (I − 1)δ}, i 6= j. The Zis are correlated due
to their dependence on a common control arm. The expectation of Zi is a measure of
the difference between treatment i and the control and we define E(Zi) = ∆i/σ, where
σ2 = {1− (I − 1)δ}/{δ(1− Iδ)}. For I = 2, for example, Z1
Z2
 ∼ N
 ∆1/σ
∆2/σ
 ,
 1 ρ
ρ 1
 .
With equal allocation, i.e. δ = 1/3, the correlation is ρ = 1/2.
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Such Zi could, for instance, be contrasts based on normally distributed observations, with
known, constant variance. Let Yij be the (scaled) response from subject j on treatment
i = 0, 1, . . . , I, where i = 0 is the control arm. All observations are assumed to be
independent. After rescaling to get unit variance, we have Y0j ∼ N(µ0, 1) and Yij ∼
N(µi, 1), i = 1, . . . , I. Then ∆i =
√
N(µi − µ0) and Zi =
√
N{(Y¯i − Y¯0)/σ}. In the more
typical case in which Yij ∼ N(µi, τ2), with unknown variance, one could use the t-statistic
for Zi and asymptotically the assumed normal distribution of Zi would still be correct.
With binary responses, assume Yij ∼ Bernoulli(pii) and let
ψi =
pii/(1− pii)
pi0/(1− pi0) ,
i = 0, 1, . . . , I, where pii is the success rate in treatment i. For large N, log ψˆi ∼
N(logψi, V ar(log ψˆi)) (Armitage et al., 2002, p.127), where
ψˆi =
pˆii/(1− pˆii)
pˆi0/(1− pˆi0)
and
V ar(log ψˆi) =
1
n0pi0(1− pi0) +
1
nipii(1− pii) .
Then we use
V̂ ar(log ψˆi) =
1
n0pˆi0(1− pˆi0) +
1
nipˆii(1− pˆii) .
We scale the log odds ratios to get Zi with unit variance, so that
Zi =
log ψˆi√
V̂ ar(log ψˆi)
= log
(
pˆii/(1− pˆii)
pˆi0/(1− pˆi0)
)√
n0nipˆi0pˆii(1− pˆi0)(1− pˆii)
nipˆii(1− pˆii) + n0pˆi0(1− pˆi0) .
Then the Zis follow the assumptions above.
Similarly, for survival data, if Cox’s proportional hazards model is used then we can
calculate our Zi statistics as follows. Let Yij be the survival time of the jth patient
on the ith treatment, being independent with some unknown distribution with hazard
hi(t) = h0(t) exp(∆i) for the ith active arm, where h0(t) is the baseline hazard at time t
in the control arm. Then the hazard ratio HRi = hi(t)/h0(t) = exp(∆i). A natural and
asymptotically normal test statistic will be based on the estimated log hazard ratio, i.e.
Zi = log(ĤRi)/se(log(ĤRi)), which again meets the assumptions above. Alternatively,
one could use the log rank statistics comparing arm i to the control arm.
Thus the methods developed and described in this thesis are applicable whenever inference
regarding a single treatment compared to control would be based on a statistic that is
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(approximately) normally distributed. The specific examples of models just given cover
most applications in clinical trials. The only restriction to the work given here is that
it applies only to large sample sizes. Within this context, however, the results are very
general.
It will often be useful to reorder the Zi and we will use the notation Xj to represent the
jth largest Zi, so that X1 > X2 > · · · > XI . The joint likelihood of the data is
L(∆1, ...,∆I ; z1, ..., zI) = φ(z1 −∆1/σ, ..., zI −∆I/σ; ρ), (2.1)
where φ(·; ρ) is the probability density function of a multivariate normal random variable
with mean vector zero, unit variances and a known constant covariance ρ between all pairs
of variables.
2.2 Hypotheses
Given the model defined in Section 2.1, there are several null and alternative hypotheses
which can be defined. We will use standard notations for these throughout this thesis, since
many apparently similar methods in the literature actually test different hypotheses, or
make different model assumptions. To test an individual experimental treatment i against
the control, or to test each ∆i as a separate hypothesis, we have H
∗
0i : ∆i = 0 against
H∗1i : ∆i 6= 0, for a two-sided test, and H0i : ∆i ≤ 0 against H1i : ∆i > 0, for a one-sided
test. These would typically be tested using a two- or one-sided Z-test respectively, which
are the likelihood ratio tests.
Considering all experimental arms together, we define the null hypothesis of equality
H∗0 : ∆ = 0 against the alternative H∗1 : ∆ 6= 0, where ∆ = [∆1, . . . ,∆I ]′ and 0 is an
I-dimensional vector of zeros. This would typically be tested using a χ2-test. Finally,
we define the hypotheses which are of interest in this thesis, H0 : ∆i ≤ 0, ∀i = 1, . . . , I,
against H1 : ∆i > 0, for at least one i. In this case, it is not immediately obvious what
the test should be. Various options are described in this chapter.
It might seem from the previous paragraph that, when considering all arms together, there
are only two possibilities, corresponding to one-sided and two-sided tests. However, most
of the literature on order restricted inference concentrates on testing the equality null H∗0
against the one-sided alternative H1. This implicitly assumes that we are working under
the order restricted model, i.e. under the assumption that no experimental treatment can
be worse than the control.
CHAPTER 2. MODEL AND TEST PROCEDURES 35
As can be seen, there are several different hypotheses which can be tested. Careful thought
must be given to which is appropriate for a specific trial, because apparently minor dif-
ferences can lead to quite different results. We assume that the aim of the trial is to
demonstrate that at least one experimental treatment is better than the control and to se-
lect the best treatment. We argue that a single hypothesis test of H0 : ∆i ≤ 0, i = 1, . . . , I,
against H1 : ∆i > 0, for at least one i, should be carried out to establish (or fail to estab-
lish) superiority of at least one experimental treatment over the control. The aim of the
test is typically to convince regulators, potential users, senior management or the public
that our trial provides sufficient evidence to demonstrate improvement over the standard
treatment (the control). This is in contrast to multiple comparison methods for comparing
several experimental treatments with a control, which aim to test H0i against H1i, for all
i ∈ {1, . . . , I}, i.e. each experimental treatment is tested against the control. However,
in our applications, there is no need to find all treatments which are efficacious, since
we assume that ultimately only one will be recommended for use. Multiple comparison
tests would be appropriate if, for example, each experimental arm was being considered
separately for licensing, so that we need to make I separate decisions.
When the null hypothesis is rejected we need to select a treatment from among the ex-
perimental arms. When the ordering of the estimated effects is the same as the ordering
of the significance of the effects, then selection is straightforward: one simply selects the
treatment corresponding to the largest estimated effect. That is the situation that we con-
sider here because, by design, (approximately) equal numbers will be randomized to all
treatment arms (except possibly the control arm). It might be argued that it is necessary
to test the best treatment against each of the others to establish that it really is the best.
However, in the types of trials we are discussing, this is meaningless. Consider a situation
in which at least one experimental treatment is significantly better than the control, but
there is no significant difference between the best two experimental arms. What then do
we recommend? Usually, a single treatment will be recommended for practical use and
clearly we will recommend that which we estimate to give the best response. Therefore,
even if we carry out a test of each treatment against the best, it will have no impact on
the final recommendation. Such tests might be useful in other situations, for example,
if it was intended to withhold licenses from any treatment deemed to be inferior to the
best. Note that here we discuss only efficacy, assuming that safety issues are dealt with
separately.
In summary, we consider multi-arm trials, in which I experimental treatments are com-
pared with a control. We test H0 : ∆i ≤ 0∀i against H1 : ∆i > 0 for at least one i, to
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establish efficacy. If H0 is rejected, treatment i
∗ is recommended, where i∗ = arg maxZi.
This seems to be logically consistent with how the null hypothesis of equality H∗0 is tested
against the two-sided alternative H∗1 when the aim is to recommend one of several treat-
ments, with none being identified as a control. Then, typically, we would carry out a
χ2 test to ensure that we are not just interpreting noise and then recommend the treat-
ment which gives the best estimated response. Multiple comparison tests of all pairs of
treatments do not add anything which might change our recommendation.
Of course not all three-arm trials fit into the framework described here. For example, if
the treatments are different doses of a drug, a dose response model might be assumed,
especially in early phase trials, or a strictly non-decreasing response (a simple order)
might be assumed. However in several situations a threshold appears to occur so that
dose response models would be inefficient. In other cases it might be known a priori
that the experimental treatments will be no worse than the control, so that the null
hypothesis of equality can be used. However there are pragmatic trials, which seek to
recommend a treatment for application, and some phase-II/III trials in drug development,
where there are two or more new candidate drugs, for which it is not reasonable to assume
anything about the ordering of the treatments and the objectives can be met by testing
our hypothesis. In these circumstances, the testing and selection procedure described here
is appropriate, although it seems to be quite rarely used. In this thesis, we compare and
develop methodologies required to carry out this procedure efficiently.
The three trials described briefly in Chapter 1 all fit into the framework described here.
Consider the ATAC trial for comparing tamoxifen, the common control, anastrozole and
a combination of anastrozole plus tamoxifen. In this situation the above hypothesis is
appropriate. It will provide the evidence in favour of a new treatment over the standard
and, if this is shown, either anastrazole or the combination would be recommended. In
fact, anastrozole alone turned out to be beneficial and we will see the data analysis in
Chapter 3.
The DASH trial compared a control diet, a diet high in fruit and vegetables and a “com-
bination” diet high in fruit, vegetables and low-fat dairy products on blood pressure. As
noted in Chapter 1, one wants to know whether there is convincing evidence (a significant
result) that a change of diet will be beneficial and, if so, we make a recommendation as
to what change should be made. This is exactly what our recommended procedure does.
In the trial, Appel et al. (1997) actually performed all pairwise comparisons, but we see
no benefit in doing this. If it is clear that a change in diet is beneficial, but there is
CHAPTER 2. MODEL AND TEST PROCEDURES 37
no significant difference between the two experimental treatments, we would not wish to
withhold a public health recommendation while further comparison of these two diets is
carried out. Instead, we would simply recommend that which seems best and any further
trials could be done with this as the new control.
In the MORE trial, the point was again to establish evidence that raloxifene was efficacious
(through a hypothesis test) and, if it was, to recommend one of the doses. The dose-
response relationship is not of interest in itself, although the use of our testing and selection
procedure does not preclude further such secondary analyses from being carried out.
Thus the methods developed in this thesis are relevant to all of these examples. In all
cases, the crucial question is whether at least one experimental treatment is better than
the control. In these applications, it is necessary to carry out a hypothesis test in order to
establish improved efficacy of at least one experimental treatment over the control. When
efficacy is demonstrated, it is clear that the experimental treatment with the best estimated
response will be recommended for use in practice. It is not necessary to demonstrate that
the recommended arm is superior to all other experimental arms, nor is it necessary to
establish individually whether or not each experimental arm is better than the control.
An important question is whether or not the selected experimental arm, i.e. the one with
largest Zi, has a mean response greater than that for the control arm. In addition to
the usual type I and type II errors, another type of error can happen. It is also possible
to correctly reject the null hypothesis but to select the wrong experimental arm, e.g. for
I=2, to reject H0 and select experimental arm 2 when ∆2 ≤ 0 but ∆1 > 0. For practical
purposes this can be treated like a type I error, but is associated with parameter values that
are within the set of alternatives. It is logically analogous to carrying out a two-sided test
in a two arm trial, rejecting the null hypothesis with a positive value of the test statistic
and then wrongly concluding that the experimental treatment is better than (rather than
simply different from) the control. Both of these are type-III errors, as described by
Mosteller (1948) and formally defined by Harter (1957). Most of the literature which
refers to type-III errors concerns two-sided tests in which a wrong directional decision is
made. As we will see in Chapter 3, however, some authors have also discussed type-III
errors in contexts much closer to ours.
We can formally take account of the probability of a type-III error in defining the size of
the test. The corrected size is defined as
α† = max
θ∈Θ
(α, P (type-III error)) ,
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where θ is a vector of parameters and Θ is the set of all possible θ. α† is the probability
of rejecting H0 in favour of i
∗ | i∗ is no better than control.
In two arm trials, a two-sided test has α† = α. However, in multi-arm trials with one-sided
tests this is not necessarily true. The probabilities of type-III errors are discussed further
in Section 3.5.
For 0 < ∆2 < ∆1, the related outcome of selecting treatment 2 will be called a type-IV
error, i.e. we select a treatment which is suboptimal, but is still better than the control.
Type-III errors could have very deleterious consequences, but will be quite rare, whereas
type-IV errors will be much more common, but have consequences which are less serious,
since they still lead to an improvement in treatment. Different authors have included
type-III or -IV errors in their power comparisons in different ways and we will describe
some of these in more detail in Chapter 3.
In two-arm trials these complications do not arise with one-sided tests, since there is a
direct correspondence between a one-sided test and selection of a treatment. In multi-arm
trials we have to consider the possibility of correctly rejecting the null hypothesis, but
selecting a sub-optimal treatment, and particularly the possibility of selecting a treatment
that is inferior to control.
2.3 Test procedures
Since both the null hypothesis H0 and the alternative H1 are composite hypotheses, a
uniformly most powerful test is not known, so we now describe several possible test pro-
cedures. We also discuss relationships among the different test procedures and how they
are related to other procedures in the literature. The performances of the most promising
procedures are compared in the next chapter.
2.3.1 Families of test statistics
First, we define three families of test statistics, which have not appeared in the literature in
these forms. In later subsections, we will show that several procedures which have appeared
in the literature can be rewritten in terms of particular members of these families of test
statistics and this allows us to see relationships between them, as well as simplifying the
terminology and notation.
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First, we consider test statistics which arise naturally in two-sided tests and define
S0k =
(
I∑
i=1
Zki
) 1
k
for some integer k > 0. Because we take positive powers, the larger k is, the more weight
is put on effects which are further from zero. However, this family of test statistics does
not seem sensible for the one-sided alternative, unless there is prior knowledge that no
treatment can be worse than the control, since negative values of Zi can dominate.
It seems logical to only include contributions from Zi which take positive values, so a
natural family of test statistics is
T 0k =
(
I∑
i=1
Z+ki
) 1
k
, (2.2)
where A+ = max(0, A) and k > 0. Here larger values of k give more weight to treatments
which give larger responses, as long as these are greater than the control. If the Zi were
independent, then there would be no reason to adjust the contributions from different Zi,
so that using T 0k would be logical. However, the correlation between them means that
the knowledge that any one Zi is large makes it more likely that the others will be large
and including the full contribution from each exaggerates the evidence against H0. An
unusually small estimate for the control will make all other arms appear to be good.
We adjust for the correlation among Zi using the general results for conditional multi-
variate normal random variables (Krzanowski and Marriott, 1994, p.25) and evaluating
expectations at ∆i = 0, ∀i = 1, . . . , I. Then
E (Zi|Z1, . . . , Zi−1) = ρ{1 + (i− 2) ρ}
i−1∑
j=1
Zj (2.3)
and
V ar (Zi|Z1, . . . , Zi−1) = {1 + (i− 1) ρ} (1− ρ){1 + (i− 2) ρ} , (2.4)
for i ∈ {1, . . . , I} .
Considering the ordered univariate statistics, X1 > · · · > XI , it is clear that if X1 < 0,
there is no evidence against H0 and any sensible test statistic should take value zero. Hence
the first contribution to a test statistic should come from X+1 . Using the conditional
expectation and variance results, Xi should only contribute to the test statistic if it is
greater than
Ei =
ρ
{1 + (i− 2) ρ}
i−1∑
j=1
Xj , (2.5)
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so that the contribution should be based on (Xi − Ei)+. This is scaled to have unit
variance, so that the ith term in the test statistic should be (Xi − Ei)+/
√
Vi, where
Vi =
{1 + (i− 1) ρ} (1− ρ)
{1 + (i− 2) ρ} . (2.6)
It remains only to decide on which scale these terms should jointly contribute to the test
statistic. We can define a family of test statistics
Tk =
[
X+k1 +
I∑
i=2
{
(Xi − Ei)+√
Vi
}k] 1k
, (2.7)
for k > 0. Clearly larger values of k will put more emphasis on the treatment with the
largest effect. As k is decreased more weight is given to the other treatments which have
positive effects.
In the following sections we will consider some members of these families, in particular
with k = 1, 2,∞.
2.3.2 Combining one-dimensional tests
Dunnett-type tests
Since we want to choose the best treatment, a natural and simple approach is to consider
each ∆i as a separate hypothesis, test the one-sided alternative using the uniformly most
powerful test and then combine the results. Thus if one computes the usual test statistic
for H0i : ∆i ≤ 0 against H1i : ∆i > 0, for each i, and takes the maximum, one obtains
max(Zi), where i = 1, ..., I. We will actually use
T∞ = max(0, Z1, . . . , ZI),
since this is a member of the family of test statistics defined in (2.7), although this makes
no difference for any sensible significance level since the critical value will be greater than
zero. Note also that T 0∞ = T∞. The multiple comparisons being made must be taken into
account when calculating the rejection boundaries, which is usually done using the well
known procedure of Dunnett (1955), originally developed for obtaining confidence intervals
for each comparison with the control, while controlling the overall coverage. Note that
Dunnett’s procedure is defined using t-statistics (assuming unknown variance), so that T∞
can be obtained from the asymptotic case as the degrees of freedom tend to ∞.
Assume that Dunnett’s procedure is used to obtain one-sided confidence intervals for
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∆i, i = 1, . . . , I of the form (∆ˆi − C,∞), for some positive constant C such that
P
(
I⋂
i=1
{∆ˆi − C < ∆i}
)
= 1− α
and that we reject H0 if at least one confidence interval excludes 0. Then, we reject H0 if
0 /∈ (∆ˆi − C,∞) for at least one i ⇒ reject H0 if 0 < ∆ˆi − C for at least one i ⇒ reject
H0 if max(∆ˆi) > C, which is equivalent to T∞, since C > 0.
Note also that P (Do not reject H0) = P (∆ˆi < C ∀i) = P
(⋂I
i=1{∆ˆi − C < 0}
)
. Hence,
by considering ∆i = 0 ∀i, we see that the test has size α and C is the cutpoint of the
rejection region for T∞. Considering ∆i ≥ 0, with at least one strict inequality, it is clear
that maximising C is equivalent to minimising the power of T∞ for a test of fixed size.
Hence, published results on Dunnett’s procedure apply immediately to T∞. Much research
effort has been expended on finding good approximations to the cutpoint C. Most authors
who discuss testing H0, as defined above, have used Dunnett’s test and most other tests
in the literature are similar to this test. This approach makes no use of the size of the
treatment differences other than the maximum. Although it is commonly used in practice
and is known to have high power if only one treatment is better than the control, there is
no reason to expect it to have good properties, such as high power, in all situations.
Hochberg’s procedure
The step-up procedure of Hochberg (1988) for multiple testing gives a simple modification
of T∞, which allows us to reject H0 : ∆i ≤ 0 ∀i, if several treatment differences are big but
not quite big enough to cross the rejection boundary for T∞. To test I hypotheses, order
the p-values for the independent hypothesis tests p(1) < p(2) < · · · < p(I), corresponding
to reordered null hypotheses H0(1), H0(2), . . . ,H0(I) where H0(i) is H0j : ∆j ≤ 0 for j such
that p(i) corresponds to H0j . If p(k) < α/(I − k + 1) for any k = 1, ..., I, then reject H0(i)
at the 100α% level for all i ≤ k.
In our application to multi-arm clinical trials we have test statistics Z1, . . . , ZI . Order
these to get X1 > · · · > XI , corresponding to null hypotheses H0(i) : ∆(i) ≤ 0, i = 1, ..., I.
Letting zα be the upper 100α% point of the standard normal distribution, reject H0(i) at
the 100α% level for all i ≤ j, if Xj ≥ zα/(I−j+1) for any j = 1, ..., I. These individual tests
can then be combined to assess H0.
For example, for I = 2, X1 = max(Z1, Z2) and X2 = min(Z1, Z2). Then
• if X2 ≥ zα, reject H0(1) and H0(2) (⇒ reject H0);
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• if X2 < zα, but X1 ≥ zα/2, reject H0(1), but do not reject H0(2) (⇒ reject H0);
• if X2 < zα and X1 < zα/2, do not reject H0(1) or H0(2) (⇒ do not reject H0).
Thus the rejection region is{
Z1 > zα/2
⋃
Z2 > zα/2
⋃(
Z1 > zα
⋂
Z2 > zα
)}
= A
and
P (A) = P
(
Z1 > zα
⋂
Z2 > zα
)
+ P
(
Z1 > zα/2
⋂
Z2 < zα
)
+P
(
Z2 > zα/2
⋂
Z1 < zα
)
.
In the case of I = 2, Hochberg’s procedure is equivalent to those of Simes (1986) and
Dunnett and Tamhane (1992) and so our results for this case apply equally to these
procedures. Simes (1986) proved that if the tests are independent, the overall size of the
test is exactly α. Hochberg’s test is based on the assumption that for non-independent
tests, this is conservative. Hochberg and Rom (1995) showed that this is true for many
cases, but not always, and Shaffer (1995) argued that the use of the Hochberg procedure
should be backed up by simulations or theoretical results. Simes (1986) did simulations for
many multivariate normal cases, showing conservativeness in each case. Since for I = 2
Hochberg’s procedure is conservative with correlated multivariate normal data (Simes,
1986), we present the results of a modified Hochberg procedure which uses a nominal
significance level, α∗, in order to achieve a size of exactly α.
For I > 2, Simes’ and Hochberg’s procedures differ and each requires its own nominal α∗
in order to ensure size α. Although Simes’ and Dunnett and Tamhane’s procedures are
known to be more powerful than Hochberg’s for the same nominal level of significance,
this is not true when the significance levels are adjusted to give exact size α. Here we
decided to pursue just one of these and have used the Hochberg procedure.
2.3.3 Likelihood ratio based test statistics
A more natural and direct approach to evaluating hypotheses of the type considered here
is via order restricted testing (Barlow et al., 1972; Robertson et al., 1988; Silvapulle and
Sen, 2005), rather than through multiple one-dimensional tests. There has been little
application of order restricted inference in medical statistics (Mukerjee et al., 1987).
In a two-arm trial, the likelihood ratio test (LRT) statistic for the one-sided alternative
hypothesis H1i : ∆i > 0 is identical whether the null hypothesis is H0i : ∆i ≤ 0 or
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H∗0i : ∆i = 0, i.e. whether the model allows the possibility of the experimental treatment
being worse than the control or not. Therefore, for the test statistics described in Section
2.3.2, which are based on multiple one-dimensional tests, it is natural to use the same
procedure whether the null hypothesis is H0 : ∆i ≤ 0 ∀i or H∗0 : ∆i = 0 ∀i. However,
in the case of several experimental treatments against a control, the likelihood ratio test
statistics are different for testing H0 or H
∗
0 against the one-sided alternative H1.
Likelihood ratio test of equality H∗0 in order restricted model
Most of the literature (Barlow et al., 1972; Robertson et al., 1988; Silvapulle and Sen,
2005; Peddada et al., 2006; Zhao, 2007) on order restricted inference concentrates on
testing the simple null hypothesis H∗0 : ∆ = 0 against the alternative H1 under the order
restricted model, i.e. under the assumption that no experimental treatment can be worse
than the control. The LRT of H∗0 versus H1 leads to a test statistic given by Barlow
et al. (1972), which for three arms takes the form {(X1 − ρX2)+2/(1− ρ2)}+X+22 , where
X1 = max(Z1, Z2) and X2 = min(Z1, Z2), when I = 2 and A
+ = max (A, 0). Several
authors (Mukerjee et al., 1985, 1987; Zhao, 2007) have compared such tests with Dunnett’s
test. Although it is developed from the wrong model, this test could conceivably be useful
for our problem.
This test statistic is decreasing in X2 for X1 > 0, X2 ≤ ρX1, and for X1 < 0, X2 < ρ−1X1
and therefore not monotone increasing in X2. Consider for example, the cases for ρ = 0.5
with X1 = 2, X2 = 0 and X1 = 2, X2 = 1. In the former case, the test statistic takes
value 513 and in the latter case it takes value 4. Thus at some level of significance we
would reject H0 in the first case, but not the second. This is clearly undesirable, since the
evidence against H0 is stronger in the second case.
Related test statistics
Tang and Lin (1997) proposed a test that is similar to the LRT of Robertson but replaces
the maximum likelihood estimates with “more easily computed” approximate estimates.
This test has similar properties to Robertson’s and suffers from the same inconsistency.
Peddada et al. (2006) used a version of T∞, but with the estimate of the control mean
replaced by that of Hwang and Peddada (1994). This replaces the simple tree order with
an arbitrary simple order and then uses the isotonic regression estimates obtained from
this simple order. Despite seeming very unnatural, Hwang and Peddada (1994) showed
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that this procedure gives good estimation of µ0, the control mean. However, the test of
Peddada et al. (2006) does not seem to perform better than the LRT for this situation.
Zhao (2007) developed another version of T∞, but replacing the global estimates of each
∆i with MLEs obtained under the assumption of a simple tree order. This is appropriate
only if a simple tree order can be assumed initially. If used for our problem, this statistic
also suffers from the problem of being decreasing over certain values of X2.
The approaches described in this and the previous subsubsections do not allow for negative
∆i, which is an inappropriate restriction for our problem, and it is not surprising that it
leads to inappropriate test statistics. Note also that the issue of type III errors does not
arise in this set up.
Generalized likelihood ratio test for unrestricted model
We saw in the previous subsection that the LRT statistic developed for H∗0 has undesirable
properties if used for H0. Now we show the development of the correct likelihood ratio
test statistic under H0. The likelihood ratio test statistic is given by
λ = 2 log
{
L(y; ∆ˆ)
L(y; ∆˜)
}
, (2.8)
where ∆ = (∆1 · · · ∆I)′, the likelihood is given in equation (2.1), ∆ˆ is the maximum
likelihood estimator (MLE) of ∆ under the model defined in Section 2.1 and ∆˜ is the
restricted maximum likelihood estimator of ∆ under H0 : ∆i ≤ 0, ∀i ∈ {1, . . . , I}.
The unrestricted MLEs are the ordinary maximum likelihood estimators, e.g. in the case
of normal data, the mean of each arm, µi = µ0 + (∆i/
√
N), is estimated by its sample
mean. The restriction that each experimental arm is no better than the control, which
is our null hypothesis, defines a simple tree order (Barlow et al., 1972; Robertson et al.,
1988). It is shown by Barlow et al. (1972) that the MLEs are obtained from the isotonic
regression for this partial order. Barlow et al. (1972) showed that the isotonic regression
estimators ∆˜ can be obtained from the pool adjacent violators algorithm (PAVA) in the
case of normally distributed data. Barlow et al. (1972) gave the description of how to
calculate MLEs using PAVA, but did not give any general form of the MLEs.
We now present a theorem which gives a general expression for the MLEs under H0 in a
simple form. This applies not just to the case of normally distributed data Yij , but for
any normally distributed univariate statistics Zi. We start with some preliminaries.
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We define a set of orthogonalized transformed random variables,
U1 = Z1 (2.9)
and
Ui = (Zi − E∗i ) /
√
V ∗i , (2.10)
i = 2, . . . , I, where E∗i = E (Zi|Z1, . . . , Zi−1) and V ∗i = V ar (Zi|Z1, . . . , Zi−1) are the
conditional expectation and variance of Zi respectively, as given in (2.3) and (2.4). Then
U1, . . . , UI are independent normally distributed random variables with unit variance, as
shown in section 2.5.1 in the appendix.
The joint likelihood of the Ui is
L =
(
1√
2pi
)I
exp
[
−1
2
I∑
i=1
{Ui − E(Ui)}2
]
. (2.11)
Then the log likelihood, ignoring constants, can be written as
logL = − 1
2σ2
I∑
i=1
g(i)2
f(i)
,
where
f(i) = {1 + (i− 2) ρ} {1 + (i− 1) ρ} (1− ρ) , (2.12)
g(1) = σ(1− ρ)U1 − (1− ρ) ∆1 (2.13)
and
g(i) = σ
√
f(i)Ui − {1 + (i− 2) ρ}∆i + ρ
i−1∑
j=1
∆j , (2.14)
for i ∈ {2, . . . , I}.
The unrestricted MLEs are ∆ˆi = σZi (i = 1, . . . , I), since E(Zi) = ∆i/σ. Let ∆˜i be the
MLEs of the restricted model under the null hypothesis. Assume that ∆ˆ1 ≥ ∆ˆ2 ≥ · · · ≥ ∆ˆI
(other orders follow by symmetry). The calculations depend on the number of violations
there are. If ∆ˆ1 ≤ 0, there are no violations, while if it is necessary to pool J treatments
with the control, there are J violations. We need to calculate ∆˜i for the following cases:
• Case 0: ∆ˆi ≤ 0 ∀i = 1, ..., I;
• Case J , J = 1, . . . , I: ∆ˆ1 > 0, ∆ˆ2 > ρ∆ˆ1, . . . , ∆ˆJ > ρ
∑J−1
j=1 ∆ˆj
1+(J−2)ρ , but ∆ˆJ+1 ≤
ρ
∑J
j=1 ∆ˆj
1+(J−1)ρ .
For Case 0, the restricted and unrestricted MLEs are the same, i.e. ∆˜i = ∆ˆi ∀i. For Case
J we show the form of the restricted MLEs by using the following results from Thompson
(1962), restated in our notation.
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Lemma 1 (Thompson, 1962) If logL(∆) is differentiable at ∆˜ then a necessary con-
dition for ∆˜ to maximize logL(∆), subject to ∆i ≤ 0, i = 1, . . . , I, is that for each
i ∈ {1, . . . , I} , either:
(a) ∆˜i = 0 and
∂ logL(∆)
∂∆i
∣∣∣
∆= ˜∆
≥ 0; or
(b) ∆˜i < 0 and
∂ logL(∆)
∂∆i
∣∣∣
∆= ˜∆
= 0.
Corollary 2 (Thompson, 1962) If logL(∆) is strictly concave, then ∆˜ is a unique
maximum.
Thus, since our log-likelihood is strictly concave (multivariate normal), the restricted
MLEs under H0 will be the unique values ∆˜ which satisfy all conditions (a) and (b) in
Lemma 1. These are given by the following theorem.
Theorem 3 Assume that the unrestricted MLEs ∆ˆi are such that ∆ˆ1 ≥ ∆ˆ2 ≥ · · · ≥ ∆ˆI
(other orders follow by symmetry). If, for some 1 ≤ J ≤ I,
∆ˆ1 > 0, ∆ˆ2 > ρ∆ˆ1, . . . , ∆ˆJ >
ρ
1 + (J − 2)ρ
J−1∑
j=1
∆ˆj ,
but
∆ˆJ+1 ≤ ρ
1 + (J − 1)ρ
J∑
j=1
∆ˆj ,
then the order restricted MLEs ∆˜i are given by
∆˜i =
 0, i = 1, . . . , J ;σ {Zi − ρ1+(J−1)ρ∑Jj=1 Zj} , i = J + 1, . . . , I. (2.15)
The proof is given in Section 2.5.2 in the appendix. Most of this is done by simple but
tedious algebraic manipulation. We need to show that (2.15) provide a solution to (a)
∂ logL
∂∆k
= 0, k = J + 1, . . . , I, and then show that ∆˜i in (2.15) give (b)
∂ logL
∂∆k
∣∣∣
∆k=∆˜k
≥ 0
for k = 1, . . . , J . We need to show (a) for the cases: (i) k = J + 1 (Lemma 5); and (ii)
k ≥ J + 2 (Lemma 6). Similarly we show (b) for the cases: (i) k = J (Lemma 7); (ii)
k = J − 1 (Lemma 8); and (iii) k ≤ J − 2 (Lemma 10). We present this series of lemmas
in Section 2.5.2 in the appendix.
Mukerjee et al. (1985) and Robertson et al. (1988) worked out the likelihood ratio test
statistics for our H0 against H1, in the case of normally distributed data, and studied
some of its properties. This is extended to any univariate normal statistics Zi and related
to our family of test statistics in the following theorem.
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Theorem 4 The likelihood ratio test statistic of H0 versus H1 can be written as λ = T
2
2 ,
where
T2 =
√√√√X+21 + I∑
j=2
(Xj − Ej)+2
Vj
,
as defined in equation (2.7).
This Theorem is proved in Section 2.5.3 in the appendix by substitution of ∆ˆ = σZ and
∆˜, as defined in (2.15), into (2.8). We also carried out extensive numerical checks to check
that the result is correct.
For two arms E2 = ρX1, Vi = 1− ρ2 and the test statistic simplifies to
T2 =
√
X+21 +
(X2 − ρX1)+2
1− ρ2 .
Mukerjee et al. (1985) and Robertson et al. (1988) mainly used this test, in a different
form and with signs reversed, for checking the assumption of the order restriction before
testing H∗0 against H1 under that assumption. It was also described in a general form by
Silvapulle and Sen (2005). There seems to have been little or no direct use of this LRT to
test our hypothesis of interest and none of these authors dealt with the problem of type-III
errors or considered the corrected size defined in Section 2.2. Note the difference between
this statistic and the LRT for H∗0 versus H1 given at the begining of this section. The
difference is that X1 and X2 have been interchanged. Whereas previously the statistic
was not monotone in X2, T2 is monotone in X2.
A simpler test statistic
For ρ = 0, e.g. if separate trials were conducted with separate control groups for each
experimental treatment, T2 reduces to T
0
2 =
√∑I
i=1 Z
+2
i . This is another possible test
statistic which we will study, since it might be that ignoring the correlation does little
harm and this test statistic is easier to compute than T2. T
0
2 can also be considered as
a simple modification of the χ2 test statistic S02 for the two-sided alternative hypothesis,
with differences in the negative direction replaced by zero. We do not consider S02 , since
it is clearly inappropriate to give so much weight to large negative Zis.
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2.3.4 Single contrast and related tests
Single contrast test
When all of the ∆i are known to be equal, then the labelling of experimental arms is
irrelevant and, in the case of normally distributed observations, a test based on the single
contrast
(∑I
i=1 Y¯i/I
)
− Y¯0 is most powerful. Here we consider the test statistic
S01 =
I
√
N
σ
(
I∑
i=1
Y¯i
I
− Y¯0
)
=
I∑
i=1
Zi,
which is a special case of a test suggested by Abelson and Tukey (1963) and Schaafsma and
Smid (1966) for testing H∗0 against H1, when prior knowledge is available about the relative
sizes of the alternatives. This is sometimes known as the Abelson-Tukey-Schaafsma-Smid
contrast test, but we will continue to refer to it as S01 . However, this test is not even
consistent against all outcomes in H1 and a large negative value of one mean can cancel
the positive contribution from a favorable treatment.
Mukerjee et al. (1987) suggested a family of test statistics for the simple null hypothesis
H∗0 , which can be expressed as a weighted average of T∞ and S01 , with the weights chosen
to make the two parts orthogonal. Their main motivation was to obtain a test statistic
whose null distribution could be obtained analytically and they noted that “the LRT
seems very difficult to beat provided . . . that its null . . . distribution can be . . . reasonably
approximated.”
A modified test
A modification of S01 , which avoids the inconsistency, is obtained by ignoring negative
contributions. We define
T 01 =
I∑
i=1
Z+i .
The simplicity of this test statistic is its main attraction and we study it, along with
others, in the next chapter.
A further refinement
The above test statistic can be further refined by giving more weight to X1 to give
T1 = X
+
1 +
I∑
j=2
(Xj − Ej)+√
Vj
,
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where Ej and Vj are defined in (2.5) and (2.6) respectively. For two arms this simplifies
to
T1 = X
+
1 +
(X2 − ρX1)+√
1− ρ2 .
It is easy to see that this test is consistent in the sense that H0 will be rejected with
probability 1 as some ∆i →∞, regardless of the values of other ∆j .
2.4 Conclusions
In this chapter, we have defined several test statistics, which could be used to test H0 :
∆i ≤ 0 ∀i against H1 : ∆i > 0 for at least one i. It is not known which is best and it is
clear that there is no uniformly most powerful test statistic. It is therefore necessary to
compare the properties of these test statistics, such as their power, and this is done in the
next chapter.
The extension of these tests to non-inferiority trials is conceptually straightforward. A
typical scenario might be that there are several experimental treatments, one of which
could potentially replace, or compete with, the standard treatment if it can be shown to
be not inferior in terms of efficacy. The argument in favour of one-sided non-inferiority
trials over equivalence trials is similar to the argument we have made above in favour of
one-sided trials, i.e. an experimental treatment should not be rejected for being superior
to the control. In a non-inferiority trial, the null hypothesis becomes H†0 : ∆i ≤ −δ†∀i,
where δ† is the non-inferiority margin, and the alternative is H†1 : ∆i > −δ† for at least
one i. All of the test statistics defined above can be used, with Zi replaced by Zi + δ
†
in their definitions. Hence all of the methods described here can be used immediately,
although we will not emphasise this potential application in this thesis.
2.5 Appendix: proofs
2.5.1 Preliminaries
We defined the orthogonalized transformed random variables, U1, . . . , UI , in equations
(2.9) and (2.10). Substituting (2.3) and (2.4) into these equations, we obtain
Ui =
{1 + (i− 2)ρ}Zi − ρ
∑i−1
j=1 Zj√{1 + (i− 2)ρ} {1 + (i− 1)ρ} (1− ρ) , (2.16)
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where, throughout this appendix,
∑0
j=1 a(j) is defined to be zero, no matter what function
a(·) is used. Then
E(Ui) =
{1 + (i− 2)ρ}∆i − ρ
∑i−1
j=1 ∆j
σ
√{1 + (i− 2)ρ} {1 + (i− 1)ρ} (1− ρ) .
The variances are V ar(U1) = V ar(Z1) = 1 and, for i = 2, . . . , I,
V ar(Ui) =
V ar(Zi) + V ar(E
∗
i )− 2Cov(Zi, E∗i )
V ∗i
=
1
V ∗i
1 + ρ2{1 + (i− 2) ρ}2

i−1∑
j=1
V ar(Zj) + 2
i−2∑
j=1
i−1∑
k=j+1
Cov(Zj , Zk)

−2 ρ
1 + (i− 2)ρ
i−1∑
j=1
Cov(Zi, Zj)

=
1
V ∗i
[
1 +
ρ2
{1 + (i− 2) ρ}2
{
i− 1 + 2(i− 1) (i− 2)
2
ρ
}
− 2 (i− 1) ρ
2
1 + (i− 2)ρ
]
=
1 + (i− 2) ρ
{1 + (i− 1) ρ} (1− ρ)
1 + (i− 2) ρ− (i− 1) ρ2 − 2 (i− 1) ρ2
1 + (i− 2) ρ
= 1.
We obtain covariances as follows. For i = 2, . . . , I
Cov(U1, Ui) = Cov
(
Z1,
Zi − ρ1+(i−2)ρ
∑i−1
j=1 Zj
V ∗i
)
=
1
V ∗i
ρ− ρ
V ∗i {1 + (i− 2) ρ}
{1 + (i− 2) ρ}
= 0.
For 1 < i < j ≤ I,
Cov(Ui, Uj) = Cov
(
Zi − ρ1+(i−2)ρ
∑i−1
k=1 Zk
V ∗i
,
Zj − ρ1+(j−2)ρ
∑j−1
k=1 Zk
V ∗j
)
=
1
V ∗i V
∗
j
(
ρ− ρ (i− 1) ρ
1 + (i− 2) ρ −
ρ {1 + (j − 2) ρ}
1 + (j − 2) ρ
+
ρ2 [(i− 1) + {(i− 1) (j − 1)− (i− 1)} ρ]
{1 + (i− 2) ρ} {1 + (j − 2) ρ}
)
=
1
V ∗i V
∗
j
[
ρ2 (i− 1) {1 + (j − 2) ρ}
{1 + (i− 2) ρ} {1 + (j − 2) ρ} −
ρ2 (i− 1)
1 + (i− 2) ρ
]
= 0.
Thus U1 . . . UI are independent normal variables with unit variance.
Substituting the values of Ui from (2.16) into the joint likelihood of the Ui given in (2.11),
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taking logL and ignoring the constant term we have
logL = − 1
2σ2
(
(σU1 −∆1)2 +
I∑
i=2
[
σ
√{1 + (i− 2) ρ} {1 + (i− 1) ρ} (1− ρ)Ui − {1 + (i− 2) ρ}∆i + ρ∑i−1j=1 ∆j]2
{1 + (i− 2) ρ} {1 + (i− 1) ρ} (1− ρ)
 .
= − 1
2σ2
I∑
i=1
g(i)2
f(i)
, (2.17)
where f(i) and g(i) are defined in (2.12), (2.13) and (2.14).
Differentiating, we have
∂ logL
∂∆k
= − 1
2σ2
I∑
i=1
∂g(i)2
∂∆k
f(i)
. (2.18)
Since
∂
∂∆k
{
g(i)2
}
= 2g(i)
∂g(i)
∂∆k
and
∂g(i)
∂∆k
= −{1 + (i− 2) ρ} ∂∆i
∂∆k
+ ρ
i−1∑
j=1
∂∆j
∂∆k
,
we have
∂g(i)
∂∆k
=

ρ if k < i;
−{1 + (i− 2) ρ} if k = i;
0 if k > i.
Substituting g(i) from (2.14), we get
∂
{
g(i)2
}
∂∆k
=

2ρ
[
σ
√
f(i)Ui − {1 + (i− 2) ρ}∆i + ρ
∑i−1
j=1 ∆j
]
if k < i;
−2 {1 + (i− 2) ρ}
[
σ
√
f(i)Ui − {1 + (i− 2) ρ}∆i + ρ
∑i−1
j=1 ∆j
]
if k = i;
0 if k > i.
Substituting Ui from (2.10) and simplifying, we obtain
∂
{
g(i)2
}
∂∆k
=

2ρ
(
σ
[
{1 + (i− 2) ρ}Zi − ρ
∑i−1
j=1 Zj
]
−{1 + (i− 2) ρ}∆i + ρ
∑i−1
j=1 ∆j
)
if k < i;
−2 {1 + (i− 2) ρ}
(
σ
[
{1 + (i− 2) ρ}Zi − ρ
∑i−1
j=1 Zj
]
−{1 + (i− 2) ρ}∆i + ρ
∑i−1
j=1 ∆j
)
if k = i;
0 if k > i.
Splitting the summation over i in (2.18) into the cases i < k, i = k and i > k gives
∂ logL
δ∆k
= − 1
2σ2
[
k−1∑
i=1
∂
{
g(i)2
}
/∂∆k
f(i)
+
∂
{
g(k)2
}
/∂∆k
f(k)
+
I∑
i=k+1
∂
{
g(i)2
}
/∂∆k
f(i)
]
.
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Since, for i < k, ∂
{
g(i)2
}
/∂∆k = 0, it follows that
∂ logL
∂∆k
= − 1
2σ2
[
∂
{
g(i)2
}
/∂∆k
f(k)
+
I∑
i=k+1
∂
{
g(i)2
}
/∂∆k
f(i)
]
= − 1
σ2
−{1 + (k − 2) ρ}
f(k)
{1 + (k − 2) ρ} (σZk −∆k)− ρ
σ k−1∑
j=1
Zj −
k−1∑
j=1
∆j

+ρ
I∑
i=k+1
1
f(i)
{1 + (i− 2) ρ} (σZi −∆i)− ρ i−1∑
j=1
(σZj −∆j)
 . (2.19)
This form will be used in the proof of Theorem 3 in Section 2.5.2.
2.5.2 Proof of Theorem 3
We show that
∆˜s =
 0 if s = 1, . . . , J ;σ {Zs − ρ1+(J−1)ρ∑Jj=1 Zj} if s = J + 1, . . . , I (2.20)
provide a solution to (a) ∂ logL∂∆k = 0, k = J + 1, . . . , I, and then show that ∆˜s give (b)
∂ logL
∂∆k
≥ 0 for k = 1, . . . , J . We need to show (a) for the cases: (i) k = J + 1; and (ii)
k ≥ J+2. Similarly we show (b) for the cases: (i) k = J ; (ii) k = J−1; and (iii) k ≤ J−2.
We present these as a series of lemmas.
Lemma 5
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= 0,
for k = J + 1.
Proof. Replacing k by J + 1 in (2.19), we get
∂ logL
∂∆k
= − 1
σ2
−{1 + (J − 1) ρ}
f(J + 1)
{1 + (J − 1) ρ} (σZJ+1 −∆J+1)− ρ J∑
j=1
(σZj −∆j)

+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ} (σZi −∆i)− ρ i−1∑
j=1
(σZj −∆j)
 .
Evaluating at ∆ = ∆˜, multiplying out the summations in j and substituting
∑J
j=1 ∆˜j = 0,
we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−{1 + (J − 1) ρ}
f(J + 1)
{1 + (J − 1) ρ}(σZJ+1 − ∆˜J+1)− ρ J∑
j=1
σZj

+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ}(σZi − ∆˜i)− ρ i−1∑
j=1
σZj + ρ
i−1∑
j=1
∆˜j
 .
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Splitting up the summations over j = 1, . . . , i−1 into∑Jj=1 plus∑i−1j=J+1, where∑Jj=1 ∆˜j =
0, gives
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−{1 + (J − 1) ρ}
f(J + 1)
{1 + (J − 1) ρ}(σZJ+1 − ∆˜J+1)− ρ J∑
j=1
σZj

+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ}(σZi − ∆˜i)− ρ J∑
j=1
σZj
−ρ
i−1∑
j=J+1
σZj + ρ
i−1∑
j=J+1
∆˜j
 .
Substituting ∆˜j , for j = J + 1, . . . , i− 1, from (2.20), we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
(
− 1 + (J − 1)
f(J + 1){1 + (J − 1) ρ}σ
ZJ+1 − ZJ+1 + ρ1 + (J − 1) ρ
J∑
j=1
Zj
− ρσ
J∑
j=1
Zj

+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ}σ
Zi − Zi + ρ1 + (J − 1) ρ
J∑
j=1
Zj

−ρσ
J∑
j=1
Zj − ρσ
i−1∑
j=J+1
Zj + ρσ
i−1∑
j=J+1
{
Zj − ρ
1 + (J − 1) ρ
J∑
l=1
Zl
} .
Cancelling out the terms inside the first square brackets and cancelling Zis we get
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
ρ I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ} ρσ
1 + (J − 1) ρ
J∑
j=1
Zj − ρσ
J∑
j=1
Zj
−ρσ
i−1∑
j=J+1
Zj + ρσ
i−1∑
j=J+1
{
Zj − ρ
1 + (J − 1) ρ
J∑
l=1
Zl
}
= −ρσ
σ2
ρ I∑
i=J+2
1
f(i)
 1 + (i− 2) ρ1 + (J − 1) ρ
J∑
j=1
Zj −
J∑
j=1
Zj
−
i−1∑
j=J+1
ρ
1 + (J − 1) ρ
J∑
l=1
Zl

 .
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Since
∑i−1
j=J+1
(∑J
l=1 Zl
)
= (i− 1− J)∑Jl=1 Zl, we get
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= −ρ
2
σ
 I∑
i=J+2
1
f(i)
 1 + (i− 2) ρ1 + (J − 1) ρ
J∑
j=1
Zj −
J∑
j=1
Zj
− (i− 1− J) ρ
1 + (J − 1) ρ
J∑
j=1
Zj

 .
= −ρ
2
σ
J∑
j=1
Zj
[
I∑
i=J+2
1
f(i)
{
(i− 1− J) ρ− (i− 1− J) ρ
1 + (J − 1) ρ
}]
= 0.
Lemma 6
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= 0,
for k ≥ J + 2.
Proof. In (2.19), splitting the summations
k−1∑
j=1
(σZj −∆j) =
J∑
j=1
(σZj −∆j) +
k−1∑
j=J+1
(σZj −∆j)
and
i−1∑
j=1
(σZj −∆j) =
J∑
j=1
(σZj −∆j) +
i−1∑
j=J+1
(σZj −∆j) ,
we have
∂ logL
∂∆k
= − 1
σ2
−1 + (k − 2) ρ
f(k)
{1 + (k − 2) ρ} (σZk −∆k)− ρ J∑
j=1
(σZj −∆j)
−ρ
k−1∑
j=J+1
(σZj −∆j)

+ρ
I∑
i=k+1
1
f(i)
{1 + (i− 2) ρ} (σZi −∆i)− ρ J∑
j=1
(σZj −∆j)
−ρ
i−1∑
j=J+1
(σZj −∆j)
 .
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Substituting ∆˜s, multiplying out the brackets with
∑J
j=1 (σZj −∆j) and substituting∑J
j=1 ∆˜j = 0, we have
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (k − 2) ρ
f(k)
{1 + (k − 2) ρ}
σZk − σZk + σρ1 + (J − 1) ρ
J∑
j=1
Zj

−ρσ
J∑
j=1
Zj − ρ
k−1∑
j=J+1
{
σZj − σZj + ρσ
1 + (J − 1) ρ
J∑
l=1
Zl
}
+ρ
I∑
i=k+1
1
f(i)
{1 + (i− 2) ρ}
σZi − σZi + ρσ1 + (J − 1) ρ
J∑
j=1
Zj

−ρσ
J∑
j=1
Zj − ρ
i−1∑
j=J+1
{
σZj − σZj − ρσ
1 + (J − 1) ρ
J∑
l=1
Zl
} .
Since
∑i−1
j=J+1
(∑J
l=1 Zl
)
= (i− 1− J)∑Jl=1 Zl, we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − ρ
σ
−1 + (k − 2) ρ
f(k)
 1 + (k − 2) ρ1 + (J − 1) ρ
J∑
j=1
Zj −
J∑
j=1
Zj − ρ (k − 1− J)
1 + (J − 1) ρ
J∑
l=1
Zl

+ρ
I∑
i=k+1
1
f(i)
 1 + (i− 2) ρ1 + (J − 1) ρ
J∑
j=1
Zj −
J∑
j=1
Zj − ρ (i− 1− J)
1 + (J − 1) ρ
J∑
l=1
Zl


= − ρ{1 + (J − 1) ρ}σ
(
−{1 + (k − 2) ρ}
∑J
j=1 Zj
f(k)
[{1 + (k − 2) ρ}
−{1 + (J − 1) ρ} − ρ (k − 1− J)] + ρ
I∑
i=k+1
∑J
j=1 Zj
f(i)
[{1 + (i− 2) ρ}
−{1 + (J − 1) ρ} − ρ (i− 1− J)]
)
= 0.
Lemma 7
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
≥ 0
for k = J .
Proof. Replacing k = J and substituting ∆˜s in (2.19) we have
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (J − 2) ρf(J)
{1 + (J − 2) ρ} (σZJ − 0)− ρσ
 J∑
j=1
Zj − 0

+ρ
I∑
i=J+1
1
f(i)
{1 + (i− 2) ρ}
σZi − σ
Zi − ρ1 + (J − 1) ρ
J∑
j=1
Zj


−ρ
i−1∑
j=1
(σZj −∆j)
 .
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Splitting up the summation of σZj −∆j over j = 1, . . . , i− 1 into
∑J
j=1 plus
∑i−1
j=J+1 in
the last brackets, where
∑J
j=1 ∆˜j = 0, gives
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (J − 2) ρ
f(J)
{1 + (J − 2) ρ}σZJ − ρσ J∑
j=1
Zj

+ρ
I∑
i=J+1
1
f(i)
{1 + (i− 2) ρ}σρ
1 + (J − 1) ρ
J∑
j=1
Zj − ρσ
J∑
j=1
Zj
−ρ
i−1∑
j=J+1
{
ρσ
1 + (J − 1) ρ
J∑
k=1
Zk
} .
Substituting
∑i−1
j=J+1
(∑J
k=1 Zk
)
= (i− 1− J)∑Jj=1 Zj , we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (J − 2) ρ
f(J)
{1 + (J − 2) ρ}σZJ − ρσ J∑
j=1
Zj

+ρ
I∑
i=J+1
1
f(i)
{1 + (i− 2) ρ}σρ
1 + (J − 1) ρ
J∑
j=1
Zj − ρσ
J∑
j=1
Zj
−ρ
2σ (i− 1− J)
1 + (J − 1) ρ
J∑
j=1
Zj
 .
Taking
∑J
j=1 Zj as a common factor and simplifying, we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (J − 2) ρ
f(J)
σZJ (1 + Jρ− 2ρ+ ρ)− ρσ
J∑
j=1
Zj

+ρ2σ
J∑
j=1
Zj
{
I∑
i=J+1
1
f(i)
1 + (i− 2) ρ− 1− (J − 1) ρ− (i− 1− J) ρ
1 + (J − 1) ρ
}
=
1
σ2
1 + (J − 2) ρ
f(J)
σZJ {1 + (J − 1) ρ} − ρσ J∑
j=1
Zj
 .
Replacing σZk with ∆ˆk,
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1 + (J − 2) ρ
σ2f(J)
∆ˆJ {1 + (J − 1) ρ} − ρ J−1∑
j=1
∆ˆj

>
1 + (J − 2) ρ
σ2f(J)
[
∆ˆJ {1 + (J − 1) ρ} − ∆ˆJ
]
,
since
∆ˆJ >
ρ
1 + (J − 2)ρ
J−1∑
j=1
∆ˆj
⇒ −ρ
J−1∑
j=1
∆ˆj > −{1 + (J − 2)ρ}∆ˆJ .
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Hence,
∂ logL
∂∆k
>
1 + (J − 2) ρ
σ2f(J)
∆ˆJρ ≥ 0.
Lemma 8
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
≥ 0,
for k = J − 1.
Proof. Replacing k by J − 1 in (2.19), the ∆k and ∆j in the first square bracket become
zero, the summation before the second square bracket is over i = J, . . . , I and, splitting it
into 3 parts for i = J , i = J + 1 and i = J + 2, . . . , I, we have
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (J − 3) ρ
f(J − 1)
{1 + (J − 3) ρ}σZJ−1 − ρσ J−2∑
j=1
Zj

+ρ
1
f(J)
{1 + (J − 2) ρ} (σZJ −∆J)− ρ J−1∑
j=1
(σZj −∆j)

+ρ
1
f(J + 1)
{1 + (J − 1) ρ} (σZJ+1 −∆J+1)− ρ J∑
j=1
(σZj −∆j)

+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ} (σZi −∆i)− ρ i−1∑
j=1
(σZj −∆j)
 .
Substituting ∆˜J = 0, and
∑J−1
j=1 ∆˜j = 0 in the second square bracket, the value of ∆˜J+1
and
∑J
j=1 ∆˜j = 0 in the third square bracket and the value of ∆˜i in the fourth square
bracket, we split the summation
∑i−1
j=1 (σZj −∆j) into
∑J
j=1 (σZj −∆j)+
∑i−1
j=J+1 (σZj −∆j)
(because the value of ∆j depends on whether j = 1, . . . , J or j = J + 1, . . . , i − 1) and
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substitute the value of
∑J
j=1 ∆˜j = 0 and the value of ∆˜j for j ≥ J + 1, to obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (J − 3) ρ
f(J − 1)
{1 + (J − 3) ρ}σZJ−1 − ρσ J−2∑
j=1
Zj

+ρ
1
f(J)
{1 + (J − 2) ρ}σZJ − ρ J−1∑
j=1
σZj

+ρ
1
f(J + 1)
{1 + (J − 1) ρ}σ
ZJ+1 − ZJ+1 + ρ1 + (J − 1) ρ
J∑
j=1
Zj

−ρ
J∑
j=1
σZj

+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 1) ρ}σ
Zi − Zi + ρ1 + (J − 1) ρ
J∑
j=1
Zj

−ρ
J∑
j=1
σZj − ρ
i−1∑
j=J+1
σ
{
Zj − Zj + ρ
1 + (J − 1) ρ
J∑
l=1
Zl
} .
Simplifying the third square bracket, it becomes zero and, in the fourth square bracket,
simplifying and substituting
∑i−1
j=J+1
(∑J
l=1 Zl
)
= (i− 1− J)∑Jj=1 Zj , we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (J − 3) ρ
f(J − 1)
{1 + (J − 3) ρ}σZJ−1 − ρσ J−2∑
j=1
Zj

+ρ
1
f(J)
{1 + (J − 2) ρ}σZJ − ρ J−1∑
j=1
σZj

+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ} σρ
1 + (J − 1) ρ
J∑
j=1
Zj − ρσ
J∑
j=1
Zj
−ρ
2σ (i− 1− J)
1 + (J − 1) ρ
J∑
j=1
Zj
 .
Taking out ρσ
∑J
j=1 Zj as a common factor in the third square bracket and simplifying,
it becomes zero, so that
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (J − 3) ρ
f(J − 1)
{1 + (J − 3) ρ}σZJ−1 − ρσ J−2∑
j=1
Zj

+ρ
1
f(J)
{1 + (J − 2) ρ}σZJ − ρ J−1∑
j=1
σZj
 .
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Now substituting in the values of f(J − 1) and f(J), we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−{1 + (J − 3) ρ}
[
{1 + (J − 3) ρ}σZJ−1 − ρσ
∑J−2
j=1 Zj
]
{1 + (J − 3) ρ} {1 + (J − 2) ρ} (1− ρ)
+
ρ
[
{1 + (J − 2) ρ}σZJ − ρ
∑J−1
j=1 σZj
]
{1 + (J − 2) ρ} {1 + (J − 1) ρ} (1− ρ)
 .
Taking over a common denominator and simplifying, we get
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2f(J)
[
− {1 + (J − 1) ρ} {1 + (J − 3) ρ}σZJ−1
+ {1 + (J − 1) ρ} ρσ
J−2∑
j=1
Zj + {1 + (J − 1) ρ}σρZJ − ρ2σ
J−1∑
j=1
Zj
 .
Rewriting
∑J−1
j=1 Zj =
∑J−2
j=1 Zj + ZJ−1 in the last term, this becomes
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2f(J)
[
− {1 + (J − 1) ρ} {1 + (J − 3) ρ}σZJ−1
+ {1 + (J − 1) ρ} ρσ
J−2∑
j=1
Zj + {1 + (J − 2) ρ}σρZJ − ρ2σ
J−2∑
j=1
Zj
−ρ2σZJ−1
]
.
Gathering σZJ−1 and ρσ
∑J−2
j=1 Zj terms, we have
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
−1
σ2f(J)
([−{1 + (J − 1) ρ} {1 + (J − 3) ρ} − ρ2]σZJ−1
+ [{1 + (J − 1) ρ} − ρ] ρσ
J−2∑
j=1
Zj + {1 + (J − 2) ρ} ρσZJ
 .
Multiplying out the two braces in the first square bracket and multiplying throughout by
−1 we get
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1
σ2f(J)
[{
1 + (J − 1) ρ+ (J − 3) ρ+ (J − 1) (J − 3) ρ2 + ρ2}σZJ−1
−{1 + (J − 2) ρ} ρσ
J−2∑
j=1
Zj − {1 + (J − 2) ρ} ρσZJ
 .
Collecting ρ and ρ2 terms, substituting σZk = ∆ˆk and simplifying gives
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1
σ2f(J)
[{
1 + 2 (J − 2) ρ+ (J − 2)2 ρ2
}
∆ˆJ−1
−{1 + (J − 2) ρ} ρ
J−2∑
j=1
∆ˆj − {1 + (J − 2) ρ} ρ∆ˆJ
 .
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Writing the first braces as a perfect square of {1 + (J − 2) ρ}2 and simplifying gives
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1 + (J − 2) ρ
σ2f(J)
{1 + (J − 2) ρ} ∆ˆJ−1 − ρ J−2∑
j=1
∆ˆj − ρ∆ˆJ
 .
Since
∆ˆJ−1 >
ρ
1 + (J − 3)ρ
J−2∑
j=1
∆ˆj
⇒ −{1 + (J − 3)ρ}∆ˆJ−1 < −ρ
J−2∑
j=1
∆ˆj ,
we get the inequality
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
>
1 + (J − 2) ρ
σ2f(J)
ρ(∆ˆJ−1 − ∆ˆJ)
≥ 0,
since ∆ˆJ−1 > ∆ˆJ .
To prove the final result, we need the following Lemma.
Lemma 9 For r = 0, . . . , J − k − 2,
{1 + (k + r) ρ} ∆ˆk − ρ
∑k+r+1
j=1 ∆ˆj
1 + (k + r) ρ
− ρ{1 + (k + r) ρ} ∆ˆk+r+2 − ρ
∑k+r+1
j=1 ∆ˆj
{1 + (k + r) ρ} {1 + (k + r + 1) ρ}
=
{1 + (k + r) ρ} ∆ˆk − ρ
∑k+r+2
j=1 ∆ˆj
1 + (k + r + 1) ρ
Proof.
{1 + (k + r) ρ} ∆ˆk − ρ
∑k+r+1
j=1 ∆ˆj
1 + (k + r) ρ
− ρ{1 + (k + r) ρ} ∆ˆk+r+2 − ρ
∑k+r+1
j=1 ∆ˆj
{1 + (k + r) ρ} {1 + (k + r + 1) ρ}
=
{1 + (k + r) ρ} {1 + (k + r + 1) ρ} ∆ˆk − ρ {1 + (k + r + 1) ρ− ρ}
∑k+r+1
j=1 ∆ˆj − ρ {1 + (k + r) ρ} ∆ˆk+r+2
{1 + (k + r) ρ} {1 + (k + r + 1) ρ}
=
{1 + (k + r + 1) ρ} ∆ˆk − ρ
∑k+r+2
j=1 ∆ˆj
1 + (k + r + 1) ρ
.
Lemma 10
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
≥ 0,
for k ≤ J − 2.
Proof. In (2.19), for k ≤ J − 2, ∆˜k and
∑k
j=1 ∆j become zero in the first large braces.
Splitting the summation before the second braces over i = k+1, . . . , I into i = k+1, . . . , J
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plus i = J + 1 plus i = J + 2, . . . , I, we get
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (k − 2) ρf(k)
{1 + (k − 2) ρ}σZk − ρσ k∑
j=1
Zj

+
ρ J∑
i=k+1
1
f(i)
{1 + (i− 2) ρ}(σZi − ∆˜i)− ρ i−1∑
j=1
(
σZj − ∆˜j
)
+ρ
1
f(J + 1)
{1 + (J − 1) ρ}(σZJ+1 − ∆˜J+1)− ρ J∑
j=1
(
σZj − ∆˜j
)
+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ}(σZi − ∆˜i)− ρ i−1∑
j=1
(
σZj − ∆˜j
) .
The summation before the second square bracket is i = k + 1, . . . , J , so both ∆˜i and
∆˜j become zero. In the third square bracket, substituting the value of ∆˜J+1 and zero
for ∆˜j , since j = 1, . . . , J , and in the fourth square bracket substituting the value of ∆˜i
and splitting
∑i−1
j=1 (σZj −∆j) into the sums over j = 1, . . . , J (where ∆˜j = 0) and over
j = J + 1, . . . , i− 1 and substituting the value of ∆˜j , we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (k − 2) ρ
f(k)
{1 + (k − 2) ρ}σZk − ρσ k∑
j=1
Zj

+ρ
J∑
i=k+1
1
f(i)
{1 + (i− 2) ρ}σZi − ρ i−1∑
j=1
σZj

+ρ
1
f(J + 1)
{1 + (J − 1) ρ}σ
ZJ+1 − ZJ+1 + ρ1 + (J − 1) ρ
J∑
j=1
Zj

−ρ
J∑
j=1
σZj

+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ}σ
Zi − Zi + ρ1 + (J − 1) ρ
J∑
j=1
Zj

−ρ
J∑
j=1
σZj − ρ
i−1∑
j=J+1
σ
{
Zj − Zj + ρ
1 + (J − 1) ρ
J∑
l=1
Zl
} .
After simplification the third square bracket becomes zero. In the fourth square bracket∑i−1
j=J+1
∑J
l=1 Zl = (i− 1− J)
∑J
j=1 Zl, since the second summation is independent of the
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first summation, so we get
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (k − 2) ρ
f(k)
{1 + (k − 2) ρ}σZk − ρσ k∑
j=1
Zj

+ρ
J∑
i=k+1
1
f(i)
{1 + (i− 2) ρ}σZi − ρ i−1∑
j=1
σZj

+ρ
I∑
i=J+2
1
f(i)
{1 + (i− 2) ρ} ρ
1 + (J − 1) ρ
J∑
j=1
σZj − ρ
J∑
j=1
σZj
−ρ
2 (i− 1− J)
1 + (J − 1) ρ
J∑
j=1
σZj
 .
In the third square bracket, taking out ρσ
∑J
j=1 Zj as a common factor and simplifying,
we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
= − 1
σ2
−1 + (k − 2) ρ
f(k)
{1 + (k − 2) ρ}σZk − ρσ k∑
j=1
Zj

+ρ
J∑
i=k+1
1
f(i)
{1 + (i− 2) ρ}σZi − ρ i−1∑
j=1
σZj

+ρ2σ
J∑
j=1
Zj
I∑
i=J+2
1
f(i)
{
1 + (i− 2) ρ− 1− (J − 1) ρ− (i− 1− J) ρ
1 + (J − 1) ρ
} .
Substituting f(k) and f(i) and noting that, after simplification, the third square bracket
becomes zero, we get
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1
σ2
(
{1 + (k − 2) ρ}σZk
{1 + (k − 1) ρ} (1− ρ) −
ρσ
∑k
j=1 Zj
{1 + (k − 1) ρ} (1− ρ)
−ρ
J∑
i=k+1
[
σZi
{1 + (i− 1) ρ} (1− ρ) −
ρ
∑i−1
j=1 σZj
{1 + (i− 2) ρ} {1 + (i− 1) ρ} (1− ρ)
])
.
Substituting σZj = ∆ˆj , this simplifies to
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1
σ2
[
{1 + (k − 2) ρ} ∆ˆk − ρ
∑k
j=1 ∆ˆj
{1 + (k − 1) ρ} (1− ρ)
−ρ
J∑
i=k+1
{1 + (i− 2) ρ} ∆ˆi − ρ
∑i−1
j=1 ∆ˆj
{1 + (i− 2) ρ} {1 + (i− 1) ρ} (1− ρ)
]
.
Splitting the summation over i = k+1, . . . , J into parts for k+1 and over i = k+2, . . . , J
and then simplifying, we obtain
∂ logL
∂∆k
∣∣∣∣∣
∆=∆˜
=
1
σ2 (1− ρ)
[ {1 + (k − 2) ρ} (1 + kρ) ∆ˆk − ρ (1 + kρ)∑kj=1 ∆ˆj − ρ {1 + (k − 1) ρ} ∆ˆk+1 + ρ2∑kj=1 ∆ˆj
{1 + (k − 1) ρ} (1 + kρ)
−ρ
J∑
i=k+2
{1 + (i− 2) ρ} ∆ˆi − ρ
∑i−1
j=1 ∆ˆj
{1 + (i− 2) ρ} {1 + (i− 1) ρ}
 .
CHAPTER 2. MODEL AND TEST PROCEDURES 63
Gathering ∆ˆk terms and
∑k
j=1 ∆ˆj terms, we get
∂ logL
∂∆k
∣∣∣∣∣
∆=∆˜
=
1
σ2 (1− ρ)

{
1 + (k − 2) ρ + kρ + k (k − 2) ρ2 + ρ2
}
∆ˆk +
(
ρ2 − ρ− kρ2
)∑k
j=1 ∆ˆj − ρ {1 + (k − 1) ρ} ∆ˆk+1
{1 + (k − 1) ρ} (1 + kρ)
−ρ
J∑
i=k+2
{1 + (i− 2) ρ} ∆ˆi − ρ
∑i−1
j=1 ∆ˆj
{1 + (i− 2) ρ} {1 + (i− 1) ρ}

=
1
σ2 (1− ρ)
[ {1 + (k − 1) ρ}2 ∆ˆk − ρ {1 + (k − 1) ρ}∑kj=1 ∆ˆj − ρ {1 + (k − 1) ρ} ∆ˆk+1
{1 + (k − 1) ρ} (1 + kρ)
−ρ
J∑
i=k+2
{1 + (i− 2) ρ} ∆ˆi − ρ
∑i−1
j=1 ∆ˆj
{1 + (i− 2) ρ} {1 + (i− 1) ρ}
 .
Taking out {1 + (k − 1) ρ} as a common factor in the first term inside the square bracket
and simplifying, we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1
σ2 (1− ρ)
[
{1 + (k − 1) ρ} ∆ˆk − ρ
∑k
j=1 ∆ˆj − ρ∆ˆk+1
1 + kρ
−ρ
J∑
i=k+2
{1 + (i− 2) ρ} ∆ˆi − ρ
∑i−1
j=1 ∆ˆj
{1 + (i− 2) ρ} {1 + (i− 1) ρ}
]
.
Rewriting −ρ∑kj=1 ∆ˆj − ρ∆ˆk+1 = −ρ∑k+1j=1 ∆ˆj + ρ∆ˆk, this becomes
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1
σ2 (1− ρ)
[
{1 + (k − 1) ρ} ∆ˆk − ρ
∑k+1
j=1 ∆ˆj + ρ∆ˆk
1 + kρ
−ρ
J∑
i=k+2
{1 + (i− 2) ρ} ∆ˆi − ρ
∑i−1
j=1 ∆ˆj
{1 + (i− 2) ρ} {1 + (i− 1) ρ}
]
=
1
σ2 (1− ρ)
[
(1 + kρ) ∆ˆk − ρ
∑k+1
j=1 ∆ˆj
1 + kρ
−ρ
J∑
i=k+2
{1 + (i− 2) ρ} ∆ˆi − ρ
∑i−1
j=1 ∆ˆj
{1 + (i− 2) ρ} {1 + (i− 1) ρ}
]
.
Again splitting the summation over i = k + 2, . . . , J into parts for k + 2 and over i =
k + 3, . . . , J and then simplifying, we obtain
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1
σ2 (1− ρ)
[
(1 + kρ) ∆ˆk − ρ
∑k+1
j=1 ∆ˆj
1 + kρ
− ρ(1 + kρ) ∆ˆk+2 − ρ
∑k+1
j=1 ∆ˆj
(1 + kρ) {1 + (k + 1) ρ}
−ρ
J∑
i=k+3
{1 + (i− 2) ρ} ∆ˆi − ρ
∑i−1
j=1 ∆ˆj
{1 + (i− 2) ρ} {1 + (i− 1) ρ}
]
.
Now, repeatedly applying Lemma 6, and writing ρ
∑J
j=1 ∆ˆj = ρ
∑J−1
j=1 ∆ˆj + ρ∆ˆJ , we get
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
=
1
σ2 (1− ρ)
[
{1 + (J − 1) ρ} ∆ˆk − ρ
∑J
j=1 ∆ˆj
1 + (J − 1) ρ
]
=
1
σ2 (1− ρ)
[
{1 + (J − 1) ρ} ∆ˆk − ρ∆ˆJ − ρ
∑J−1
j=1 ∆ˆj
1 + (J − 1) ρ
]
.
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Now ∆ˆk ≥ ∆ˆJ , k < J ⇒ ∆ˆk ≥ ∆ˆJ so replacing the first term {(J − 1) ρ} ∆ˆk by
{(J − 1) ρ} ∆ˆJ , we have the inequality
∂ logL
∂∆k
∣∣∣∣
∆= ˜∆
≥ 1
σ2 (1− ρ)
[
{1 + (J − 1) ρ} ∆ˆJ − ρ∆ˆJ − ρ
∑J−1
j=1 ∆ˆj
1 + (J − 1) ρ
]
=
{1 + (J − 2) ρ} ∆ˆJ − ρ
∑J−1
j=1 ∆ˆj
σ2 (1− ρ) {1 + (J − 1) ρ} .
Also
∆ˆJ ≥ ρ
1 + (J − 2)ρ
J−1∑
i=1
∆ˆj
⇒ {1 + (J − 2) ρ}∆ˆj ≥ ρ
J−1∑
i=1
∆ˆj ,
and so
∂ logL
∂∆k
≥ 0.
We have proved that (2.20) gives the restricted MLEs under H0.
2.5.3 Proof of Theorem 4
From (2.8), (2.13), (2.14) and (2.17), twice the log-likelihood ratio is
λ = − 1
σ2
 I∑
i=1
1
f(i)
σ√f(i)Ui − {1 + (i− 2) ρ} ∆ˆi + ρ i−1∑
j=1
∆ˆj
2
+
1
σ2
 I∑
i=1
1
f(i)
σ√f(i)Ui − {1 + (i− 2) ρ} ∆˜i + ρ i−1∑
j=1
∆˜j
2 .
Since the first square bracket with unrestricted MLEs is equal to zero, we obtain
λ =
1
σ2
 I∑
i=1
1
f(i)
σ√f(i)Ui − {1 + (i− 2) ρ} ∆˜i + ρ
i−1∑
j=1
∆˜j

2 . (2.21)
Splitting the summation into parts over i = 1, . . . , J and i = J + 1, . . . , I, we get
λ =
1
σ2
 J∑
i=1
1
f(i)
σ√f(i)Ui − {1 + (i− 2) ρ} ∆˜i + ρ i−1∑
j=1
∆˜j
2
+
I∑
i=J+1
1
f(i)
σ√f(i)Ui − {1 + (i− 2) ρ} ∆˜i + ρ i−1∑
j=1
∆˜j
2 .
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For i = 1, . . . , J , ∆˜i is zero. Hence, substituting the values of ∆˜i and Ui from (2.20) and
(2.10) respectively and simplifying we get
λ =
1
σ2
 J∑
i=1
1
f(i)
[
σ {1 + (i− 2) ρ}Zi − σρ
i−1∑
k=1
Zk
]2
+
I∑
i=J+1
1
f(i)
σ {1 + (i− 2) ρ}Zi − ρσ i−1∑
j=1
Zk − {1 + (i− 2) ρ} ∆˜i + ρ
i−1∑
j=1
∆˜j
2 .
Replacing
∑i−1
j=1 ∆˜j by
∑i−1
j=J+1 ∆˜j in the second braces, since ∆˜s = 0 for s = 1, . . . , J ,
substituting the value of ∆˜s for s = J + 1, . . . , I and simplifying we get
λ =
1
σ2
 J∑
i=1
1
f(i)
[
σ {1 + (i− 2) ρ}Zi − σρ
i−1∑
k=1
Zk
]2
+
I∑
i=J+1
1
f(i)
−ρσ i−1∑
k=1
Zk +
{1 + (i− 2) ρ}σρ
1 + (J − 1) ρ
J∑
j=1
Zj
+ρσ
i−1∑
j=J+1
{
Zj − ρ
1 + (J − 1) ρ
J∑
k=1
Zk
}2 .
Multiplying out the last braces in the second square brackets and simplifying, we get
λ =
1
σ2
 J∑
i=1
1
f(i)
[
σ {1 + (i− 2) ρ}Zi − σρ
i−1∑
k=1
Zk
]2
+
I∑
i=J+1
1
f(i)
−ρσ J∑
j=1
Zj +
{1 + (i− 2) ρ} ρσ
1 + (J − 1) ρ
J∑
j=1
Zj − (i− J − 1)σρ
2
1 + (J − 1) ρ
J∑
j=1
Zj
2 .
Simplifying the second square brackets, we obtain
λ =
J∑
i=1
1
f(i)
{1 + (i− 2) ρ}Zi − ρ i−1∑
j=1
Zj
2
+ρ
J∑
j=1
Zj
{
I∑
i=J+1
1
f(i)
−1− (J − 1) ρ+ 1 + (i− 2) ρ− (i− J − 1) ρ
1 + (J − 1) ρ
}2
=
J∑
i=1
1
f(i)
{1 + (i− 2) ρ}Zi − ρ i−1∑
j=1
Zj
2 .
Finally substituting f(i) from (2.12), we obtain
λ =
J∑
i=1
[
{1 + (i− 2) ρ}Zi − ρ
∑i−1
j=1 Zj
]2
{1 + (i− 2) ρ} {1 + (i− 1) ρ} (1− ρ)
= Z21 +
I∑
j=2
(Zj − Ej)2
Vj
.
Since in Case 0, λ = 0, it follows that λ = T 22 .
Chapter 3
Properties of Test Statistics
Since the properties of the test statistics defined in the previous chapter are not com-
pletely known, and there is no uniformly most powerful test, it is not clear which is best
for practical use in clinical trials. In this chapter we study their properties. The aim
of this chapter is to compare the performances of different test procedures, in terms of
maximising power and correctly selecting the best treatment, in the case of equal allo-
cation. Other allocations will be studied in Chapter 4. The emphasis is on three-arm
trials, though we also briefly consider trials with more arms. Various authors (Robertson
et al., 1988; Dunnett and Tamhane, 1992; Horn and Vollandt, 1998; Horn and Dunnett,
2004) have compared some of these tests in terms of power. The comparison here is more
comprehensive than those.
The null distributions of the test statistics for three arms are studied in Section 3.1.
We prove a theorem which allows us to obtain the critical values for rejecting the null
hypothesis by simulating from a single point within the parameter space defined by H0 :
∆i ≤ 0 ∀i and show that all of the test statistics we consider satisfy the conditions of
the theorem. Simulation under the null hypothesis is used to determine the boundaries of
the critical regions at 5, 2.5 and 1% for I = 2. Various graphs are given to illustrate the
null distributions and the rejection boundaries. In Section 3.2 examples of the practical
implementation of the tests are given. More simulations are reported which illustrate the
properties of the tests in Section 3.3. Power functions calculated from the simulation
results are shown in graphs and tables. A loss function, which takes account of type III
and IV errors and their impact, is defined and the expected loss is shown in graphs and
tables. Some conclusions are drawn in Section 3.4. The specific problem of the probability
of a type-III error being greater than the size of the test is considered in Section 3.5. We
also briefly study I = 3 and I = 7 in Section 3.6 and give results in terms of power and
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expected loss.
3.1 Null distributions
3.1.1 A general result for calculating the null distribution
As emphasised in earlier chapters, the null hypothesis H0 : ∆ ≤ 0 ∀i we consider is
composite, which means that the null distributions of the test statistics are not fully
determined but depend on which values the parameters take within the set defined by H0.
Hence, the probability of a type I error depends on the specific parameter values and, in
order to find critical values for a test at a fixed significance level, or to find p-values, we
need to find the maximum probability of a type I error over all parameter values in the
set defined by H0. We now show that this is easily accomplished and that we need only
calculate these probabilities when all treatments are equivalent to the control, i.e. when
∆ = 0.
Lemma 11 Let Z ∼ NI (∆,Σ), where Σ = ρJ+(1− ρ) I, I is the I-dimensional identity
matrix and J is an I×I matrix of 1s. Let ∆1 and ∆2 be I×1 vectors such that ∆1i ≤ ∆2i,
∀i ∈ {1, . . . , I}. Let Ak = {z : zi ≤ aki; i = 1, . . . , I}, k = 1, . . . ,m, where aki are real
constants.
P
(
Z ∈
m⋃
k=1
Ak
∣∣∣∣∣∆ = ∆1
)
≥ P
(
Z ∈
m⋃
k=1
Ak
∣∣∣∣∣∆ = ∆2
)
.
Proof. By the inclusion-exclusion theorem in probability,
P
(
Z ∈
m⋃
k=1
Ak
∣∣∣∣∣∆ = ∆j
)
=
m∑
k=1
(−1)k−1
∑
K∈K
P
(
Z ∈
⋂
l∈K
Al
∣∣∣∣∣∆ = ∆j
)
,
where j = 1, 2 and K is the set of K ⊂ {1, . . . ,m} such that |K| = k. Then
P
(
Z ∈
m⋃
k=1
Ak
∣∣∣∣∣∆ = ∆j
)
=
m∑
k=1
(−1)k−1
∑
K∈K
P
(
Z1 ≤ min
l∈K
(al1) , . . . , ZI ≤ min
l∈K
(alI)
∣∣∣∣∆ = ∆j)
=
m∑
k=1
(−1)k−1
∑
K∈K
Fj
(
min
l∈k
(al1) , . . . ,min
l∈k
(alI) ,
)
,
where Fj is the c.d.f. of N (∆j ,Σ) , j = 1, 2. Therefore,
P
(
Z ∈
m⋃
k=1
Ak
∣∣∣∣∣∆ = ∆j
)
=
m∑
k=1
(−1)k−1
∑
K∈K
Φ
(
min
l∈k
(al1)−∆j1, . . . ,min
l∈k
(alI)−∆jI
)
,
where Φ is the c.d.f. of N (0,Σ).
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Hence,
P
Z ∈ m⋃
j=1
Ak
∣∣∣∣∣∣∆ = ∆1
 = m∑
k=1
(−1)k−1
∑
K∈K
Φ
(
min
l∈k
(al1)−∆11, . . . ,min
l∈k
(alI)−∆1I
)
=
m∑
k=1
(−1)k−1
∑
K∈K
F2
(
min
l∈k
(al1)−∆11 + ∆21, . . .
. . . ,min
l∈k
(alI)−∆1I + ∆2I
)
= P
Z ∈ m⋃
j=1
Ck
∣∣∣∣∣∣∆ = ∆2
 ,
where Ck = {z : zi ≤ aki −∆1i + ∆2i; i = 1, . . . , I}, k = 1, . . . ,m.
Since ∆1i ≤ ∆2i, i = 1, . . . , I,
⋃m
k=1Ak ⊂
⋃m
k=1Ck and this implies that
P
Z ∈ m⋃
j=1
Ak
∣∣∣∣∣∣∆ = ∆1
 ≥ P
Z ∈ m⋃
j=1
Ak
∣∣∣∣∣∣∆ = ∆2
 .
By letting m→∞, we obtain the following corollary.
Corollary 12
P
(
Z ∈
∞⋃
k=1
Aj
∣∣∣∣∣∆ = ∆1
)
≥ P
(
Z ∈
∞⋃
k=1
Aj
∣∣∣∣∣∆ = ∆2
)
.
Then the following result follows immediately.
Theorem 13 Under H0, P (Reject H0 |∆) is maximised when ∆ = 0 if the acceptance
region of H0 can be written as
⋃m
k=1Ak or
⋃∞
k=1Ak.
Note that we do not actually require Z to have a normal distribution, although that is the
case we use in this thesis. All that is needed is that the second and higher order moments
of the distribution of Z do not depend on the mean vector ∆.
Corollary 14 Lemma 11, Corollary 12 and Theorem 13 hold for any family of distribu-
tions of Zi having cumulative distribution function Fi, where Fi(z) = F0(z −∆i) with F0
having zero expectation and unit variance.
This seems to be a useful general result which, to the best of our knowledge, has not been
previously published in this generality. Silvapulle and Sen (2005) showed the same result
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for a class of likelihood ratio test statistics, which includes T 22 , but none of the other test
procedures considered here.
Any real-valued test statistic which is non-decreasing if the value of any Zi increases, has
an acceptance region with the required form. This is clear, since any point ak on the
rejection boundary has the property that any z, such that zi ≤ aki ∀k ∈ {1, . . . , I}, is in
the acceptance region.
From the definitions of the T 0k and Tk, given in equations (2.2) and (2.7) respectively in
Chapter 2, it can be seen that each Zi contributes only if it is greater than zero and this
contribution increases with Zi. Hence, all test statistics in the families T
0
k and Tk are
non-decreasing in each Zi and hence Theorem 13 applies to all of these procedures. This
is not in general true for the family S0k , but it is true for S
0
1 , which is the only member
of this family we consider here. Hochberg’s procedure does not correspond to a single
real-valued test statistic, so we need to consider it separately.
From Chapter 2, Hochberg’s procedure rejects H0 if, for any j ∈ {1, . . . , I}, Xj ≥
zα∗/(I−j+1) for a suitably chosen constant α∗. Hence, H0 is accepted if, for all j, Xj <
zα∗/(I−j+1). This acceptance region can clearly be written in the form of a union of sets
of the form Ak and so Hochberg’s procedure satisfies Theorem 13.
All of these results can be seen graphically for I = 2 and we will do this in Section 3.1.4.
3.1.2 Evaluating the null distributions
We have shown in Section 3.1.1 that, for all test statistics considered here, if P (type I error|
∆ = 0) = α then, for any ∆ within H0, P (type I error|∆) ≤ α. Hence we consider the
null distributions at ∆ = 0. All distributional statements in the rest of this section are
to be understood as being for ∆ = 0. It should be noted, however, that when H0 is true,
the probability of rejecting H0 might be less than 100α%.
The tests statistics and the key notations defined in Chapter 2 are shown again in Table
3.1 for I = 2.
It is trivial to show that S01 ∼ N(0, 3), so standard normal tables can be used. The null
distribution of T∞ can be obtained by numerical integration of the bivariate normal density
(Dunnett, 1955), which is available in several packages, including R (R Development Core
Team, 2009). The Hochberg procedure does not use a univariate test statistic so the
decision to accept or reject H0 is based directly on the bivariate normal density function
CHAPTER 3. PROPERTIES OF TEST STATISTICS 70
Table 3.1: Test statistics and some key notations from Chapter 2.
S01 = Z1 + Z2
T 01 = Z
+
1 + Z
+
2
T 02 =
√
Z+21 + Z
+2
2
T∞ = max(Z1, Z2)+
T1 = max(Z1, Z2)
+ + (min(Z1,Z2)−ρmax(Z1,Z2))
+√
1−ρ2
T2 =
√
max(Z1, Z2)+2 +
(min(Z1,Z2)−ρmax(Z1,Z2))+2
1−ρ2
A+ = max(0, A)
ρ = Cov(Z1, Z2) = δ/{1− δ}
E(Zi) = ∆i/σ, i = 1, 2
σ2 = {1− δ}/{δ(1− 2δ)}
and so is easily computed, but here we use an adjusted α∗, which is not known, to achieve
true size α, so that further work is required to find the rejection region. Mukerjee et al.
(1985) and Robertson et al. (1988) showed that the LRT statistic T 22 has a mixture of
χ2 distributions but with unknown mixing probabilities. They developed approximations
which are quite complex to compute and whose accuracy is not completely known. Indeed,
Sen and Silvapulle (2001) suggested that these difficulties were the main reason for the
lack of application of likelihood ratio tests in the general area of order restricted inference.
Nothing is known about the null distribution of any of the other test statistics used here.
3.1.3 Simulations
The distributions of all the test statistics were approximated by Monte Carlo simulations,
including for comparability those which can be calculated directly, in order to compare
their properties. These simulations are then used to determine the boundaries of the
critical regions at 5, 2.5 and 1%. The correlation was set to be ρ = 0.5, which corresponds
to equal numbers of subjects in each arm.
The null distributions were approximated by simulating one million values of Z1 and Z2
with ∆1 = ∆2 = 0 using the mvrnorm function in R, specifying the expectation to be a
zero vector and the covariance matrix to be
Σ = (1− ρ)I + ρJ,
where I is the I × I identity matrix and J is an I × I matrix of ones. The value of each
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test statistic is calculated from each of these pairs of Z1 and Z2. For all tests except the
Hochberg procedure, the critical region at 100α% was defined by the biggest 100α% of the
one million values of the test statistic, since the tests are one-sided. Although the critical
points estimated were reasonably stable, in order to improve the accuracy we repeated
this whole procedure 1000 times and the mean of the critical points was used. The null
hypothesis should be rejected if the value of the test statistic is greater than the calculated
critical value.
For Hochberg’s procedure, the nominal α∗ was found iteratively so as to achieve the
required size in a separate batch of two million simulations. We also used the tabulated
critical values, i.e. the procedure of Hochberg (1988) in its original form, and found that
they are indeed conservative, as expected. Since all the other procedures studied here
have exact size α (up to the accuracy of the simulations), we do not present the results
from the conservative Hochberg procedure and in the remainder of this chapter references
to Hochberg’s procedure refer to the modified procedure with exact size α.
3.1.4 Results
The estimated mean cutpoints at which the 5%, 2.5% and 1% rejection region boundaries
cross the Z1 and Z2 axes for each of the test statistics is shown in Table 3.2, along
with their estimated standard errors. The standard errors are estimated by taking the
sample variance of each of 10 batches of 100 simulated cutpoints, each from one million
simulations, and pooling them to obtain an estimate of the variance of cutpoints calculated
from a billion simulations. The square root of this is the standard error reported. Since
each set of one million simulations takes several minutes to run, obtaining more precision
would take a considerable amount of computing time, at least using the R (R Development
Core Team, 2009) package.
The estimated standard errors show that the cutpoints are precise to at least three decimal
places, and reasonably precise to four decimal places, although the critical values for
1% are slightly less well estimated than the others. Using the pmnorm function in R
(R Development Core Team, 2009) for numerical integration of bivariate normal density
functions we calculated, by repeated interpolation, the upper 95%, 97.5% and 99% values
for T∞ to be 1.91633, 2.21214 and 2.55782 respectively. The mean cutpoints in Table
3.2 to one additional decimal place are 1.91635, 2.21210 and 2.55772 and so are accurate
enough, at least for T∞, for all practical purposes. For S01 the distribution is N(0, 3),
from which we can easily calculate the values 2.85030, 3.39575 and 4.02275, for 5%, 2.5%
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Table 3.2: Mean (s.e.) of the cutpoints of the rejection region boundaries with ρ = 0.5.
Test 5% 2.5% 1%
S01 2.8488 3.3948 4.0291
(0.00011) (0.00014) (0.00021)
T1 2.1537 2.5289 2.9839
(0.00008) (0.00010) (0.00015)
T2 1.9545 2.2579 2.6120
(0.00006) (0.00008) (0.00012)
T∞ 1.9163 2.2121 2.5577
(0.00006) (0.00008) (0.00011)
T 01 2.8505 3.3950 4.0291
(0.00011) (0.00014) (0.00021)
T 02 2.1671 2.5301 2.9584
(0.00002) (0.00010) (0.00014)
Hoch∗ 1.9381 2.2265 2.5662
* Simulated separately and based on nominal α∗ such that the size is α.
and 1% respectively, compared with the mean cutpoints from the simulations of 2.84883,
3.39476 and 4.02912. Although these are not as close as for T∞ (see also the estimated
standard errors in Table 3.2), they are good enough for practical purposes. For example,
they are at least an order of magnitude better than using 2.58, rather than 2.5758, for the
upper 0.5% point in a standard normal distribution. In Section 3.3, we will consider the
impact of the variances of the cutpoints on the power of the tests.
For the modified Hochberg procedure used, the nominal α∗ values are 0.02631, 0.01299
and 0.00514 for 5%, 2.5% and 1% respectively. Since this was based on a separate batch
of two million simulations, these cutpoints are less precise. A rough calculation suggests
that their standard errors should be about
√
500 times those shown, giving approximately
0.002, so the cutpoints should be precise to two, and reasonably precise to three, decimal
places.
Figure 3.1 shows histograms of the null distributions for five of the test statistics at 5%,
with zeros deleted to make the pattern clearer. Around one third of the simulations gave
zero for all the test statistics except S01 , corresponding to the case where both experimental
arms give worse responses than the control. The theoretical value of this is exactly 1/3,
since, with equal sample sizes, it is completely random chance which of the three arms gives
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the highest response. Note that in this and several of the following figures, T3 refers to
T∞. All the distributions seem from the histograms to be fairly close to normal truncated
below their means, but normal probability plots (not shown) show that this is not a good
enough approximation. Since the null distribution of S01 is known to be N(0,3), we do not
show it. Hochberg’s procedure does not use a real-valued test statistic, so we do not plot
its null distribution.
The rejection boundary at the 5% level of significance for each test statistic is plotted,
along with the contours of the joint p.d.f. of Z1 and Z2 under H0 at ∆ = 0, in Figure 3.2.
It can be seen that every rejection boundary crosses each other boundary at some point,
since all tests are at 5%. Each test “slices off” 5% of the bivariate probability distribution,
but uses a different pattern to slice off a different 5%. It is also immediately clear that all
the rejection boundaries meet the conditions for Theorem 13 to hold.
We see that T∞, T2 and Hochberg’s procedure are all fairly similar, but have noticeable
differences close to Z1 = Z2. The simplest rejection boundary is that of T∞ and this is
one reason for its popularity in practice. T2 has the seemingly attractive property that its
boundary is smooth and more closely follows the contours of the null distribution in the
upper right quadrant. In comparison, the boundaries of T∞ and the Hochberg procedure
change abruptly. With T2, the null hypothesis is never rejected with a p.d.f. > 0.03, but
this is not true for any of the other tests. This seems like a desirable property of T2, that
it rejects H0 when Z has values which have the smallest probability density under H0.
This, of course, is a consequence of its equivalence to the likelihood ratio test. With T 01 ,
for some values with p.d.f. < 0.01, we still do not reject H0, but for some values with
p.d.f. > 0.04, H0 is rejected. This seems undesirable. It can be seen that the Hochberg
test is close to T∞ when Z1 and Z2 are dissimilar, but is closer to T2 near Z1 = Z2. T1
appears to be quite different from T2, T∞ and Hochberg. The disadvantage of S01 can also
be seen, as the rejection boundary keeps changing linearly beyond the axes, where a large
positive value of Z1, for example, can be cancelled out by a large negative value of Z2.
Figure 3.3 shows the same rejection boundaries, but with the contours of the null distri-
bution when ∆1 = −2 and ∆2 = −1. In this figure the contours are in steps of 0.001, in
order to better show the extremes of the distribution. The results of Theorem 13 can be
illustrated by comparing Figure 3.3 with Figure 3.2. They show clearly that H0 is less
likely to be rejected when ∆1 < 0 and ∆2 < 0 than when ∆1 = ∆2 = 0.
The distribution of Z1 and Z2 under H1, with ∆1 = 2 and ∆2 = 0 is shown in Figure
3.4, along with the rejection boundaries. They show clearly that H0 is more likely to be
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Figure 3.1: Histogram of the null distribution excluding zero for T1, T2, T∞, T 01 and T 02 .
The percentage at zero is 33.329%.
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rejected when it is false than when it is true. It is also easily seen that, at these particular
values of ∆1 and ∆2, the probability of rejecting H0, i.e. the power, is different for different
test procedures. For example, it is immediately obvious that the rejection region for S01
includes less than 50% of the probability distribution, whereas those for T2, T∞ and the
Hochberg procedure include more than 50%.
3.2 Examples
We now discuss the two examples of three-arm trials mentioned in the introduction to
illustrate our test statistics described in Chapters 1 and 2. We consider trials with fairly
large sample sizes, so that we can assume that we can use the normal approximation in
our summary statistics.
3.2.1 Example 1
The DASH (Dietary Approaches to Stop Hypertension) trial (Appel et al., 1997) was a
randomized trial consisting of two experimental diets and a control diet for studying the
effect of dietary pattern on blood pressure. The control diet had the fat content of a
typical United States diet and was low in fruits, vegetables and dairy products. Diet 1
was a diet rich in fruits and vegetables and diet 2 was a “combination” diet rich in fruits,
vegetables and low-fat dairy products and with reduced saturated and total fat.
Let Di denote the unscaled difference in blood pressure between the control diet and ex-
perimental diet i, where i = 1, 2. In our notation Zi = Dˆi/se(Dˆi), which has unit variance.
In fact, the estimated standard errors were not given in the paper, so we calculated them
from the confidence intervals given. This is subject to rounding error as only one decimal
place was shown, but the results should be accurate enough for illustration. The number
of subjects on the control, fruit and combination diet were 154, 151 and 154 respectively.
We treat these as approximately equal allocations, so that ρ = 0.5.
From the results in the paper, for systolic blood pressure, we get D1 = 2.8, D2 = 5.5 and
se(Dˆi) = 0.884. Then Z1 = 2.8/0.884 = 3.3472 and Z2 = 5.5/0.884 = 6.5748. Therefore,
we can calculate
S01 = 6.5748 + 3.3472 = 9.9220,
T1 = 6.5748 +
(3.3472− 0.5× 6.5748)√
1− 0.52 = 6.6538,
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Figure 3.4: Rejection boundaries with contours of the joint null distribution of Z1 and Z2
with (∆1,∆2) = (2, 0). For key, see Figure 3.2.
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T2 =
√
6.57482 +
(3.3472− 0.5× 6.5748)2
1− 0.52 = 6.5751,
T∞ = 6.5748,
T 01 = 6.5748 + 3.3472 = 9.9220,
T 02 =
√
6.57482 + 3.34722 = 7.3778
and, compared with the cutpoints in Table 3.2, we can see that they are all clearly signif-
icant at the 1% level. Since Z1 > 2.5662, this is also true for the Hochberg procedure.
For diastolic blood pressure, Dˆ1 = 1.1, Dˆ2 = 3.0 and se(Dˆi) = 0.602. Hence Z1 =
1.1/0.602 = 1.8263 and Z2 = 3/0.602 = 4.9809. Note that the second best experimental
diet, i.e. the fruit and vegetable diet, is not bigger than ρ times the best diet, so it does
not contribute to the test statistics T1 and T2. Here T1, T2 and T∞ all have the same
value of 4.9809, S01 = T
0
1 = 4.9809 + 1.8263 = 6.8072, T
0
2 =
√
4.98092 + 1.82632 = 5.3052
and all are significant at the 1% level from Table 3.2. Also, since Z2 > 2.5662, Hochberg’s
procedure rejects H0 at the 1% level.
For both systolic and diastolic blood pressure, we conclude that at least one diet is better
than control. From the estimates, we would recommend the combination diet.
3.2.2 Example 2
We use the results from the ATAC (Arimidex, Tamoxifen Alone or in Combination) ran-
domized breast cancer trial (The ATAC Trialists’ Group, 2002), comparing the efficacy
of tamoxifen (T) with anastrozole (A) alone and the combination of the two (A+T) in
terms of 3 years disease-free survival, which we treat as a binary outcome, and in terms
of the survival time. Tamoxifen is the control treatment. Disease-free survival at 3 years
was 87.4%, 89.4% and 87.2% on tamoxifen, anastrozole and the combination respectively.
The number of subjects was 3125 for both anastrozole and the combination and 3116 for
tamoxifen, so that a normal approximation should be good and the sample sizes are almost
equal.
Let
ψi =
pii/(1− pii)
pi0/(1− pi0) ,
i = 1, 2, be the odds ratio of disease-free survival for treatment i and control, i = 0, i.e.
tamoxifen, where pii is the disease-free survival for treatment i. This will be estimated by
ψˆi =
pˆii/(1− pii)
pˆi0/(1− pˆi0) .
CHAPTER 3. PROPERTIES OF TEST STATISTICS 80
For large N, log ψˆi ∼ N(logψi, V ar(log ψˆi)) (Armitage et al., 2002, p.127), where
V ar(log ψˆi) =
1
n0pi0(1− pi0) +
1
nipii(1− pii) .
Then we use
V̂ ar(log ψˆi) =
1
n0pˆi0(1− pˆi0) +
1
nipˆii(1− pˆii) .
We scale the log odds ratios to get Zi with unit variance, so that
Zi =
log ψˆi√
V̂ ar(log ψˆi)
= log
(
pˆii/(1− pˆii)
pˆi0/(1− pˆi0)
)√
n0nipˆi0pˆii(1− pˆi0)(1− pˆii)
nipˆii(1− pˆii) + n0pˆi0(1− pˆi0) .
Using pˆi1 = 0.894, the survival in anastrozole, and pˆi2 = 0.872 in the combination group
and comparing with the tamoxifen group, which gave pˆi0 = 0.874, we have Z1 = 2.4644
and Z2 = −0.2373. Then T1, T2, T∞, T 01 and T 02 all equal 2.4644 so that all except
T 01 show significance at the 5% level and T2 and T∞ also show significance at 2.5%.
Since Z1 > 2.2265 Hochberg’s procedure also leads to rejection at the 2.5% level. Here
S01 = 2.4644 − 0.2373 = 2.2271, so that it does not show significance even at 5%. This
example illustrates clearly the weakness of S01 , that one inferior treatment cancels out
the gain from the superior treatment so that one would fail to reject H0. T
0
1 , while less
extreme, also fails to detect a difference in this case.
We also use the hazard ratios (HR) of disease-free survival times on experimental arms
versus the control estimated from the log-rank test statistics. The estimated HR for A
against T was 0.83 (95% CI 0.71-0.96) and for A+T against T was 1.02 (95% CI 0.89-
1.18). Our asymptotically normal test statistics are based on the log HRs. Let Di be the
log HR for treatment i against control, so that Dˆ1 = − log 0.83 and Dˆ2 = − log 1.02 with
se(Dˆ1) = (log 0.96− log 0.71)/4 = 0.07544 and se(Dˆ2) = (log 1.18− log 0.89)/4 = 0.07051.
Then Z1 = Dˆ1/se(Dˆ1) = 2.4706 and Z2 = Dˆ2/se(Dˆ2) = −0.2808. Hence, the results are
almost identical to those for three-year survival and, in particular, the decisions to reject
H0 or not are identical. This is as expected, since more than 85% of the observations were
censored, and tests are known to be similar in these circumstances (Cuzick, 1982).
3.3 Comparing the test performances
The tests are compared in terms of power, an adjusted power function and a loss function.
We use the standard definition of power, namely the probability that H0 is rejected, given
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that it is false. As usual, the power depends on unknown parameters, here ∆1 and ∆2.
Some authors use adjusted power functions and often refer to these simply as “power”.
In particular, in the multiple comparisons literature, e.g. Dunnett and Tamhane (1992),
Horn and Vollandt (1998) and Horn and Dunnett (2004), it is common to use an adjusted
power, which is the probability that at least one false H0i : ∆i ≤ 0 is rejected. This
“any-pair power” is not quite relevant for our study, since we are interested in the overall
H0 : ∆i ≤ 0 ∀i. In contrast, the literature on order restricted inference (Robertson et al.,
1988) usually uses the standard definition of power, as we do here, since they do not
consider the individual hypotheses. In fact, they typically do not consider the problem of
selection, so the issues of type III and IV errors do not arise.
Here, we define the adjusted power function to be
Adjusted power = power − P (type III error)− P (type IV error),
where, as defined in Chapter 2, a type III error is the rejection of H0 in favour of a treat-
ment which is no better than the control, while a type IV error is rejection of H0 in favour
of a treatment which is better than the control, but worse than the best experimental
treatment. Whereas Horn and Vollandt (1998) stated that their adjustment to the power
made almost no difference, that does not follow here, since we consider type IV errors
which are very common when ∆2 is close to ∆1, as well as type III errors which are rare
when ∆1 is reasonably large.
Although it seems reasonable to take account of the probability of incorrect selection, the
adjusted power might not be the best way of doing so. It treats the selection of a treatment
which is only very slightly worse than the best in the same way as selection of a treatment
which is much worse than the control. It seems more appropriate to use a function which
takes account of the impact of incorrect selection as well as its probability.
We define the loss as
Loss =

0 if we select treatment 1;
∆1 −∆2 if we select treatment 2;
∆1 if we fail to reject H0.
We compare the different tests in terms of the expected loss, calculated as
E(loss) = 0× (adjusted power) + (∆1 −∆2)× P (type III/IV error) + ∆1 × (1− power)
= (∆1 −∆2)× P (type III/IV error) + ∆1 × P (type II error).
Note that the expectation is taken over the sampling distribution of Z1 and Z2 and is
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a function of the unknown parameters ∆1 and ∆2. No use is being made here of prior
distributions.
The simulation program generates 100,000 values of bivariate normal variables W1 and
W2 with expectations zero, unit variances and correlation 0.5, in the same way as Z1 and
Z2 were simulated under the null distribution, in order to create simulated data. The
correlation was set to be ρ = 0.5 which corresponds to equal numbers of patients in each
arm, as in Section 3.1. Observed values of Z1 and Z2 are calculated by using w1i+(∆1/σ)
and w2i + (∆2/σ) respectively, for each simulation 1 = 1, . . . , 100, 000, i.e. the same set of
values w1 and w2 were used for each different pair of values of ∆1 and ∆2. Hence the same
simulated data were used for each significance level α. We define di = ∆i/σ for i = 1, 2.
d1 ranged from 0 to 4 and d2 from 0 to d1.
The null hypothesis is rejected if the value of the test statistic was greater than the
critical value given in Section 3.1.4 for the corresponding test. The power is estimated by
the proportion of 100,000 simulations which rejected H0. For ∆1 > ∆2, the probability of
a type III or IV error is P (Z1 < Z2
⋂
reject H0). For the values with ∆1 = ∆2, type IV
error is not relevant and this calculation would give simply 12 ×power. The approximation
from the simulation is
P (type III or IV error) = P (test statistic > C
⋂
Z1 < Z2)
=
number of (Z1 < Z2)
⋂
reject H0
100, 000
.
From this, we can easily estimate the adjusted power and the expected loss.
Ignoring simulation error in the cutpoints used, the estimated power from the simulations
has standard error equal to
√
p(1− p)/√100, 000, where p is the true power. Hence, when
expressed as a percentage, as in the rest of this thesis, the standard errors of powers are
approximately 0.158, 0.126 and 0.069 for 50%, 80% and 95% power respectively. Thus
the results presented can be assumed to be fairly precise to about 0.25%. The standard
error of a difference between two independently simulated powers would be
√
2 times the
standard errors given above. However, because we have used the same simulated errors,
our powers are positively correlated, which reduces the standard error of a difference. It
is not easy to calculate what it should be, but we can be confident that any differences
greater than about 0.4% power are probably real and not due to simulation variation.
Results for power and expected loss are shown for size 5%, 2.5% and 1%. We also show
some results for the adjusted power at size 5%, although we believe that it is less useful,
since it does not take account of the differences between treatments.
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3.3.1 Power results
In the tables in this section, we present only configurations which, for tests at the 5% level,
give powers in the range 65 − 95%. These are typically the types of powers of interest.
More complete results are presented in the figures. Note that the tests used here are not
unbiased. A test of size α is said to be unbiased if P (Reject H0|∆) ≥ α for all ∆ such
that H1 is true. This is obviously not true here. Consider ∆1 = ε1, for some small positive
constant ε1 and ∆2 → −∞. Then Tk and T 0k will equal Z1 and S01 will tend to −∞. Hence
the upper 5% point of the distribution will be 1.6465 + ε2, for some small constant ε2 and
from the cutpoints in Table 3.2, we will reject H0 less than 5% of the time. However,
unbiasedness of tests is not generally considered to be a very important property, since it
concerns parameter values which, though in the set defined by H1, are very close to the
set defined by H0.
The power at 5% for each of the tests considered is shown in Table 3.3 for various config-
urations di = ∆i/σ for i = 1, 2. Further results are illustrated in Figure 3.5. Note that in
this and subsequent figures, T∞ is referred to as T3 and Hochberg’s procedure is referred
to as Hoch. The first point to note is that the differences between the tests are not very
large, except that S01 and T
0
1 have much lower power than the others when d2 = 0. In
Figure 3.5, T2, T∞ and Hochberg are indistinguishable. In Table 3.3, we see that when
d2 = 0, T∞ is slightly better than Hochberg, which is very slightly better than T2. T 02
and T1 are a little worse than these three, and about equal to each other. As seen from
the top left panel in Figure 3.5, T 01 and S
0
1 are vastly inferior to the others when d2 = 0.
When d2 = d1/2, T2 has the highest power, but is only very slightly better than Hochberg,
which is very slightly better than T∞. T 02 is slightly worse and T1 slightly worse again.
Again, T 01 and S
0
1 are somewhat worse than the other tests (upper right panel in Figure
3.5). When d2 = d1, S
0
1 is the most powerful among these tests, being very slightly better
than T 01 , which is very slightly better than T
0
2 and T1. T2 is slightly worse than these,
but very slightly better than Hochberg, which is slightly better than T∞ (lower panel of
Figure 3.5).
Some results at 5% with negative ∆2 are shown in Table 3.4. Comparing these with the
results in Table 3.3 for ∆2 = 0, we see that for T1, T2, T∞ and Hochberg’s procedure,
the power is almost the same. For T 01 and T
0
2 , it is somewhat reduced and for S
0
1 it is
greatly reduced. This illustrates an important advantage of the Tk family of test statistics:
because they only include contributions from the second largest treatment effect when it
is at least half as big as the biggest (ρ = 1/2), they are not much affected by changes in
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Table 3.3: Power of the tests at 5% for selected values of d1 and d2, where di = ∆i/σ.
d1 d2 T1 T2 T∞ T 01 T 02 S01 Hoch
2.5 0 64.691 71.169 72.242 47.651 65.089 42.094 71.677
2.7 0 71.587 77.508 78.532 53.813 71.829 46.693 77.937
2.9 0 77.798 83.113 84.015 60.187 77.943 51.309 83.491
3 0 80.653 85.477 86.330 63.205 80.705 53.625 85.822
3.5 0 91.376 93.956 94.398 77.787 91.299 64.820 94.138
2.5 1.25 72.941 74.586 74.349 70.345 73.859 70.020 74.537
2.7 1.35 78.788 80.402 80.249 76.199 79.627 75.800 80.330
2.9 1.45 83.886 85.425 85.353 81.308 84.682 80.879 85.399
3 1.5 86.084 87.579 87.490 83.581 86.863 83.133 87.502
3.5 1.75 94.094 94.926 94.909 92.260 94.494 91.881 94.897
2. 2 73.814 71.518 70.028 74.893 73.824 74.917 70.982
2.5 2.5 88.688 87.151 85.937 89.463 88.782 89.466 86.714
2.7 2.7 92.540 91.300 90.259 93.136 92.547 93.148 90.950
2.9 2.9 95.253 94.381 93.613 95.657 95.322 95.661 94.106
3. 3 96.247 95.565 94.877 96.565 96.269 96.564 95.320
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Figure 3.5: Power at 5%. di = ∆i/σ for i = 1, 2.
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Table 3.4: Power of the tests at 5% when d2 < 0.
d1 d2 T1 T2 T∞ T 01 T 02 S01 Hoch
2.5 -0.625 63.920 70.976 72.181 40.841 63.726 28.817 71.554
3 -0.75 80.360 85.422 86.315 57.986 80.049 36.510 85.790
3.5 -0.875 91.296 93.945 94.396 74.919 91.098 44.975 94.135
2.5 -1.25 63.759 70.946 72.173 37.735 63.345 17.793 71.535
3 -1.5 80.334 85.419 86.313 56.434 79.952 21.843 85.787
3.5 -1.75 91.294 93.945 94.396 74.410 91.070 26.358 94.135
the size of the smaller effect close to zero.
The power of the tests at the 2.5% level of significance for various configurations of d1
and d2 are shown in Table 3.5 and plotted, for a larger set of values, in Figure 3.6. The
plots show a very similar pattern to those from the tests at 5%, but with slightly greater
differences between the tests. The ordering of the test statistics in terms of power are
exactly the same as for the tests at 5%, although as noted from the graphs the differences
are slightly greater. Some results with negative ∆2 are shown in Table 3.6 and, as with
the 5% significance level, they show that the results for the Tk family and Hochberg’s test
are almost the same as when ∆2 = 0, while the other test statistics are adversely affected.
The corresponding results for testing at the 1% level of significance are given in Table 3.7
and Figure 3.7. Again these results are broadly similar to those at the other significance
levels. In a few cases the ordering of tests changes slightly, but this is probably just due
to simulation variation, which we noted is greater at 1% than at the other significance
levels. The results with negative values of ∆2, shown in Table 3.8, again show that T1,
T2, T∞ and Hochberg’s test are not greatly affected by whether the value of ∆2 is zero or
negative.
Our results are consistent with those of Mukerjee et al. (1985), also briefly summarised by
Robertson et al. (1988), which showed that Dunnett’s procedure was more powerful than
the LRT when ∆2 = 0, but not towards the middle of the rejection region, i.e. close to
∆2 = ∆1. It is worth noting some differences between our simulation study and theirs.
First, the simulation study reported here is more comprehensive, covering more testing
procedures and more different values of ∆1 and ∆2. Secondly, we have used the same
simulation program to generate the cutpoints for all the test procedures, whereas they
used different numerical approximation procedures for the different test statistics. Hence,
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Table 3.5: Power of the tests at 2.5%.
d1 d2 T1 T2 T∞ T 01 T 02 S01 Hoch
2.7 0 57.790 67.445 68.996 37.710 58.914 34.492 68.483
2.9 0 65.240 74.225 75.647 43.295 66.205 38.776 75.191
3 0 68.767 77.348 78.625 46.267 69.613 41.063 78.205
3.5 0 83.828 89.460 90.294 61.856 84.167 52.587 90.037
2.5 1.25 60.802 63.821 63.574 58.392 62.593 58.281 63.673
2.7 1.35 67.575 70.871 70.726 65.033 69.444 64.904 70.744
2.9 1.45 73.965 77.119 77.026 71.266 75.732 71.109 77.060
3 1.5 76.920 79.988 79.871 74.209 78.635 74.044 79.914
3.5 1.75 88.696 90.888 90.916 86.092 89.866 85.865 90.901
2 2 62.825 60.075 58.011 63.881 62.951 63.888 58.835
2.5 2.5 81.649 79.358 77.255 82.460 81.705 82.461 78.168
2.7 2.7 87.109 85.184 83.486 87.787 87.182 87.786 84.189
2.9 2.9 91.355 89.811 88.366 91.911 91.420 91.912 88.967
3 3 93.077 91.699 90.340 93.564 93.076 93.564 90.909
Table 3.6: Power of the tests at 2.5% when d2 < 0.
d1 d2 T1 T2 T∞ T 01 T 02 S01 Hoch
3 -0.75 68.377 77.284 78.612 38.331 68.527 25.452 78.178
3.5 -0.875 83.696 89.441 90.292 55.940 83.704 32.954 90.030
3 -1.5 68.330 77.274 78.610 35.600 68.321 13.716 78.175
3.5 -1.75 83.688 89.441 90.292 54.522 83.654 17.143 90.030
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Figure 3.6: Power at 2.5%. di = ∆i/σ for i = 1, 2.
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Table 3.7: Power of the tests at 1%.
d1 d2 T1 T2 T∞ T 01 T 02 S01 Hoch
2.9 0 47.556 61.631 63.593 27.126 50.150 25.767 63.294
3 0 51.509 65.451 67.313 29.377 53.984 27.701 67.042
3.5 0 70.162 81.522 82.960 42.296 71.804 38.014 82.732
2.9 1.45 59.170 64.969 64.886 57.528 62.694 57.495 64.980
3 1.5 62.712 68.576 68.493 60.952 66.185 60.918 68.603
3.5 1.75 78.284 83.525 83.644 76.187 81.398 76.128 83.649
2.5 2.5 70.575 67.465 64.408 71.410 70.668 71.411 65.201
2.7 2.7 77.951 75.087 72.174 78.749 78.119 78.749 72.932
2.9 2.9 84.177 81.711 79.086 84.731 84.272 84.731 79.863
3 3 86.750 84.595 82.177 87.345 86.883 87.345 82.879
3.5 3.5 95.438 94.390 93.029 95.754 95.537 95.754 93.440
Table 3.8: Power of the tests at 1% when d2 < 0.
d1 d2 T1 T2 T∞ T 01 T 02 S01 Hoch
3 -0.75 50.950 65.349 67.302 20.033 52.348 15.194 67.019
3.5 -0.875 69.951 81.500 82.957 33.164 70.943 20.875 82.727
3 -1.5 50.894 65.347 67.302 16.310 51.950 7.220 67.019
3.5 -1.75 69.937 81.498 82.957 30.547 70.812 9.394 82.726
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Figure 3.7: Power at 1%.
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Table 3.9: Power of the tests using exact cutpoints for T∞ and S01 at 5, 2.5 and 1%.
5% 2.5% 1%
d1 d2 T∞ S01 T∞ S01 T∞ S01
2 0 53.820 31.307 41.977 21.043 29.263 12.121
2.5 0 72.243 42.091 61.564 30.361 47.887 18.876
3 0 86.330 53.620 78.624 41.063 67.311 27.696
3.5 0 94.398 64.819 90.294 52.587 82.957 38.010
2 1 56.897 53.620 44.450 41.063 31.045 27.696
2.5 1.25 74.350 70.014 63.573 58.281 49.509 43.689
3 1.5 87.490 83.133 79.870 74.044 68.490 60.912
3.5 1.75 94.909 91.881 90.916 85.865 83.641 76.124
2 2 70.028 74.914 58.009 63.888 43.016 49.446
2.5 2.5 85.938 89.465 77.255 82.461 64.404 71.405
3 3 94.877 96.564 90.338 93.564 82.174 87.340
our numerical results are not identical to those of Mukerjee et al. (1985), but the overall
conclusions are consistent with theirs. Our results are also broadly consistent with many
in the multiple comparisons literature, e.g. Horn and Dunnett (2004), who found that
Dunnett’s procedure, Hochberg’s procedure and several other methods have similar any-
pair powers. Again, exact comparisons of the results are not possible, due to the slightly
different objectives of the tests.
3.3.2 Effect of estimating the cutpoints
We noted in Section 3.1.4 that, for those test statistics for which exact distributions are
known, the cutpoints estimated from the simulations were very close to those calculated
from the exact distributions. We now check to see what impact they have on the estimated
powers. These are shown in Table 3.9. Comparing these with the results in Tables 3.3,
3.5 and 3.7, we find very little difference between them, in many cases no difference.
Even in the worst case, S01 at 1%, the powers are precise to two decimal places. This
gives us additional confidence in the precision of our cutpoints. As noted above, even if
the cutpoints were exact, the simulation variance in the powers would be greater than
the differences we have found here, so that this is clearly a more important source of
imprecision than the estimated cutpoints.
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Table 3.10: Adjusted power of the tests at 5% when ∆2 = 0.
d1 d2 T1 T2 T∞ T 01 T 02 S01 Hoch
2.5 0 64.429 70.959 72.060 47.385 64.845 41.828 71.471
2.7 0 71.419 77.377 78.415 53.648 71.681 46.527 77.810
2.9 0 77.694 83.036 83.948 60.085 77.853 51.207 83.417
3 0 80.576 85.421 86.280 63.131 80.636 53.551 85.769
3.5 0 91.365 93.946 94.388 77.775 91.287 64.808 94.128
Table 3.11: Adjusted power of the tests at 5% when ∆2 = ∆1/2
d1 d2 T1 T2 T∞ T 01 T 02 S01 Hoch
2.5 1.25 65.730 68.057 68.162 62.995 66.864 62.668 68.099
2.7 1.35 72.232 74.394 74.534 69.546 73.211 69.146 74.388
2.9 1.45 78.081 80.016 80.194 75.436 78.986 75.003 80.043
3 1.5 80.642 82.490 82.611 78.083 81.523 77.633 82.458
3.5 1.75 90.476 91.451 91.544 88.622 90.919 88.243 91.449
3.3.3 Adjusted power results
Table 3.10 shows the adjusted powers at the 5% level for the same sets of values as the
powers in Table 3.3 above with ∆2 = 0, when type-III errors could influence the result.
The adjusted power is very similar to the power, since in this case type III errors are very
rare. This is reassuring in the sense that, when H0 is rejected, it is, with high probability,
in favour of a treatment which is better than the control.
When ∆2 = ∆1/2, as shown in Table 3.11 the adjustment based on the probability of
type-IV error makes some difference. In terms of this adjusted power function, T∞ seems
better, relative to T2, than in terms of power. Again, though, T2 and Hochberg are very
close to T∞.
Note that when ∆2 = ∆1 the adjusted power is identical to the power, since no type III
or IV error is possible in this case, and so it is not shown.
Although it is straightforward to produce the adjusted powers for all simulations, we do
not present any more of these, because we do not believe that the adjusted power (as
defined here) is a useful concept. For example, if ∆2 is very close, but not equal, to ∆1,
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then the probability of type IV error approaches 1/2 and the adjusted power then drops
to almost half of the power. There is then a discontinuity when ∆2 = ∆1, unless we
arbitrarily define treatment 1 to be optimal and count the selection of treatment 2 as a
type IV error in the latter case. However, in practice this is meaningless, since the choice
of a treatment which is equally as good as the best (or even very close) cannot sensibly be
defined as an error. Given the power and the expected loss, the adjusted power does not
seem to add anything. Hence, we do not pursue the adjusted power further in this thesis.
3.3.4 Expected loss results
Tables 3.12 to 3.14 show the expected loss for each of the test statistics considered, for
the same set of values of ∆1 and ∆2 as were given for the power. In these tables, we also
show a reasonable upper bound on the expected loss, which is what we would get from
randomly rejecting H0 with probability α and then randomly selecting a treatment. This
is calculated as
E(loss) = (1− α)∆1 + α
I
I∑
i=2
(∆1 −∆i).
These and additional results over a wider set of values of d1 and d2 are presented graphically
in Figures 3.8 to 3.10.
The first thing we note from the figures is that, across the values of d1 and d2, the most
difficult cases for the tests, i.e. those that give the highest expected loss, seem to be
when ∆2 = 0 and/or d1 ≈ 1.5, as can be seen in the figures. The former is consistent
with the power being lowest for these configurations, while the latter is interesting, if not
completely surprising. Smaller values of ∆1 mean that type II and type III/IV errors
have high probability, but the consequences of any wrong decision are less important,
so the expected loss is small. Larger values of ∆1 mean that type II errors are very
unlikely and type III/IV errors are either very unlikely (if ∆2 is small) or have unimportant
consequences (if ∆2 is close to ∆1), so again the expected loss is small.
The ordering of the test procedures is almost exactly the same as for power. Note, however,
that it is not identical, e.g. for tests at the 2.5% level, when ∆1 = 2.9 and ∆2 = 1.45,
T2 has higher power than Hochnerg’s procedure, but higher expected loss. Overall, T∞
is best when ∆2 = 0, being slightly better than the Hochberg procedure and T2. T2, T∞
and Hochberg are about equally good when ∆2 = ∆1/2. Among these three tests, T2 is
clearly best when ∆2 = ∆1, but in this case S
0
1 is best overall.
Expected losses for negative values of ∆2 are shown in Tables 3.15 to 3.17 for 5%, 2.5%
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Table 3.12: Expected loss at 5%.
d1 d2 Bound T1 T2 T∞ T 01 T 02 S01 Hoch
2.5 0 2.4375 0.8893 0.7260 0.6985 1.3154 0.8789 1.4543 0.7132
2.7 0 2.6325 0.7717 0.6108 0.5828 1.2515 0.7646 1.4438 0.5991
2.9 0 2.8275 0.6469 0.4920 0.4655 1.1575 0.6423 1.4150 0.4809
3 0 2.925 0.5827 0.4374 0.4116 1.1060 0.5809 1.3935 0.4269
3.5 0 3.4125 0.3022 0.2119 0.1964 0.7779 0.3050 1.2317 0.2055
2.5 1.25 2.4063 0.7666 0.7170 0.7186 0.8332 0.7410 0.8414 0.7170
2.7 1.35 2.5988 0.6612 0.6103 0.6104 0.7324 0.6367 0.7432 0.6113
2.9 1.45 2.7913 0.5515 0.5011 0.4996 0.6272 0.5268 0.6397 0.5011
3 1.5 2.8875 0.4991 0.4490 0.4485 0.5750 0.4742 0.5885 0.4506
3.5 1.75 3.3688 0.2700 0.2384 0.2371 0.3346 0.2553 0.3478 0.2389
2 2 1.9000 0.5237 0.5696 0.5994 0.5021 0.5235 0.5016 0.5804
2.5 2.5 2.3750 0.2828 0.3212 0.3516 0.2634 0.2804 0.2634 0.3322
2.7 2.7 2.5650 0.2014 0.2349 0.2630 0.1853 0.2012 0.1850 0.2443
2.9 2.9 2.7550 0.1377 0.1630 0.1852 0.1259 0.1357 0.1258 0.1709
3 3 2.8500 0.1126 0.1330 0.1537 0.1030 0.1119 0.1031 0.1404
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Table 3.13: Expected loss at 2.5%.
d1 d2 Bound T1 T2 T∞ T 01 T 02 S01 Hoch
2.7 0 2.6663 1.1432 0.8816 0.8392 1.6852 1.1123 1.7721 0.8534
2.9 0 2.8638 1.0102 0.7491 0.7075 1.6466 0.9820 1.7776 0.7210
3 0 2.9625 0.9387 0.6808 0.6423 1.6136 0.9131 1.7697 0.6550
3.5 0 3.4563 0.5664 0.3692 0.3400 1.3354 0.5545 1.6598 0.3490
2.5 1.25 2.4531 1.0565 0.9705 0.9706 1.1171 1.0081 1.1199 0.9711
2.7 1.35 2.6494 0.9528 0.8540 0.8526 1.0212 0.8990 1.0247 0.8547
2.9 1.45 2.8456 0.8303 0.7303 0.7279 0.9086 0.7760 0.9131 0.7295
3 1.5 2.9438 0.7660 0.6664 0.6652 0.8474 0.7122 0.8523 0.6663
3.5 1.75 3.4344 0.4553 0.3743 0.3706 0.5462 0.4130 0.5542 0.3725
2 2 1.9500 0.7435 0.7985 0.8398 0.7224 0.7410 0.7222 0.8233
2.5 2.5 2.4375 0.4588 0.5161 0.5686 0.4385 0.4574 0.4385 0.5458
2.7 2.7 2.6325 0.3481 0.4000 0.4459 0.3298 0.3461 0.3298 0.4269
2.9 2.9 2.8275 0.2507 0.2955 0.3374 0.2346 0.2488 0.2346 0.3200
3 3 2.9250 0.2077 0.2490 0.2898 0.1931 0.2077 0.1931 0.2727
Table 3.14: Expected loss at 1% .
d1 d2 Bound T1 T2 T∞ T 01 T 02 S01 Hoch
2.9 0 2.8855 1.5224 1.1138 1.0565 2.1148 1.4469 2.1542 1.0652
3 0 2.985 1.4559 1.0374 0.9812 2.1198 1.3815 2.1701 0.9895
3.5 0 3.4825 1.0446 0.6470 0.5966 2.020 0.9871 2.1698 0.6046
2.9 1.45 2.8783 1.2463 1.0678 1.0635 1.2929 1.1405 1.2939 1.0629
3 1.5 2.9775 1.1808 0.9955 0.9911 1.2327 1.0732 1.2338 0.9901
3.5 1.75 3.4738 0.8133 0.6240 0.6157 0.8863 0.7025 0.8884 0.6170
2.5 2.5 2.4750 0.7356 0.8134 0.8898 0.7148 0.7333 0.7147 0.8700
2.7 2.7 2.6730 0.5953 0.6727 0.7513 0.5738 0.5908 0.5738 0.7308
2.9 2.9 2.8710 0.4589 0.5304 0.6065 0.4428 0.4561 0.4428 0.5840
3 3 2.9700 0.3975 0.4622 0.5347 0.3797 0.3935 0.3797 0.5136
3.5 3.5 3.4650 0.1597 0.1964 0.2440 0.1486 0.1562 0.1486 0.2296
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Figure 3.8: Expected loss at 5%.
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Figure 3.9: Expected loss at 2.5%.
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Figure 3.10: Expected loss at 1%.
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Table 3.15: Expected loss at 5% when d2 < 0.
d1 d2 Bound T1 T2 T∞ T 01 T 02 S01 Hoch
2.5 -0.625 2.4531 0.9028 0.7262 0.6959 1.4798 0.9075 1.7804 0.7117
3 -0.75 2.9438 0.5893 0.4375 0.4107 1.2605 0.5986 1.9048 0.4264
3.5 -0.875 3.4344 0.3047 0.2120 0.1962 0.8779 0.3116 1.9259 0.2053
2.5 -1.25 2.4688 0.9061 0.7264 0.6957 1.5567 0.9165 2.0553 0.7117
3 -1.5 2.9625 0.5900 0.4374 0.4106 1.3070 0.6014 2.3447 0.4264
3.5 -1.75 3.4563 0.3047 0.2119 0.1961 0.8957 0.3126 2.5775 0.2053
Table 3.16: Expected loss at 2.5% when d2 < 0.
d1 d2 Bound T1 T2 T∞ T 01 T 02 S01 Hoch
3 -0.75 2.9719 0.9488 0.6816 0.6417 1.8502 0.9443 2.2366 0.6547
3.5 -0.875 3.4672 0.5707 0.3696 0.3398 1.5421 0.5704 2.3467 0.3490
3 -1.5 2.9813 0.9501 0.6818 0.6417 1.9320 0.9504 2.5885 0.6548
3.5 -1.75 3.4781 0.5709 0.3696 0.3398 1.5917 0.5721 2.9000 0.3490
and 1% respectively. The overall pattern is similar to that for power, in that T1, T2, T∞
and Hochberg’s show similar results as with ∆2 = 0, while the other tests perform poorly.
However, an interesting feature is that both T∞ and Hochberg’s procedure actually show
smaller expected loss with negative ∆2. For T2 the expected loss is larger when ∆2 =
−∆1/4 than when ∆2 = 0, but in some cases then decreases again when ∆2 = −∆1/2,
especially at the 5% level. Since the power is lower with negative ∆2, this is clearly due
to the reduced probability of type-III errors. This shows yet another advantage of these
three test statistics over the others. It also shows the extra subtlety of the expected loss
over the power as a measure for comparing tests.
Table 3.17: Expected loss at 1% when d2 < 0.
d1 d2 Bound T1 T2 T∞ T 01 T 02 S01 Hoch
3 -0.75 2.9888 1.4716 1.0395 0.9809 2.3991 1.4296 2.5443 0.9894
3.5 -0.875 3.4869 1.0518 0.6475 0.5965 2.3393 1.0170 2.7694 0.6046
3 -1.5 2.9925 1.4732 1.0396 0.9809 2.5107 1.4415 2.7834 0.9894
3.5 -1.75 3.4913 1.0522 0.6476 0.5965 2.4309 1.0216 3.1712 0.6046
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Over all configurations studied, T∞ has the lowest maximum loss (= 0.9929), when testing
at 5%. The next lowest maximum loss is for Hochberg (= 1.0015) followed by T2 (=
1.0069). These maxima all occur at d1 ≈ 1.5 and d2 = 0, so are not shown in the tables
above. The expected loss from T2 is never more than 0.06 higher than for T∞, while the
expected loss for T∞ can be more than 0.07, but never more than 0.08 higher than for T2.
Hochberg’s procedure’s expected loss is always between these two, but closer to T∞’s, and
is never more than 0.06 higher than for T2.
3.4 Conclusions for three-arm trials
We do not find any test that is uniformly best. Each test has its own advantages and
disadvantages, depending on the sizes of the ∆is. As anticipated, when the ∆i’s are close
to being equal, T1, T
0
1 and S
0
1 perform well, but their loss of power when ∆2 is smaller
than ∆1 is too great for them to be recommended, unless there is strong prior knowledge
that the experimental treatments will be similar to each other. When one of the ∆is is
close to zero, T∞ performs best, but T2 is slightly better otherwise, as anticipated.
The conclusions from the comparisons of power and expected loss are broadly similar,
though not identical. The power is the major component in the calculation of expected
loss, E(loss) = (∆1 − ∆2) × P (type III/IV error) + ∆1 × (1 − power), since type-III/IV
errors have either small probability, relative to type-II errors, or a very small impact (when
∆2 is close to ∆1). The greatest difference is around ∆2 = ∆1/2, where the impact of
a type-IV error is important and the probability of a type-IV error is non-negligible. In
these cases the expected loss seems to favour T∞ over T2 slightly more than the power.
The few cases we noted where different conclusions were reached about the ordering of
tests are not enough to make a difference to our overall recommendations, but they do
serve as a warning that the power should not be blindly accepted as the only measure of
test performance.
Overall, T2, T∞ and Hochberg’s procedure give a stable performance for a wide range of
values of ∆1 and ∆2 and any of them is probably acceptable in practice. The performance
of T2 seems very slightly better than the others and we recommend it for practical appli-
cations, although up to now it does not seem to have been used. However, some might
prefer T∞ due to its simplicity and almost equally good performance. Although almost as
good as these two tests, Hochberg’s procedure is more complicated to use, especially for
more than three arms, and does not seem to have any particular advantages over T2 and
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T∞. If Hochberg’s procedure is used without adjustment, it is conservative and is then
not as good as T2 and T∞.
3.5 A technical problem regarding type-III errors
The results in Section 3.3 and further results (not shown) with ∆2 = 0 show that the
probability of a type-III error is not large enough to be of any practical consequence.
However, it is of interest to consider whether type-III error can ever be large enough to
be important. In particular, when a test is being conducted at significance level α, it is
desirable, perhaps essential, that the probability of a type-III error cannot be greater than
α for any configuration of ∆. As noted in Chapter 2, for practical purposes, a type-III
error can be considered as equivalent to a type-I error, so that our test procedure must
control for type-III errors as well as type-I errors. In this section, we study this issue.
First we show that there cannot be a problem with T∞. Next we perform calculations
which show that, for S01 it is possible that P (type-III error) > α, though only for very
small α. Finally, we carry out simulations to show that the same can be true for T1 and
T2.
First, though, we note that P (type-III error) ≤ Power/2, since P (reject H0
⋂
Z2 > Z1) ≤
P (reject H0)/2 if ∆2 < ∆1. Therefore, no problem can arise for very small values of d1,
but only for those values which are large enough to give a power greater than 2α. However,
large values of d1 will make it very unlikely that a type-III error will occur. Informally,
this might immediately suggest that the problem we are considering could not possibly
arise. However, although this is true for practical values of α, we shall see that it is not
true for very small values of α, since in this case a power of 2α occurs when d1 is still very
small.
3.5.1 Type-III errors for T∞
Consider the case where ∆2 = 0, which maximises the probability of a type-III error.
When using T∞, a type-III error can only occur when Z2 is greater than the cutpoint of
the rejection region. Since this cutpoint Cα is the upper α point on the distribution of
max(Z1, Z2), it is larger than z1−α. Hence, for T∞,
P (type-III error) = P (T∞ > Cα
⋂
Z2 > Z1|d1 = d, d2 = 0)
= P (max(Z1 + d, Z2) > Cα
⋂
Z2 > Z1 + d|d1 = d2 = 0),
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where d > 0. Then, continuing to condition on d1 = d2 = 0, but dropping it from the
notation (for simplicity),
P (type-III error) = P (max(Z1 + d, Z2) > Cα|Z2 > Z1 + d)P (Z2 > Z1 + d)
= P (Z2 > Cα|Z2 > Z1 + d)P (Z2 > Z1 + d)
= P (Z2 > Cα
⋂
Z2 > Z1 + d)
≤ P (Z2 > Cα
⋂
Z2 > Z1)
< P (max(Z1, Z2) > Cα
⋂
Z2 > Z1)
=
α
2
This extends to more than two experimental arms, since in the above result the upper α
point on the distribution of max(Z1, Z2) is replaced by the upper α point on the distri-
bution of max(Z1, . . . , ZI) and z1−α is replaced by the upper α point on the distribution
of max(ZJ , . . . , ZI) for some 2 ≤ J ≤ I. Clearly, the above inequalities would also hold
in this case. Therefore, with T∞, there is no need to be concerned about the probability
of a type-III error becoming greater than the size of the test. This result and the proof
are quite similar to the result of Bofinger (1985), who showed that for Tukey’s multiple
comparison test for all pairwise comparisons, with a two-sided alternative, the probability
of a type-III error is always less than α.
3.5.2 Type-III errors for S01
We consider the case of equal allocation, so that Cov(Z1, Z2) = 1/2. In this case the distri-
bution of S01 is known to beN(d1+d2, 3), it is straightforward to calculate P (type-III error)
for any α and check whether or not it is greater than α. Let D01 = Z1−Z2 ∼ N(d1−d2, 1)
and therefore Cov(S01 , D
0
1) = 0. Consider d2 = 0, so that S
0
1 ∼ N(d1, 3) andD01 ∼ N(d1, 1).
Then
P (type-III error) = P
(
Reject H0
⋂
Z2 > Z1
)
= P
(
S01 > Cα
⋂
D01 < 0
)
,
where Cα is the cutpoint of the rejection region for S
0
1 . Since P
(
S01 > Cα|d1 = d2 = 0
)
=
α, Cα =
√
3z1−α.
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Now, since S01 and D
0
1 are independent,
P (type-III error) = P
(
S01 >
√
3z1−α
)
P
(
D01 < 0
)
= P
(
S01 − d1√
3
> z1−α − d1√
3
)
P
(
D01 − d1 < −d1
)
=
{
1− Φ
(
z1−α − d1√
3
)}
Φ(−d1)
= Φ
(
zα +
d1√
3
)
Φ (−d1) .
It is, therefore, simple to calculate the probability that S01 gives a type-III error for any α
and any d1.
The results are shown in Figure 3.11 for α = 0.01% and it is immediately clear that the
probability of a type-III error can be greater than α for a range values of d1 from less than
1 to greater than 2. In fact this happens for at least some values of d1 for all α < 0.000753
(to 6 decimal places). At this significance level, P (type-III error) > α for d1 = 1.15 and
values very close (equal to two decimal places) to this only.
3.5.3 Type-III errors for other test statistics
The results for S01 are reassuring in the sense that they show that problems arise only for
very small values of α which are unlikely to be used in practice to perform a significance
test. However, they also show that there is a possibility of a problem arising. For T1 and
T2, it is necessary to carry out simulations to check for possible problems. A set of two
million errors were simulated and used to obtain rejection cutpoints for different levels of
significance. Various values of d1 were added to the errors with d2 = 0 to estimate the
probability of type-III error. For tests at the 5%, 2.5% and 1% levels, the probability of
a type-III error never approaches α, as shown in Table 3.18. However, we also carried out
simulations of tests at the 0.1%, 0.01% and 0.001% levels of significance and these results
are shown in Table 3.19.
The results show that T1 fails even at 0.1%, where S
0
1 is still satisfactory. On the other
hand, T2 fails at 0.001%, but is still clearly satisfactory at 0.01%. More extensive simu-
lations are needed if a very small level of significance is to be used, although the overall
pattern of results is clear. As proved above, T∞ never has any problem and we can see that
the probability of a type-III error remains less than α/2 throughout. Thus, T∞ appears
to be the only test statistic for which the probability of a type-III error is never greater
than the size of the test.
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Figure 3.11: Probability of type-III error for S01 at 0.01%.
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Table 3.18: Percentage of type-III errors when d2 = 0 at 5, 2.5 and 1%
Significance level
5% 2.5% 1%
d1 T1 T2 T∞ S01 T1 T2 T∞ S
0
1 T1 T2 T∞ S
0
1
0.125 2.593 2.535 2.491 2.651 1.364 1.272 1.225 1.364 0.572 0.519 0.511 0.563
0.25 2.604 2.450 2.394 2.691 1.376 1.252 1.196 1.409 0.618 0.534 0.504 0.601
0.5 2.615 2.272 2.173 2.745 1.449 1.195 1.097 1.474 0.683 0.522 0.471 0.662
1 2.169 1.739 1.581 2.262 1.328 0.979 0.835 1.323 0.655 0.428 0.375 0.630
1.5 1.401 1.080 0.967 1.473 0.917 0.657 0.542 0.915 0.533 0.319 0.244 0.488
Table 3.19: Percentage of type III errors when d2 = 0 with small sizes
Test statistic
100α d1 T1 T2 T3 S
0
1
0.1 1 0.1098 0.0568 0.0412 0.0953
1.1 0.1110 0.0570 0.0399 0.0952
1.2 0.1108 0.0574 0.0384 0.0962
1.3 0.1093 0.0565 0.0362 0.0935
0.01 1 0.0153 0.0075 0.0043 0.0133
1.1 0.0166 0.0082 0.0042 0.0154
1.2 0.0173 0.0090 0.0041 0.0160
1.3 0.0188 0.0091 0.0039 0.0163
0.001 1 0.0020 0.0010 0.0004 0.0021
1.1 0.0026 0.0011 0.0004 0.0023
1.2 0.0027 0.0011 0.0004 0.0023
1.3 0.0026 0.0012 0.0004 0.0024
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3.5.4 Proposed solution
The results in this section show why it was necessary to redefine the size of the test, as
in Section 2.2, to be α† = max
[
α,max∆{P (type-III error)}
]
. Given that the best test
statistics are T∞, where α† = α for all α, and T2, where α† = α for all except very
small values of α, it is unlikely that this will ever make any difference in practice. In
particular, all results reported in this thesis remain unchanged with this new definition of
size. However, it is important to note that, should anyone ever desire to use T2 to carry
out a significance test at a level of significance less than 0.01%, further work will be needed
to determine the true cutpoints of the null distribution. The problem is more serious for
T1 and could have a bearing on practical tests, but we would not recommend this test
statistic anyway.
3.6 Trials with more than three arms
The methodology described above can be applied to trials with any number of experimental
arms and we might expect similar results, although there are more different configurations
with more arms. Rather than try to be comprehensive, we look at just four-arm and eight-
arm trials with a few different configurations. For I = 3, we consider configurations of
the types (d1, d1, 0), (d1, 0, 0) and (d1, 0.5d1, 0.25d1). For I = 7 we consider configurations
with one non-zero, two non-zero, etc. and some other mixed sizes of effects. We also
restrict attention to tests in the Tk family.
The simulations were run exactly as before except that we give cutpoints based on only 1
million simulation runs. The standard errors of these cutpoints are of the order of 0.003,
based on the previous results, but should be slightly smaller than this due to greater
stability with more arms. Again, we can have confidence that they are precise to two
decimal places.
3.6.1 Four-arm results
Cutpoints for I = 3 are shown in Table 3.20, those for 2.5% having been done later in a
separate simulation. These are obviously at larger values than for I = 2, since there is
more chance of at least one arm being greater than any particular amount.
We present the power and expected loss only at the 5% level. The power for various
configurations is shown in Table 3.21. Some of these configurations, with more different
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Table 3.20: Cutpoints of the rejection region for four arms.
Test 5% 2.5%∗ 1%
T1 2.5102 2.9291 3.4426
T2 2.1282 2.4321 2.7814
T∞ 2.0581 2.3496 2.6837
∗ 2.5% critical values from a separate simulation.
values of d1, are illustrated in Figure 3.12. The overall pattern is what we expect. When
all treatments have similar effects, T1 is best, but this test is clearly inferior in other
circumstances. Overall, there are only small differences in power between T2 and T∞,
with T∞ being slightly better when one treatment is considerably better than the others,
but T2 being slightly better when several treatments have large effects. We can see that
with more arms there are perhaps more configurations which make T2 better than T∞.
For example, configurations like (2, 2, 0) cannot occur with I = 2.
The corresponding results for expected loss are shown in Table 3.22 and Figure 3.13. These
are broadly in line with those for power, although perhaps very slightly more in favour of
T∞, presumably because of the impact of type III/IV errors.
3.6.2 Eight-arm results
The cutpoints for I = 7 are shown in Table 3.23.
Again we present the power and expected loss only for 5% for a few different configurations.
The powers for several cases are shown in Table 3.24 and a few of these are illustrated over
a wider range of d1 values in Figure 3.14. The same general comments apply as before,
but we note that with just three arms better than the control, T2 is already better than
T∞. For the irregular configurations in the bottom section of the table, we see that T2
can be considerably better than T∞. The differences between tests can be quite large in
this case, with T∞ having almost 5% greater power than T2 and vice versa.
The corresponding expected losses are shown in Table 3.25 and Figure 3.15. The overall
pattern of results is very much similar to what we described regarding the power. The last
section of the table shows that there are many different configurations for which T2 gives a
smaller expected loss than T∞. In particular, if suboptimal treatments give results which
are fairly close, but not very close, to the optimum, then T2, by exploiting contributions
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Table 3.21: Power for four-arm trials at 5%.
d1 d2 d3 T1 T2 T∞
2.5 0 0 51.769 64.948 67.109
3 0 0 69.592 80.869 82.679
2.5 1.25 0 61.655 68.502 69.176
3 1.5 0 77.413 83.285 83.916
2.5 1.25 0.625 63.540 69.104 69.448
3 1.5 0.75 78.481 83.585 84.033
2.5 1.25 1.25 68.280 71.292 70.903
3 1.5 1.5 82.131 85.034 84.936
2 2 0 63.624 65.157 64.316
2.5 2.5 0 81.929 82.764 81.903
3 3 0 93.092 93.429 92.972
2 2 1 67.353 66.869 65.399
2.5 2.5 1.25 84.052 83.704 82.440
3 3 1.5 93.964 93.792 93.183
2 2 2 77.483 75.078 72.852
2.5 2.5 2.5 91.354 89.693 88.040
3 3 3 97.579 96.884 96.099
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Figure 3.12: Power at 5% for four arms.
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Table 3.22: Expected loss at 5% for four-arm trials.
d1 d2 d3 Bound T1 T2 T∞
2.5 0 0 2.4583 1.2149 0.8843 0.8294
3 0 0 2.9500 0.9157 0.5771 0.5223
2.5 1.25 0 2.4375 1.0398 0.8629 0.8423
3 1.50 0 2.9250 0.7536 0.5735 0.5511
2.5 1.25 0.625 2.4271 1.0120 0.8633 0.8492
3 1.50 0.75 2.9125 0.7331 0.5745 0.5565
2.5 1.25 1.25 2.4167 0.9402 0.8517 0.8537
3 1.50 1.50 2.9000 0.6756 0.5796 0.5761
2 2 0 1.9333 0.7314 0.7001 0.7164
2.5 2.5 0 2.4167 0.4528 0.4318 0.4532
3 3 0 2.9000 0.2075 0.1973 0.2111
2 2 1 1.9167 0.6927 0.6976 0.7243
2.5 2.5 1.25 2.3958 0.4344 0.4397 0.4694
3 3 1.50 2.8750 0.2071 0.2109 0.2279
2 2 2 1.900 0.4503 0.4984 0.5430
2.5 2.5 2.5 2.3750 0.2162 0.2577 0.2990
3 3 3 2.8500 0.0726 0.0935 0.1170
Table 3.23: The critical values at 5%, 2.5% and 1% for 8-arm.
Test 5% 2.5% 1%
T1 3.3764 3.8756 4.4848
T2 2.4937 2.7895 3.1366
T∞ 2.3436 2.6163 2.9357
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Figure 3.13: Expected loss at 5% for four arms.
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Table 3.24: Power at 5% for eight-arm trials.
d1 d2 d3 d4 d5 d6 d7 T1 T2 T∞
3 0 0 0 0 0 0 38.656 69.786 74.523
3.5 0 0 0 0 0 0 56.545 84.405 87.616
2.5 2.5 0 0 0 0 0 60.031 71.855 72.796
3 3 0 0 0 0 0 79.204 87.218 87.533
3.5 3.5 0 0 0 0 0 91.579 95.504 95.548
2 2 2 0 0 0 0 55.904 61.866 61.399
2.5 2.5 2.5 0 0 0 0 76.939 81.303 80.533
3 3 3 0 0 0 0 90.859 92.957 92.374
2 2 2 2 0 0 0 66.653 68.853 67.254
2.5 2.5 2.5 2.5 0 0 0 85.198 86.402 84.888
3 3 3 3 0 0 0 95.240 95.588 94.735
2 2 2 2 2 0 0 73.772 73.756 71.387
2.5 2.5 2.5 2.5 2.5 0 0 89.715 89.525 87.753
2 2 2 2 2 2 0 78.770 77.351 74.539
2.5 2.5 2.5 2.5 2.5 2.5 0 92.474 91.657 89.753
2 2 2 2 2 2 2 82.402 80.100 76.981
2.5 2.5 2.5 2.5 2.5 2.5 2.5 94.273 93.069 91.212
2.5 2 1.5 1 0.5 0 -0.5 59.577 67.277 67.315
2.5 2.25 2 0.5 0.5 -0.5 -0.5 67.707 73.561 73.070
2.5 2 1 0 0 -2 -2 51.961 64.177 65.416
3.2 1.6 0.8 0.4 0.2 0.1 0.05 59.051 79.124 81.571
2 1.5 1.5 1.5 1.5 1.5 1.5 65.071 63.352 60.298
2.25 1.75 1.75 1.75 1.75 1.75 1.75 76.198 74.511 71.413
2.2 1.95 1.85 1.5 1.5 0 0 66.203 67.741 65.882
2.7 2.6 2.5 2 0 0 0 84.340 86.191 84.964
2.8 2.8 2.7 2.6 1.5 0 0 91.208 91.742 90.480
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Figure 3.14: Power at 5% for eight arms.
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from them to reject H0 seems somewhat better than T∞. In practice, we would not be
surprised to see configurations of this sort, rather than the extreme case where only one
or two treatments are better than the control, so this seems like an important practical
result in favour of T2.
3.6.3 Conclusions
The conclusions regarding three-arm trials seem to hold for trials with more arms. In
particular, in the absence of strong prior knowledge that all experimental treatments will
have similar effects, we should avoid using T1. Overall, we would recommend T2, but
T∞ is very nearly as good and simpler to calculate. However, the differences between
test procedures is greater with more arms, so if there is prior knowledge that only a
small number of treatments is likely to be better than the control, then we could use T∞.
Generally, either T2 or T∞ is acceptable in all cases.
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Table 3.25: Expected loss at 5% for eight-arm trials.
d1 d2 d3 d4 d5 d6 d7 Bound T1 T2 T∞
3 0 0 0 0 0 0 2.9786 1.8458 0.9115 0.7691
3.5 0 0 0 0 0 0 3.4750 1.5224 0.5473 0.4347
2.5 2.5 0 0 0 0 0 2.4643 1.0029 0.7067 0.6827
3 3 0 0 0 0 0 2.9571 0.6245 0.3839 0.3744
3.5 3.5 0 0 0 0 0 3.4500 0.2948 0.1574 0.1559
2 2 2 0 0 0 0 1.9571 0.8864 0.7664 0.7750
2.5 2.5 2.5 0 0 0 0 2.4464 0.5774 0.4681 0.4873
3 3 3 0 0 0 0 2.9357 0.2743 0.2114 0.2288
2 2 2 2 0 0 0 1.9429 0.6688 0.6245 0.6561
2.5 2.5 2.5 2.5 0 0 0 2.4286 0.3702 0.3401 0.3779
3 3 3 3 0 0 0 2.9143 0.1428 0.1324 0.1580
2 2 2 2 2 0 0 1.9286 0.5254 0.5256 0.5728
2.5 2.5 2.5 2.5 2.5 0 0 2.4107 0.2572 0.2619 0.3062
2 2 2 2 2 2 0 1.9143 0.4250 0.4533 0.5095
2.50 2.50 2.50 2.50 2.50 2.50 0 2.3929 0.1882 0.2086 0.2562
2 2 2 2 2 2 2 1.9000 0.3520 0.3980 0.4604
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.3750 0.1432 0.1733 0.2197
2.5 2 1.5 1 0.5 0 -0.5 2.4500 1.1734 0.9854 0.9786
2.5 2.25 2 0.5 0.5 -0.5 -0.5 2.4518 0.9339 0.7940 0.8035
2.5 2 1 0 0 -2 -2 2.4893 1.3050 1.011 0.9779
3.2 1.6 0.8 0.4 0.2 0.1 0.05 3.1546 1.3729 0.7332 0.6523
2 1.5 1.5 1.5 1.5 1.5 1.5 1.9214 0.9186 0.9423 0.9909
2.25 1.75 1.75 1.75 1.75 1.75 1.75 2.1589 0.7933 0.8216 0.8790
2.2 1.95 1.85 1.5 1.5 0 0 2.1357 0.9134 0.8776 0.9113
2.7 2.6 2.5 2 0 0 0 2.6300 0.5412 0.4917 0.5220
2.8 2.8 2.7 2.6 1.5 0 0 2.7114 0.3151 0.2998 0.3336
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Figure 3.15: Expected loss at 5% for eight arms.
Chapter 4
Design Issues in Multi-Arm Trials
In clinical trials, as in any other experiment, it is important to decide how many subjects
are required for a particular experiment and how they should be allocated to treatments.
The bigger the trial, the more expensive it is to run and, in particular in clinical trials,
recruiting subjects can be a difficult task. However, bigger trials are also more informa-
tive about the relative performances of the treatments. Therefore it is very important
for an experimenter or drug company to try to produce a convincing result with limited
resources by selecting an appropriate sample size. If the practicalities allow it, experi-
menters should also allocate proportions of subjects to the different treatments in such a
way as to maximise the information on their comparison. In this chapter we address these
problems.
The comparison of test statistics in Chapter 3 was based on each arm, including the
control, having equal numbers of subjects allocated to it. However, given the emphasis
on comparisons with the control, we can expect to get better results by allocating more
subjects to the control than to each experimental arm. In this chapter we focus on how
the proportion of subjects on the control arm influences the power and the expected loss
for I = 2. For three arm trials, we consider a range of values between 1/3 and 1/2 for
the proportion on control. Throughout, we will assume equal numbers of subjects on each
experimental arm, since it would be practically and ethically more difficult to do anything
else and this is optimal (Bechhofer and Nocturne, 1972) in the absence of prior knowledge
about the relative performances of the treatments.
After reviewing the existing literature in Section 4.1, a general strategy is described in
Section 4.2. A simulation study is described in Section 4.3 which compares different
sample allocations in terms of power and expected loss at sizes 5% and 1% and estimates
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the optimal allocations to maximise power at size 5%. We also address the question
of choosing the sample size to achieve a required power or expected loss in Section 4.4.
Finally, some general comments are made in Section 4.5.
4.1 Background Literature
Several authors, including Dunnett (1955, 1964), Bechhofer and Tamhane (1983), Fleiss
(1986), Hsu (1989), Tang and Lin (1997), Liu (1997), Horn and Vollandt (1998) and
Dunnett et al. (2001), look at sample size calculations or allocation in multiple comparisons
of I treatments with a control. Most of this literature is based on Dunnett type tests,
i.e. testing the individual hypotheses H0i. Tang and Lin (1997) obtain sample sizes for
an approximate LR test for H∗0 : ∆ = 0, as well as some other tests, but, as noted in
Chapter 2, such tests are not sensibly applicable to our null hypothesis. Horn and Vollandt
(1998) consider multiple t tests without adjustment for multiple comparisons, as well as
Dunnett’s test, but this is not of interest in this thesis. Hence, the results available in the
literature are relevant only to our test statistic T∞.
Many of these authors give tables of sample sizes needed to achieve a specified power
for one- or two-sided alternatives or both. Others study the proportion of subjects to
allocate to the control to achieve maximum power or minimum total sample size for fixed
power. Several authors, including Dunnett (1955), Bechhofer and Tamhane (1983), Hsu
(1989) and Liu (1997), consider optimal allocations to ensure the maximum coverage of
one-sided (or two-sided) confidence intervals of fixed finite endpoint (or fixed width), or
highest/lowest endpoint (or minimum width) for a fixed coverage. As noted in Chapter
2, rejecting H0 : ∆i ≤ 0 ∀i if at least one one-sided confidence interval includes zero
is equivalent to testing using T∞ and maximising the endpoint of Dunnett’s one-sided
confidence intervals is equivalent to maximising the power of T∞.
Dunnett (1955) gave numerical results to show that the optimal allocation gives slightly
fewer subjects to the control than the allocation which minimises the average variance
of the estimators ∆ˆi, the so-called square root allocation. This has n0/ni =
√
I and, in
terms of δ is given by δ = (1 − I−1/2)/(I − 1) for I = 2, 3, . . . (Finney, 1952). Dunnett
also showed that the square root allocation gives very close to maximum power and can
be used for all practical purposes if maximum power is required.
Better numerical approximations are used to improve the accuracy of Dunnett’s results by
Bechhofer (1969), later superseded by Bechhofer and Nocturne (1972), who also consider
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the two-sided case. Extensive tables of optimal allocations are given by Bechhofer and
Tamhane (1983) and this can be considered the most complete set of recommendations to
date. All of these results were obtained by numerical integration.
In many papers on sample size calculations, the power considered is the probability of
rejecting H0i : ∆i ≤ 0 for all i such that ∆i > ∆∗, where ∆∗ is some specified practically
important difference. Therefore their results are only relevant to T∞ in the case that
exactly one ∆i is positive, the rest being zero.
Horn and Vollandt (1998), however, consider several different power characteristics, in-
cluding what they call “any-pair” power which is the probability of rejecting at least one
false H0i and so is directly relevant to T∞. Note, however, that their any-pair is not
identical to the power of T∞, since it is possible that a true H0i is rejected, while all false
H0i are not rejected, in which case H0 is false and is correctly rejected, even though no
true H0i is rejected. It is also different from the adjusted power calculated in Chapter
3, since in that calculation, if a false H0i is rejected and corresponds to the largest Zi,
this is counted as a type-III error irrespective of whether one or more true H0is are also
rejected. This can be considered as an extension of the consideration of directional errors
in two-sided tests, as considered by Hsu (1989). Therefore, we do not expect to replicate
their results. However, for large ∆i, we would expect the difference between their any-pair
power and the power of T∞ to be negligible. Horn and Vollandt note that the different
types of power require different sample sizes. Following the arguments from Chapter 3,
in addition to the power of the hypothesis test, we prefer to consider the expected loss,
rather than the adjusted power or Horn and Vollandt’s any-pair power when considering
the selection of the best treatment.
Horn and Vollandt, and others such as Liu (1997), argue that, if any difference of at
least ∆∗ is of interest, then we should choose the sample size to ensure a power of at
least 1 − β for any configuration of ∆is. Therefore, they recommend using the least
favourable configuration (LFC), which, in the absence of prior knowledge, is (∆∗, 0, . . . , 0).
A slightly different version of the LFC is used by Thall et al. (1988), who defined a
marginal improvement ∆∗1 and called (∆∗,∆∗1, . . . ,∆∗1) the LFC. In their examples they
use ∆∗1 = ∆∗/4. They use the adjusted power and argue that it is not reasonable to try to
detect very small differences between treatments and so do not consider values of ∆2 close
to ∆1. Horn and Vollandt also consider the case of prior knowledge that at least g of the
treatments will differ from the control by at least ∆∗ and consider configurations of the
form (∆∗, . . . ,∆∗, 0 . . . , 0), although they suggest that this is of little practical importance
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in clinical trials.
Horn and Vollandt give tables of results for equal allocation and for the square root
allocation. They find that, although the latter allocation is better, the differences are
not very great. Marschner (2007) follows the methodology of Horn and Vollandt (1998)
very closely, but concentrates on the most favourable configuration (MFC), where ∆i =
∆∗ ∀i ∈ {1, . . . , I}, noting that the choice of an appropriate configuration to choose the
sample size is not an obvious one.
4.2 A Strategy for Choosing the Sample Size
The practical question of which configuration of ∆is to choose the sample size for has
received very little attention in the literature. Using the LFC is rather extreme and can
lead to over-powered studies if the true configuration is different from the LFC.
Note that this question does not arise in two-arm trials. In these, choosing a sample size
to achieve a power of 1 − β to detect a difference of ∆∗ leads to a power which changes
smoothly from 1−β as the true difference changes from ∆∗. In multi-arm trials, however,
choosing a sample size to achieve a power of 1−β to detect at least one difference when the
differences are ∆∗ = [∆∗1, . . . ,∆∗I ] leads to a power function which changes in different ways
as ∆ changes from ∆∗ in different directions. For example, in a two-arm trial, ensuring
80% power for a difference of ∆∗ will ensure less than 80% power for any difference of
less than ∆∗. In a three-arm trial, ensuring 80% power for ∆1 = ∆∗,∆2 = 0 will achieve
considerably more than 80% power for ∆1 and ∆2 both slightly less than ∆
∗. The LFC
approach might, therefore, lead to excessively large sample sizes being chosen.
If we were to run I separate trials to compare each experimental treatment to the control,
in practice we would choose a sample size for each to achieve a specified power to detect
a difference of ∆∗. Considering the multi-arm trial as a way to save resources over indi-
vidual trials would then suggest using the MFC to choose the sample size and allocation.
This is rather extreme in the opposite direction from the LFC and could easily lead to
studies which are too small to detect treatment differences in all but the most favourable
configuration.
Instead of either of these two approaches, it might be sensible to ensure a power of 1− β
for ∆1 = ∆
∗ and a best guess as to how much worse the inferior experimental treatments
will be. If there is reason to believe that the treatments will have similar effects, ∆i = (I+
CHAPTER 4. DESIGN ISSUES IN MULTI-ARM TRIALS 121
1− i)∆1/I might be a reasonable guess, while otherwise ∆i = ∆1/i might be a reasonable
and moderately conservative choice. For I = 2, these both imply that ∆2 = ∆1/2, which
we will study later, along with the extreme configurations.
In a review paper promoting the use of Bayesian thinking in frequentist statistics, Bayarri
and Berger (2004) suggest a procedure which, in our problem, would involve specifying a
prior distribution for ∆ and choosing a sample size to ensure at least 80% power averaged
over that prior. In this chapter, we study the power at different values and configurations
of ∆ and recommend a procedure to choose the sample size which depends on a prior
point estimate of each ∆i. It would be a simple modification of this to implement Bayarri
and Berger’s procedure but, in keeping with the likelhood-based approach taken here, we
do not go as far as using Bayesian methods. This does, however, argue against using the
LFC or MFC as the basis for choosing the design, as these would correspond to minimax
and minimin procedures respectively, i.e. they represent the most extreme possible prior
beliefs.
Note also that, if the argument for using the LFC is accepted, the results in Chapter 3
suggest that we should use the test statistic T∞, whereas the argument for using the MFC
would lead to us using S01 . There, however, we argued that T2 was better over a broader
range of configurations and should at least be considered as a strong competitor to T∞.
The attitude we take to choosing the allocation and sample size in this chapter is logically
coherent with that conclusion.
In Section 4.3, we study the effect of the allocation for the test statistics T1, T2 and T∞
for I = 2 at the 5% and 1% levels of significance. Although Hochberg’s procedure also
seems good, giving results in between those of T2 and T∞, it is more complicated to use in
practice. It has no univariate test statistic and, for each allocation, requires us to find a
new nominal significance level α∗ to achieve the correct size. We will not study it further
in this thesis. The other test statistics studied in Chapter 3 seemed clearly inferior or at
least had some disadvantages and no clear advantages, so we do not study them further.
For each of the statistics considered, we look for the choice of δ (the proportion of subjects
on each experimental arm) which maximises the power. Some of the authors mentioned
in Section 4.1 instead look for the allocation which minimises the sample size required to
achieve a particular power, typically 80%. These are essentially different ways of looking
at the same issue, but by exploiting a suitable version of the scaling used in Chapters 2
and 3, we can present the results in a form which allows us to illustrate the results across
a reasonable range of powers, such as 65-95%, simultaneously.
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Given prior information, we will see in Section 4.4.1 how these can be used to choose
the sample size to achieve a specified power, conditional on the allocation chosen. By
separating the choice of allocation from the sample size, we allow suboptimal allocations
to be used if this is appropriate for ethical or practical reasons, i.e. a simple method for
calculating the sample size can be used whatever allocation proportions have been chosen.
In Section 4.3 we also consider the impact of patient allocation on the expected loss.
4.3 Effects of Allocation on Power and Expected Loss
Changing the proportion, δ, of subjects allocated to each experimental arm also controls
the correlation, ρ. For I = 2, ρ = δ/(1 − δ). By increasing δ we increase ρ and by
increasing the number of subjects on the control arm we decrease ρ. The range of δ and
ρ are therefore 0 < δ < 1/2 and 0 < ρ < 1, respectively. δ = 0 would mean no subjects
on the experimental arms, while δ = 1/2 would mean no subjects on the control. Getting
uncorrelated estimators of the ∆i by having a different control group for each experimental
arm would not help, because we lose power by increasing the variances of the treatment
comparisons, i.e. each comparison is between two groups of N/4 subjects, rather than
between two groups of, say, N/3 subjects. This was confirmed by Proschan and Follmann
(1995), who showed that, even if we fail to adjust for multiple testing when performing
separate experiments, higher power is still obtained in a single experiment with a common
control.
The optimal allocation depends on the relative sizes of the unknown ∆i, but exact results
can be obtained in only a few special cases. At one extreme, if one assumes that ∆i = ∆ ∀i
and S01 =
∑I
i=1 Zi is used, i.e. the test is based on a single contrast comparing the control
with the average of the active treatments which are all considered identical, then the
trial reduces to the two-arm case and δ = 1/(2I) is optimal, so that half the subjects
would receive the control treatment. We would expect a similar proportion to be optimal
for T1 = X
+
1 +
∑I
i=2
(Xi−Ei)+√
Vi
(which excludes arms which contribute less than expected
taking into account the correlation ρ under H0), which we saw in Chapter 3 was somewhat
better than S01 over a range of configurations.
At the other extreme, we noted in Chapter 3 that T∞ is best for a set of values of the
form (∆, 0, . . . , 0). Several authors have studied this situation, as described in Section 4.1,
mainly for Dunnett’s test, from which we can obtain the results for T∞ as a special case.
We note there that the square root allocation δ = 1/(I +
√
I) has been found to be very
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close to optimal for maximising the power.
These extremes suggest that, for I = 2, a sensible range of values of δ is
[
1
4 ,
1
3
]
, i.e.
between 1/3 and 1/2 of subjects should be allocated to the control. General results for T1
and T2 cannot be obtained, so we proceed by simulation. For completeness, and to check
for consistency with published results, we also simulate results for T∞. Details of the
simulation are described in Subsection 4.3.1 and the results are described in Subsections
4.3.2 and 4.3.4.
4.3.1 Simulations
The simulations described in the previous chapter had to be modified to allow for dif-
ferent patient allocations. In Chapter 3, the simulated values of Zi, for i = 1, 2, were
calculated by wi + (∆i/σ), where wi is a random value from the null distribution of
Zi and E(Zi) = ∆i/σ. However, if we change the patient allocation δ, the value of
σ =
√{1− (I − 1)δ}/{δ(1− Iδ)} and hence E(Zi) changes. In other words, the standard-
isation used is different for different patient allocations. To compare different allocations,
we need to use a single standardisation.
We choose a baseline value of σ, denoted σ∗, and calculate Zi from wi + (∆i/σ∗) so that
data from different patient allocations are being simulated from the same population.
The particular baseline we choose is the minimum value of σ for I = 2. By differentiating
σ2 = (1− δ)/{δ(1−2δ)} with respect to δ and equating to zero, we find δ∗ = arg minσ2 =
1− (1/√2) and hence σ∗ = 1/√3− 2√2. We define d∗i = ∆i/σ∗ = √3− 2√2∆i. Apart
from this, the simulations proceed as in Chapter 3. Note that for the allocation δ = δ∗,
di and d
∗
i are the same.
Various values of the proportion on the control, 1 − 2δ, between 1/3 and 1/2 were used,
along with 0.2 and 0.6, to show how much lower the power is outside the sensible range
of allocations. To save computing time, we did not simulate one billion sets of data to
get mean cutpoints. Instead, a fresh set of 100,000 simulations was used for each value
of δ and used to obtain the critical values of the test statistics and the same values
used to estimate the powers. As in Chapter 3, each set of simulations was generated
simultaneously to obtain results for all test statistics and for all values of d∗1 and d∗2,
i.e. they are all subject to the same random errors. As in Chapter 3, the approximate
standard error for any estimated power is about 0.158, 0.126 and 0.069 for 50%, 80%
and 95% power respectively. For comparing different allocations, therefore, the estimated
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standard error of a difference will typically be
√
2 × 0.126 = 0.178 and so any difference
in power greater than about 0.35% can safely be interpreted as being real and not due to
simulation variance. For comparing tests at the same allocation, the standard error of a
difference will be smaller than this, due to the use of the same set of simulated errors.
Results were calculated for d∗1 ∈ {2, 2.5, 3, 3.5, 4} and d∗2 ∈ {0, d∗1/2, 3d∗1/4, d∗1}. However,
in Subsection 4.3.2 we present the results only for cases which gave power between 65 and
95% for size 5% and 1% tests. In Subsection 4.3.4 we present the expected losses for the
same cases.
4.3.2 Effect of Allocation Proportion on Power
Table 4.1 shows the simulated powers against the proportion on the control, 1 − 2δ, for
tests at the 5% level of significance for various values of d∗1 and d∗2. Figure 4.1 shows the
same information graphically for the configuration ∆2 = 0. In this and other graphs, T3
refers to T∞. Note that T1 does not appear in the top left panel, since its power is always
lower than 65%. In this situation, T∞ is expected to be the best statistic and it is known
that the optimal allocation for T∞ is when 1 − 2δ is slightly less than
√
2 − 1 ≈ 0.414.
This is confirmed by the results, which show the highest powers for T∞ at 1 − 2δ = 0.4.
Interestingly, the highest power for each of the other tests is also attained very close to
0.4. However, the tables and figure show that the power is stable over a wide range of
allocations, so that choosing the optimal allocation is not crucial. In Chapter 3 we saw
that T2 is only slightly worse than T∞ for equal allocation with this configuration. The
results here show that this is true across all allocations.
The corresponding results for testing at the 1% level of significance are given in Table
4.2 and illustrated in Figure 4.2. The slight jumpiness in this plot is due to simulation
variation and suggests that we have done only just enough simulations to see the correct
pattern for testing at 1%. These results show a similar overall pattern to the results for
5%, but the differences between the tests are somewhat greater. However, as d∗1 increases,
the difference between tests decreases again. The optimal allocation seems to be close to
0.4 for all the test statistics.
Table 4.1 and Figure 4.3 show the powers for testing at 5% for ∆2 = ∆1/2, with d
∗
1
increasing from 2.5 to 3.5. The corresponding results for the 1% significance level are
shown in Table 4.2 and Figure 4.4. As well as confirming the result from the Chapter 3
that T2 is slightly better than T∞ in this case, these simulations show some interesting
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Table 4.1: Power for different proportions on the control at the 5% level.
Control
d∗1 d∗2 Test .5 .45
√
2− 1 .4 .35 1/3
2.5 0 T1 61.634 63.160 63.475 63.514 63.352 63.117
2.5 0 T2 68.907 70.147 70.317 70.496 69.940 69.570
2.5 0 T∞ 70.329 71.538 71.626 71.950 71.179 70.685
3 0 T1 77.514 79.083 79.365 79.610 79.462 79.193
3 0 T2 83.485 84.594 84.757 85.064 84.595 84.376
3 0 T∞ 84.674 85.662 85.799 86.107 85.487 85.101
3.5 0 T1 89.099 90.191 90.559 90.637 90.548 90.299
3.5 0 T2 92.851 93.525 93.709 93.751 93.528 93.326
3.5 0 T∞ 93.512 94.111 94.264 94.342 94.036 93.722
2.5 1.25 T1 74.704 74.647 74.243 73.894 72.371 71.745
2.5 1.25 T2 75.052 75.438 75.115 75.061 73.835 73.236
2.5 1.25 T∞ 73.826 74.625 74.442 74.673 73.564 72.926
3 1.5 T1 87.251 87.397 86.959 86.718 85.734 85.056
3 1.5 T2 87.876 88.047 87.913 87.949 87.044 86.531
3 1.5 T∞ 86.972 87.537 87.567 87.720 86.856 86.370
3.5 1.75 T1 94.679 94.772 94.591 94.483 93.812 93.387
3.5 1.75 T2 95.095 95.334 95.244 95.197 94.669 94.434
3.5 1.75 T∞ 94.703 95.059 95.082 95.091 94.625 94.317
2.5 1.875 T1 83.519 83.406 82.773 82.226 80.640 79.735
2.5 1.875 T2 81.609 81.623 81.108 80.870 79.441 78.730
2.5 1.875 T∞ 79.385 79.775 79.556 79.566 78.256 77.523
3 2.25 T1 93.382 93.250 92.773 92.661 91.459 90.911
3 2.25 T2 92.282 92.343 92.017 91.874 90.860 90.342
3 2.25 T∞ 90.858 91.102 90.957 91.028 90.048 89.518
2 2 T1 76.844 76.510 75.843 75.184 73.448 72.535
2 2 T2 73.909 73.595 73.119 72.865 71.201 70.286
2 2 T∞ 71.034 71.129 71.082 71.061 69.551 68.646
2.5 2.5 T1 90.891 90.735 90.222 89.833 88.490 87.760
2.5 2.5 T2 88.849 88.947 88.437 88.120 86.826 86.100
2.5 2.5 T∞ 86.760 87.165 86.838 86.672 85.587 84.833
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Figure 4.1: Power for different patient allocations with d∗1 = 2.5, 3, 3.5 and ∆2 = 0 (at
5%).
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Table 4.2: Power for different proportions on the control at the 1% level.
Control
d∗1 d∗2 Test .5 .45
√
2− 1 .4 .35 1/3
3.5 0 T1 64.957 67.447 67.733 69.189 68.298 68.341
3.5 0 T2 79.058 80.698 80.515 81.133 80.022 80.008
3.5 0 T∞ 80.797 82.159 82.270 82.736 81.511 81.357
4 0 T1 80.608 82.550 82.939 83.996 83.281 83.302
4 0 T2 90.277 91.467 91.179 91.589 90.988 90.776
4 0 T∞ 91.345 92.281 92.191 92.479 91.856 91.570
3 1.5 T1 65.738 65.675 64.587 65.041 61.919 60.857
3 1.5 T2 68.900 69.931 68.920 69.309 67.176 66.751
3 1.5 T∞ 66.949 68.440 68.206 68.700 67.068 66.586
3.5 1.75 T1 80.774 80.628 79.766 80.165 77.529 76.782
3.5 1.75 T2 83.732 84.440 83.871 84.093 82.430 82.157
3.5 1.75 T∞ 82.368 83.440 83.294 83.733 82.328 82.083
4 2 T1 90.991 91.065 90.349 90.583 88.887 88.324
4 2 T2 93.010 93.533 92.989 93.125 92.215 91.868
4 2 T∞ 92.236 92.923 92.740 92.983 92.232 91.955
3 2.25 T1 79.619 79.080 77.885 78.026 74.890 73.719
3 2.255 T2 77.321 77.668 76.417 76.436 73.955 73.274
3 2.25 T∞ 72.765 73.854 73.480 73.664 71.661 70.966
3.5 2.625 T1 91.169 91.019 89.990 90.048 87.892 86.968
3.5 2.625 T2 89.874 90.163 89.250 89.202 87.470 86.878
3.5 2.625 T∞ 86.800 87.451 87.158 87.331 85.744 85.365
2.5 2.5 T1 75.027 74.560 73.307 73.410 70.036 68.958
2.5 2.5 T2 70.658 70.938 69.581 69.361 66.510 65.699
2.5 2.5 T∞ 64.860 65.847 65.437 65.551 63.215 62.481
3 3 T1 89.936 89.735 88.660 88.663 86.384 85.406
3 3 T2 87.096 87.392 86.191 86.128 83.884 83.053
3 3 T∞ 82.740 83.412 83.061 83.144 81.205 80.449
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Figure 4.2: Power for different patient allocations with d∗1 = 3.5, 4 and ∆2 = 0 (at 1%).
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Figure 4.3: Power for different patient allocations with d∗1 = 2.5, 3, 3.5 and ∆2 =
1
2∆1 (at
5%).
points. First, for T∞, the optimal allocation for testing at 5% remains close to 1−2δ = 0.4,
but at 1% moves towards 0.45. However, for T2, it is better to increase the proportion
of subjects on the control, the optimum being close to 0.45. For T1, it is even higher,
being somewhere between 0.45 and 0.5. Figures 4.3 and 4.4 show that the power curves
even cross and, at its optimal allocation, T1 is more powerful than T∞ for testing at 5%,
even though it is considerably less powerful when equal allocation is used. Similarly, at its
optimal allocation, T2’s advantage over T∞ is somewhat greater than at equal allocation,
especially when testing at the 1% level.
Results with ∆2 = 3∆1/4 at the 5% level are shown in Table 4.1 and Figure 4.5. The
results for the 1% level are given in Table 4.2 and Figure 4.6. In this case, the optimal
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Figure 4.4: Power for different patient allocations with d∗1 = 3, 3.5, 4 and ∆2 =
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2∆1 (at
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Figure 4.5: Power for different patient allocations with d∗1 = 2.5, 3 and ∆2 =
3
4∆1 (at 5%).
allocation on control is close to 0.45 for all tests, or between 0.45 and 0.5 for T1. Again
the advantages of T1 and T2 over T∞ are greater at their optimal allocation than at equal
allocation and are greater at 1% than at 5%. In Table 4.2, for example, we see that T2
can have almost 4% higher power than T∞, much greater than any advantage of T∞ over
T2 that we have observed.
Finally, results for ∆2 = ∆1 are shown in Table 4.1 and Figure 4.7 for the 5% level of
significance and in Table 4.2 and Figure 4.8 for the 1% level of significance. As expected,
the optimal allocation for T1 is close to 0.5 and for T2 it gets closer to 0.5 than 0.45 for
testing at 5%, though not for 1% tests. For T∞, the optimal proportion on the control is
around 0.45. Once again, we see that the differences in power are bigger when testing at
the 1% level, with T2 giving more than 5% higher power than T∞ in some cases in Table
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Figure 4.6: Power for different patient allocations with d∗1 = 3, 3.5 and ∆2 =
3
4∆1 (at 1%).
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Figure 4.7: Power for different patient allocations with d∗1 = 2, 2.5 and ∆2 = ∆1 (at 5%).
4.2.
It can be seen that, along with the values of ∆1 and ∆2, the optimality of allocation
depends on which test statistic is being used and on the significance level. With lower
values of ∆2 the optimal allocation is around 1− 2δ = 0.4. As seen before, T∞ works best
for this configuration. As ∆2 gets bigger relative to ∆1 the optimal allocation changes
towards 1−2δ = 0.5 for T1 and, more slowly, in the same direction for the other tests. For
T∞ this occurs later than for the other two tests. For these configurations, T2 is better
than T∞ and, for the larger values of ∆2, T1 is even better.
The fact that the optimal allocation for Tk gets closer to 1−2δ = 0.5 for smaller k and for
larger ∆2 is not surprising. It is known that if ∆2 = ∆1, S
0
1 with 1− 2δ = 0.5 is optimal
and T1 and T2 can be seen as compromises between S
0
1 and T∞. It was less predictable
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Figure 4.8: Power for different patient allocations with d∗1 = 2.5, 3 and ∆2 = ∆1 (at 1%).
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that the differences would be so much greater at 1% than at 5%, but this is probably due
to the impact of the differences being greater in the tails of the distributions.
In all cases the balanced design (δ = 1 − 2δ = 1/3) is sub-optimal. Within the range
of values of δ suggested, differences in the power are reasonably small but, especially for
testing at the 1% level, not negligible. Of course, more extreme values of δ would lead to
much lower powers.
The results obtained here seem to confirm that both T2 and T∞ are reasonable testing
procedures, but suggest that, if unequal allocations can be used, T2 has worthwhile ad-
vantages unless there is a strong prior belief that only one treatment will be better than
the control.
4.3.3 Approximating the Allocation which Maximises Power
The simulated values presented in Subsection 4.3.2 give a good idea of the optimal value
of δ. To get a smoother approximation of the dependence of the power on δ, we fit
a quadratic regression of power at 5% on 1 − 2δ and check for lack of fit by adding a
cubic term. If the quadratic model is a good fit, then we estimate the maximum by
differentiating the quadratic function and equating to zero. The R2 values were all at
least 90%, the quadratic terms were all highly significant and in only one case was a
cubic term (marginally) significant. Hence, the quadratic curve seems to give a very good
approximation to the dependence of the power on δ.
The estimated optimal proportions on the control treatment are shown in Table 4.3. The
first section of the table confirms the result of Dunnett (1955) that, for T∞ with the
least favourable configuration, the optimal proportion on the control is slightly less than
√
2 − 1 ≈ 0.4142. Bechhofer and Tamhane (1983), using an approximation to the prob-
abilities, found the optimal proportion on the control to be 0.399. Our simulations give
systematically slightly higher optimal proportions to the control. Note also that our cut-
point for the test is obtained internally from the simulations and so tends to the exact
value as the number of simulations increases, while the approximate cutpoint of Dunnett,
used by Bechhofer and Tamhane, is known to give a test of size slightly greater than α.
The results are close enough to give essentially the same practical conclusions. It can be
seen that for larger ∆2, the optimal proportion on the control treatment for T∞ increases
steadily to 0.452 when ∆2 = ∆1.
The optimal allocation for the other test statistics is similar, but for the LFC they require a
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Table 4.3: Estimate of optimum allocation in the control arm for different configurations
of d∗1, d∗2 for maximising power of tests at 5%.
Configuration T1 T2 T∞
(2.5,0) 0.3900 0.4049 0.4101
(3,0) 0.3852 0.3977 0.4071
(3.5,0) 0.3865 0.4005 0.4082
(2.5,1.25) 0.4767 0.4517 0.4306
(3,1.5) 0.4702 0.4502 0.4277
(3.5,1.75) 0.4617 0.4441 0.4287
(2.5,1.875) 0.4865 0.4759 0.4474
(3,2.25) 0.4873 0.4695 0.4471
(2,2) 0.4982 0.4851 0.4521
(2.5,2.5) 0.4886 0.4739 0.4524
slightly smaller proportion of subjects on the control arm. However, the optimal allocation
changes more quickly as ∆2 increases. For T2 the optimum is about 0.40 for the LFC, but
reaches around 0.48 at the MFC. For T1 the change is even greater, the optimum going
from about 0.39 at the LFC to almost 0.5 at the MFC.
Although these results are interesting, they do not make a large difference in practice, as
was seen in Subsection 4.3.2. Nothing here contradicts Dunnett’s advice that allocating
a proportion
√
2 − 1 to the control gives powers which are nearly optimal for T∞ across
a range of configurations. We could add that the same is also true for the other test
statistics studied, unless there is a strong prior belief that the ∆is will be nearly equal.
4.3.4 Effect of Allocation Proportion on Expected Loss
As noted in Chapter 3, the power does not tell the full story about the properties of the
test statistics. In particular, if we assume that a selection will be made after performing
the test, the probability of incorrect selection is also of interest. However, as was argued
in Chapter 3, the probability itself is insufficient, as it does not take account of the
consequences of an incorrect decision. There we also calculated the expected loss, defined
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as E(Loss), where
Loss =

0 if we select treatment 1;
∆1 −∆2 if we select treatment 2;
∆1 if we fail to reject H0.
It is perfectly possible to choose a patient allocation to minimise the expected loss, rather
than to maximise the power. Similarly, the sample size could be chosen to achieve a
specific expected loss and this is discussed in Subsection 4.4.2.
When running the simulations described in Subsection 4.3.1, we calculated the expected
loss, as well as the power. The results for testing at the 5% level of significance, when
∆2 = 0 are shown in Table 4.4 and Figure 4.9. The conclusions from these are that
the optimal allocation is to have a proportion around 0.4 on the control and that T∞ is
consistently slightly better than T2 and considerably better than T1. These are similar to
the conclusions drawn from comparing the powers in Subsection 4.3.2.
The corresponding results for the 1% significance level are given in Table 4.5 and Figure
4.10. These show that the optimal allocation is close to 0.4 for all the test statistics.
The results at 5% when ∆2 = ∆1/2 are shown in Table 4.4 and Figure 4.11. For this
configuration, the optimal proportion on control is close to 0.4 for T∞, slightly greater
than 0.4 for T2 and 0.45 for T1. T2 consistently gives the smallest expected loss, but T∞
is not much worse. This is slightly different from the results found for power in that, for
T2, slightly fewer subjects should be allocated to the control to minimise the expected loss
than to maximise the power.
The corresponding results for testing at the 1% level are shown in Table 4.5 and Figure
4.12. These show a more complex pattern, with the optimal allocation for T∞ being
around 0.4 and for T1 and T2 decreasing from around 0.45 to around 0.4 as ∆1 increases.
Note that this is rather different from the conclusions in Subsection 4.3.2 for finding the
allocation which maximises the power, even though the same simulated data sets are being
used. Hence the decision about which allocation to use should depend on whether we are
aiming to maximise the power or make the best treatment selection. We also note that,
in terms of expected loss, the advantage of T2 over T∞ is greater at 1% than at 5%, but
perhaps not so dramatically as when we considered power. Perhaps this is because T∞
avoids type-III/IV errors better than T2.
The expected losses when ∆2 = 3∆1/4 when testing at 5% are shown in Table 4.4 and
Figure 4.13. The corresponding results for 1% are shown in Table 4.5 and Figure 4.14.
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Table 4.4: Expected loss for different proportions on the control at the 5% level.
Control
d∗1 d∗2 Test .5 .45
√
2− 1 .4 .35 1/3
2.5 0 T1 0.9771 0.9348 0.9229 0.9227 0.9241 0.9298
2.5 0 T2 0.7914 0.7574 0.7496 0.7457 0.7575 0.7668
2.5 0 T∞ 0.7540 0.7209 0.7158 0.7082 0.7257 0.7382
3 0 T1 0.6843 0.6343 0.6234 0.6156 0.6191 0.6271
3 0 T2 0.5035 0.4678 0.4606 0.4514 0.4647 0.4711
3 0 T∞ 0.4664 0.4348 0.4288 0.4197 0.4375 0.4491
3.5 0 T1 0.3850 0.3457 0.3318 0.3290 0.3314 0.3404
3.5 0 T2 0.2533 0.2288 0.2214 0.2198 0.2270 0.2343
3.5 0 T∞ 0.2299 0.2079 0.2017 0.1990 0.2092 0.2203
2.5 1.25 T1 0.7586 0.7514 0.7553 0.7592 0.7875 0.8008
2.5 1.25 T2 0.7370 0.7203 0.7222 0.7196 0.7418 0.7549
2.5 1.25 T∞ 0.7584 0.7322 0.7320 0.7231 0.7436 0.7573
3 1.5 T1 0.5084 0.4909 0.4969 0.4988 0.5183 0.5352
3 1.5 T2 0.4816 0.4638 0.4620 0.4553 0.4725 0.4848
3 1.5 T∞ 0.5008 0.4733 0.4672 0.4577 0.4742 0.4863
3.5 1.75 T1 0.2959 0.2776 0.2772 0.2743 0.2883 0.3000
3.5 1.75 T2 0.2769 0.2541 0.2506 0.2459 0.2549 0.2605
3.5 1.75 T∞ 0.2866 0.2603 0.2536 0.2472 0.2542 0.2625
2.5 1.875 T1 0.5654 0.5634 0.5755 0.5859 0.6200 0.6406
2.5 1.875 T2 0.6050 0.6002 0.6095 0.6130 0.6434 0.6592
2.5 1.875 T∞ 0.6536 0.6407 0.6433 0.6415 0.6692 0.6852
3 2.25 T1 0.3797 0.3763 0.3869 0.3858 0.4161 0.4301
3 2.25 T2 0.4076 0.3989 0.4049 0.4049 0.4294 0.4424
3 2.25 T∞ 0.4451 0.4316 0.4324 0.4269 0.4505 0.4640
2 2 T1 0.4631 0.4698 0.48314 0.4963 0.5310 0.5493
2 2 T2 0.5218 0.5281 0.5376 0.5427 0.5760 0.5943
2 2 T∞ 0.5793 0.5774 0.5784 0.5788 0.6090 0.6271
2.5 2.5 T1 0.2277 0.2316 0.2445 0.2542 0.2878 0.3060
2.5 2.5 T2 0.2788 0.2763 0.2891 0.2970 0.3294 0.3475
2.5 2.5 T∞ 0.3310 0.3209 0.3291 0.3332 0.3603 0.3792
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Figure 4.9: Expected loss for different patient allocations (5%) with d∗1 = 2.5, 3, 3.5 and
∆2 = 0.
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Table 4.5: Expected loss for different proportions on the control at 1%.
Control
d∗1 d∗2 Test .5 .45
√
2− 1 .4 .35 1/3
3.5 0 T1 1.2289 1.1410 1.1304 1.0791 1.1101 1.1085
3.5 0 T2 0.7347 0.6767 0.6827 0.6608 0.6995 0.7000
3.5 0 T∞ 0.6732 0.6252 0.6210 0.6046 0.6473 0.6525
4 0 T1 0.7766 0.6984 0.6827 0.6404 0.6688 0.6679
4 0 T2 0.3895 0.3416 0.3531 0.3366 0.3605 0.3690
4 0 T∞ 0.3466 0.3090 0.3126 0.3009 0.3258 0.3372
3 1.5 T1 1.12589 1.1169 1.1412 1.1261 1.2089 1.2359
3 1.5 T2 1.0164 0.9761 0.9983 0.9855 1.0392 1.0488
3 1.5 T∞ 1.0604 1.0089 1.0100 0.9950 1.0358 1.0476
3.5 1.75 T1 0.7685 0.7602 0.7817 0.7625 0.8451 0.8658
3.5 1.75 T2 0.6547 0.6184 0.6296 0.6176 0.6667 0.6720
3.5 1.75 T∞ 0.6913 0.6444 0.6420 0.6237 0.6648 0.6694
4 2 T1 0.4414 0.4234 0.4440 0.4302 0.4886 0.5078
4 2 T2 0.3554 0.3204 0.3342 0.3247 0.3521 0.3627
4 2 T∞ 0.3790 0.3392 0.3398 0.3266 0.3485 0.3569
3 2.25 T1 0.7673 0.7770 0.8070 0.8011 0.8849 0.9150
3 2.255 T2 0.8233 0.8084 0.8398 0.8372 0.9018 0.9178
3 2.25 T∞ 0.9447 0.9099 0.9172 0.9101 0.9619 0.9785
3.5 2.625 T1 0.4896 0.4870 0.5161 0.5113 0.5754 0.6027
3.5 2.625 T2 0.5265 0.5100 0.5343 0.5327 0.5828 0.5985
3.5 2.625 T∞ 0.6227 0.5951 0.5989 0.5907 0.6362 0.6449
2.5 2.5 T1 0.6243 0.6360 0.6673 0.6648 0.7491 0.7761
2.5 2.5 T2 0.7336 0.7266 0.7605 0.7660 0.8373 0.8575
2.5 2.5 T∞ 0.8785 0.8538 0.8641 0.8612 0.9196 0.9380
3 3 T1 0.3019 0.3080 0.3402 0.3401 0.4085 0.4378
3 3 T2 0.3871 0.3782 0.4143 0.4162 0.4835 0.5084
3 3 T∞ 0.5178 0.4976 0.5082 0.5057 0.5639 0.5865
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Figure 4.10: Expected loss for different patient allocations (1%) with d∗1 = 3.5, 4 and
∆2 = 0.
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Figure 4.11: Expected loss for different patient allocations (5%) with d∗1 = 2.5, 3, 3.5 and
∆2 =
1
2∆1.
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Figure 4.12: Expected loss for different patient allocations (1%) with d∗1 = 3, 3.5, 4 and
∆2 =
1
2∆.
CHAPTER 4. DESIGN ISSUES IN MULTI-ARM TRIALS 144
0.2 0.3 0.4 0.5 0.6
0.
0
0.
4
0.
8
1.
2
(2.5, 1.875)
control
Ex
pe
ct
ed
 lo
ss
0.2 0.3 0.4 0.5 0.6
0.
0
0.
4
0.
8
1.
2
(3, 2.25)
control
Ex
pe
ct
ed
 lo
ss
 
 
 
 
T_1
T_2
T_3
Figure 4.13: Expected loss for different patient allocations (5%) with d∗1 = 2.5, 3 and
∆2 =
3
4∆1.
This shows again that, as ∆1 increases, the optimum allocation changes from close to 0.45
to closer to 0.4 for all tests. It also shows again that the advantage of T2 over T∞ is greater
for testing at 1%.
Finally, the expected losses for ∆2 = ∆1 are shown in Table 4.4 and Figure 4.15 for testing
at 5% and Table 4.5 and Figure 4.16 for testing at 1%. The optimal allocation seems to
be close to 0.5 for T1, between 0.45 and 0.5 for T2 and close to 0.45 for T∞. Again, the
benefit of using T2 over T∞ seems greater at 1% than at 5% and certainly is not negligible.
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Figure 4.14: Expected loss for different patient allocations (1%) with d∗1 = 3, 3.5 and
∆2 =
3
4∆1.
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Figure 4.15: Expected loss for different patient allocations (5%) with d∗1 = 2, 2.5 and
∆2 = ∆1.
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Figure 4.16: Expected loss for different patient allocations (1%) with d∗1 = 2.5, 3 and
∆2 = ∆1.
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4.4 Sample Size Calculations
Whether the allocation proportion is chosen to maximise the power, minimise the expected
loss or for other practical reasons, its choice can precede the calculation of a sample size
for the trial. In this section we show how to find a sample size to achieve a pre-specified
level of power or expected loss, given an allocation proportion, a level of significance and
prior values of the treatment differences.
Up to now, we have worked mainly with versions of the treatment effects which are scaled
by the number of observations. To choose a sample size, we need to relate them to
the original scale of the response variable, so that realistic prior differences between the
treatments can be used. Let
E(Zi) = E
(√
N
θi
σ
)
,
where σ is such that V ar(Zi) = 1. Then ∆i =
√
Nθi.
As above, we have d∗i = (
√
2− 1)∆i and so
d∗i = θi
√
N(
√
2− 1).
Thus for any prior values of θ1 and θ2, it is straightforward to find the required d
∗
1 and
d∗2 as functions of N . Note that in the case when Zi =
√
N(Yˆi − Yˆ0)/σ, θ1 and θ2 are on
the same scale as Yij , so that the variance of the original responses affects the sample size
through the scaling, i.e. for the same unscaled difference, θi is smaller if the variance is
larger. We then need to find the d∗1 and d∗2 which achieve the required power or expected
loss, using the same simulations as in Section 4.3, so that we can find the required sample
size by equating the expressions for either d∗1 or d∗2 to give
N =
d∗2i
θ2i (
√
2− 1)2 . (4.1)
Since the simulations were set up to find the power or expected loss for specific values of
d∗1 and d∗2, we use repeated interpolation to find the d∗1 and d∗2 which achieve a specific
power or expected loss. Note that, since the same set of simulations is used for each ∆
for a specific allocation ratio, no new simulation runs are required.
4.4.1 Sample size to achieve specified power
As an example, the top left portion of Table 4.6 shows the values of d∗1 required to achieve
80% power when ∆2 = ∆1/2 for three different allocations, equal numbers on each arm, the
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Table 4.6: Effect sizes yielding 80% power and sample size ratio to achieve 80% power for
different δ for the tests at the 5% level with d∗2 = d∗1/2.
Ratio of required
d∗1 sample sizes
δ T1 T2 T∞ T1 v. T2 T∞ v. T2
1/3 (equal) 2.7878 2.7336 2.7418 1.0400 1.0060
√
2− 1 (root) 2.7109 2.6769 2.6979 1.0256 1.0158
1/4 (half) 2.7046 2.6913 2.7273 1.0098 1.0269
Ratio of required
sample sizes
equal v. root 1.0575 1.0428 1.0328
half v. root 0.9953 1.0108 1.0219
square root allocation and half of the patients on the control. These are not immediately
interpretable, but they do allow us to compare the sample sizes required by the different
test statistics or for different allocation proportions. For a fixed value of θ1, we can
calculate the required sample size from d∗1. So the ratio of the required sample sizes for
two different test statistics, or for two different allocations, is the ratio of d∗21 for these two
cases.
The bottom portion of the table compares equal allocation and half on the control with
the square root allocation. For T2 just over 4% more observations are required for equal
allocation than for the square-root allocation to achieve 80% power, whereas it only needs
1% more subjects when half of the subjects are allocated to the control. For T∞ about 3%
and 2% more subjects are required for equal allocation and for half on the control respec-
tively compared with the square root allocation. About 6% more subjects are required
for equal allocation compared with the square root allocation for T1, but about the same
number is required for half on the control and the square root allocation. Although equal
allocation requires larger sample sizes for all three test statistics, these results show that
if it is considered advantageous for practical or ethical reasons, the increase in the number
of patients is not enormous.
For each allocation proportion, we also compare the test statistics T1 and T∞ relative
to T2 in the right hand portion of Table 4.6. For equal allocation T∞ seems to require
almost the same sample size as T2, but T1 requires 4% more than T2. When the square
root allocation is used, then T∞ and T1 require about 1.6% and 2.6%, respectively, more
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subjects than T2. With half of the subjects on the control arm, T∞ needs about 2.7%
more subjects than T2, whereas T1 requires about the same number.
The configuration we have chosen here is in the middle where T2 is best and it is not
surprising that T2 requires smaller sample sizes. Similarly we can calculate the ratios for
any other configurations of interest, but we do not pursue this further here since it is a
straightforward calculation.
Example
We use an example from Horn and Vollandt (1998) who calculate the sample size required
to achieve at least 80% power for T∞ with expected differences of 1 and 0 and variance of
observations equal to 5. We standardise these to our scale to get θ1 = 1/
√
5 and θ2 = 0.
For equal allocation, by interpolation from the simulation results, we find the required
d∗1 = 2.818. Plugging this into equation (4.1), we get
N ≥ 2.818
2 × 5
(
√
2− 1)2 = 231.5.
Our required numbers of subjects on each arm are then the smallest integers which satisfy
this inequality, which are (n0 = ni = 78), very close to Horn and Vollandt’s (n0 = ni = 77).
The slight difference could be due either to simulation error in our results, or to the fact
that Horn and Vollandt’s any-pair power does not correspond exactly to the power of T∞.
For the square root allocation, we find that T∞ requires exactly the same number of n0
and ni (n0 = 93 and ni = 66) as Horn and Vollandt.
Using the same prior values we also calculated sample sizes for T2. For the balanced
design n0 = ni = 80 and, with the square root allocation, n0 = 95 and ni = 68. Thus the
total sample sizes required for T∞ are 234 and 225 for equal and square root allocation
respectively, while for T2 they are 240 and 231 respectively. It can be seen again that the
differences between the allocations and between the test statistics are all small. However,
this example is for the least favourable configuration, i.e. only one experimental arm is
better than the control. We already know that this is the situation which is most favourable
to T∞.
4.4.2 Sample Size to Achieve Specified Expected Loss
The method described in Section 4.4.1 can be used in exactly the same way, but with a
target minimum power replaced by a target maximum expected loss. We illustrate with
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Table 4.7: Effect sizes yielding 0.5 expected loss and sample size ratio to achieve 0.5
expected loss for different δ for the tests at the 5% level with d∗2 = d∗1/2.
Ratio of required
d∗1 sample sizes
δ T1 T2 T∞ T1 v. T2 T∞ v. T2
1/3 (equal) 3.0715 2.9721 2.9739 1.0334 1.0006
√
2− 1 (root) 2.9947 2.9185 2.9370 1.0261 1.0063
1/4 (half) 3.0205 2.9727 3.0067 1.0161 1.0114
Ratio of required
sample sizes
equal v. root 1.0184 1.0125 1.0257
half v. root 1.0186 1.0237 1.0086
an expected loss of 0.5. The value of 0.5 is chosen so that the sample sizes will be similar
to those required for 80 − 90% power. Table 4.7 corresponds to Table 4.6, but for the
expected loss of 0.5. We see that, in terms of expected loss, the allocation is less crucial.
For example, for T2, equal allocation requires an increase in sample size of only about
1.25% compared with the square root allocation. We also see that the differences between
the test statistics is very small with, in this case, T∞ requiring an increase of less than 1%
in sample size relative to T2 at the square root allocation and almost no increase at equal
allocation.
The practical consequence of these results is that the decision as to whether to use equal
allocation or close to optimal allocation depends on whether one places more importance
on the power of the test, or on the quality of the treatment finally selected. In the latter
case, there is little to be gained by using anything other than equal allocation and, if this
has practical benefits, we should stick to it. The fact that the differences between test
statistics is so small might be reassuring, in that whichever we use will not give terrible
results, but it does not tell us any more about which one we should use. If ∆2 = ∆1/2
seems like a plausible prior guess, then these results do not give any reason to choose
anything other than T2. The choice of sample size proceeds exactly as for power, but with
the value of d∗1 being obtained from the expected loss, rather than the power.
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4.5 Conclusions
We have shown that the optimal allocation depends on the unknown ∆i and on the test
statistic to be used. The optimum proportion to be allocated to the control treatment is
between 0.4 and 0.5, so that equal allocation is never optimal. However, in most practical
cases, including the ATAC, DASH and MORE trials described in Chapters 1 and 2, equal
allocation is used. Other considerations can influence patient allocation, such as secondary
comparisons between the experimental treatments and information on side effects. Also,
the practicality of obtaining informed consent from subjects is easier with equal allocation.
Also, if the control is suspected of being the worst treatment, we do not want to maximise
the numbers on control. Finally, our results have shown that, although equal allocation is
clearly inferior, the difference in the required sample size is not enormous.
Hence, the equal allocation case described in Chapter 3, is still of great practical impor-
tance and the conclusions given there are important in practice. However, if appropriate,
careful consideration should be given to choosing an appropriate allocation and in this
chapter we have shown how this can be done optimally.
Chapter 5
Binary Response Data
In this chapter we consider comparing several experimental treatments with a control
using binary outcomes, paying particular attention to three arm trials. Binary responses
(including dichotomized continuous variables) are very common in many experimental
settings.
In previous chapters we assumed normality, which provides asymptotic approximations
for other types of data for large samples. Now we consider the observed proportion of
successes in experimental and control arms and use normal approximations to both the
raw binomial random variables for each arm and univariate test statistics Zi based on
log odds ratios. Using Monte Carlo simulations for some particular sample sizes and
probabilities of success, we approximate the sizes of the tests obtained by using the critical
values calculated for normal distributions.
Although it is reasonable to apply the normal approximation to binary data for large
samples, it might not be accurate enough for small samples. In this chapter we also derive
the likelihood ratio test statistic λ, using the violator algorithm, for binary data. Since, it is
not possible to obtain a standardized form of the null distribution in this case, we calculate
the exact distribution of λ conditional on the observed total number of successes. This is
somewhat in the spirit of Fisher’s exact test, which is used for testing the null hypothesis
of equality against the two-sided alternative.
In Section 5.1, we define the model and notation to be used in this chapter. Related
literature is reviewed in Section 5.2 and the general analysis strategy we recommend is
outlined in Section 5.3. Approximate methods suitable for large samples are described
and assessed in Section 5.4, for equal allocation and, more briefly, for 40% allocated to
the control. An exact conditional test is developed in Section 5.5. Examples are given in
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Section 5.6 and some final points are discussed in Section 5.7.
5.1 Model and Notation
Throughout this chapter, we assume that there are ni subjects on the ith arm, i = 0, . . . , I,
whose responses, Yij , j = 1, . . . , ni, are independent with probability of success pii. As
is standard practice, we will refer to the outcomes as “success” (Yij = 1) or “failure”
(Yij = 0). Let Yi =
∑ni
j=1 Yij . Then Yi ∼ Bin(ni, pii). Our null and alternative hypotheses
are H0 : pii ≤ pi0 ∀ i = 1, ..., I and H1 : pii > pi0, for at least one i, respectively. As in the
previous chapters, we will refer to the null hypothesis of equality as H∗0 : pi0 = pi1 = · · · =
piI and the individual null hypotheses as H0i : pii ≤ pi0 and H∗0i : pii = pi0.
5.2 Relevant literature
Several authors who have developed methods for comparing several experimental arms
with a control for continuous data have mentioned in passing that they also provide an
asymptotic approximation to the case of binary response data. Some of these authors have
evaluated the large sample methods for use with binary data. Rather fewer have dealt
with the binary case directly. Here we review what relevant literature there is. Many
authors compare different methods, often including methods which are similar, but not
identical. It is easiest to present the literature in chronological order.
The early paper by Paulson (1952), mentioned in Chapter 2, although mainly concentrat-
ing on the normal distribution, gives a brief description of the binomial case. He does
an angular transformation and then uses, in effect, T∞ to test H0. Modifications of this
approach are developed by Dunnett (1984) and Chen and Sarkar (2004).
For comparing several treatments with a control, to test H∗0 against the alternative of
a simple order, Williams (1988) considers several test statistics, including the standard
chi-squared (X2) and likelihood ratio (G2) test statistics for the two-sided alternative and
the Cochran-Armitage statistic for testing a pre-specified trend. He develops the isotonic
regression estimates for a simple order and suggests using a modified chi-squared test
statistic (X¯2), in which the isotonic regression estimators replace the observed propor-
tions. He also obtains the likelihood ratio test (LRT) statistic (G¯2) for the simple ordered
alternative. He briefly mentions the simple tree ordered alternative and says X¯2 and G¯2
can be used with these estimates but he does not pursue this. He also looked at T¯ which
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is the LRT statistic for testing equality in an order restricted model with normal data,
mentioned briefly in Chapter 2. Finally he considers Dunnett’s test.
Williams (1988) uses published approximations of the null distributions of all of these test
statistics (except G¯2) and assesses their accuracy by finding the exact null distributions,
conditional on Y =
∑I
i=0 yi (total number of successes), for Y = 1, ..., 30, and plots the
achieved sizes against Y . He finds that X2 is better than G2, but is somewhat conservative.
G2 is conservative for small Y but liberal otherwise; it’s liberality can be reduced, but
not removed, by using a Bartlett adjustment. Williams finds that the approximate size
of the Cochran-Armitage statistic is surprisingly accurate, X¯2 is no worse than X2, T¯ is
not as good as X¯2 and Dunnett’s test is even worse. He concludes that we should not
rely on continuous approximate distributions, but should instead use the exact conditional
distributions, in a manner similar to Fisher’s exact test. He goes on to show how this can
be done for a general test statistic under the null hypothesis. He notes it takes quite a lot
of computing time for X¯2 and G¯2, but recommends this as being worthwhile.
In a paper on more general multiple comparisons with binary responses, Piegorsch (1990)
briefly considers multiple comparisons with a control, using the one-sided alternative
against H∗0 . He considers the properties of procedures similar to T∞ when applied to
statistics calculated from binary data. The statistics considered are those commonly used
in generalized linear models, namely the logit, probit and complementary log-log link func-
tions. The logit link is of most interest to us since it corresponds to using the log odds
ratios of estimated proportions as the Zi in any of the test statistics defined in Chapter 2.
The tests considered are Dunnett’s test, Simes’ procedure, Hommell’s modification (which
is very similar to Hochberg’s procedure) and the likelihood ratio test LRT for H∗0 .
Piegorsch carries out a simulation study and reports that Dunnett’s procedure is too
conservative for moderate sized samples and the LRT is slightly better, but sometimes
liberal. Piegorsch recommended that the asymptotic procedures could be used for total
sample sizes above about 100. In a follow-up paper concentrating on confidence intervals,
Piegorsch (1991) found that the coverage of Dunnett-type intervals was unacceptable for
sample sizes smaller than about 300, but could be improved by applying the so-called
Jeffreys-Perks method of Beal (1987). This involves adjusting the standard error of pˆii− pˆi0
using a Bayesian procedure.
The most comprehensive study comparing methods was carried out by Chuang-Stein and
Tong (1995). They consider three methods for comparing several treatments with a con-
trol for binary outcomes, assuming the hypotheses H0i : pii = pi0 are compared against the
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two-sided alternatives H1i : pii 6= pi0 for i ∈ {1, . . . , I}. The methods are therefore directly
analogous to the two-sided test based on Dunnett’s procedure. The three methods con-
sidered all make use of the difference between the largest observed proportion of successes
and the proportion of successes on the control.
The following methods were considered by Chuang-Stein and Tong. The methods differ
only in the rejection (or equivalently acceptance) region used.
1. The asymptotic Freeman-Tukey acceptance region uses a modified angular (arc sin)
transformation of pˆii and then uses a normal approximation to find the critical value
based on Dunnett’s method.
2. The binomial acceptance region uses acceptance boundaries assuming the true pi0
and piis are equal to the pooled pˆi, i.e. the combined probability of success. They
then calculate the full discrete null distribution of the test statistic, i.e. they calcu-
late the test statistic for all possible values of y0, y1, . . . , yI and the corresponding
probabilities of these values under H∗0 , but with the additional assumption that
pii = pˆi ∀i ∈ {0, . . . , I}. They then use a test statistic which is like T∞ except that
they use this pooled pˆi to get the standard error in each comparison. They state
that using a fixed standard error gives more stable null probabilities than using a
different one for each arm.
3. Dunnett’s method is used directly on the binary responses, relying on the normal
approximation to the binomial distribution to give reasonable answers for large sam-
ples.
Chuang-Stein and Tong (1995) report a simulation study to check the sizes of the tests and
find that they are all rather similar. For small sample sizes they can be very conservative
whereas for moderate sample sizes they can be a bit liberal and for large sample sizes they
give close to 5% type I errors. They conclude that direct use of Dunnett’s method is as
good as any of the other procedures in most cases. However, if the pooled pˆi is between
1/3 and 2/3 then they recommend using the Freeman-Tukey transformation procedure.
Agresti and Coull (1996) consider testing H∗0 against the simple ordered alternative, with
the additional complication of having other covariates. They obtain the LRT statistic for
this case and approximate the conditional null distribution by simulation after fixing the
marginal totals. This is similar to work we will present in Section 5.5, but in a different
context.
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Koch and Hothorn (1999) consider four different versions of the T∞ test statistic, all using
large sample normal approximations, but based on different Zi’s, namely:
1. Zi = pˆii − pˆi0 (unscaled);
2. scaled by unpooled variance estimates;
3. scaled by pairwise pooled variance estimates, i.e. pii and pi0 are pooled.
4. scaled by the total pooled variance estimate, i.e. all are pij pooled, j = 0, ..., I.
They describe how to get the exact conditional distributions for binary data. They note
that options 2 and 3 above exhaust the α level better than 1 and 4, i.e. the null distribution
has more distinct discrete values so that it is possible to get an actual size closer to the
desired α.
Koch and Hothorn then go on to consider the exact unconditional null distributions of test
statistics 2 and 3 above, which depend on the unknown pi. They take the critical value to
be the smallest such that the size of the test is less than or equal to α for all values of pi, in
a manner similar to Barnard’s exact test. They then compare the exact tests for statistics
2 and 3 with statistics 2, 3 and 4 (by simulation) using Dunnett’s critical values. The exact
distribution for the unpooled statistic gives a test which is very conservative for most pi,
while the pairwise pooled statistic is slightly conservative for most pi, but rather more
conservative for large values of pi. The tests based on the large sample approximations
can be very liberal or very conservative depending on pi. The main results presented for
illustration are from a very unbalanced design with n0 = 40, n1 = 10 and n2 = 10 and
they state that this is worse than for the balanced design.
Peddada et al. (2001) extend the work of Hwang and Peddada (1994), mentioned in
Chapter 2, to binary data. Considering the null hypothesis of equality, they explore
the simple ordered and simple tree ordered alternatives. They show how to obtain the
maximum likelihood estimators under a simple tree order from the pool adjacent violators
algorithm (PAVA). They consider a test statistic similar to T∞, but with the estimator
of Hwang and Peddada (1994), i.e. the estimator of each experimental arm is replaced
with its isotonic regression estimator from an arbitrary order. They obtain p-values by
bootstrapping, but also use Bonferroni corrections assuming asymptotic normality.
It can be seen from this review that most work on binary response data uses tests which are
similar to T∞, which was described in Chapter 2, or simple modifications of it. On the other
hand, Williams (1988), Piegorsch (1990) and Agresti and Coull (1996) consider likelihood
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ratio test statistics for testing the null hypothesis of equality assuming an order restricted
model. As explained in Chapter 2, this restriction to the model is not appropriate in the
cases we are considering and test statistics based on such an assumption have undesirable
properties, such as decreasing as the response from some active arm increases. In this
chapter, we develop more appropriate likelihood ratio tests, either based on T2 with large
sample approximations, or developed directly from the binomial probability function.
5.3 A strategy for analysing binary data
Even more than is the case for the normal distribution, most literature on comparing
several experimental arms with a control using binary data deals with the null hypothesis
of equality. As noted by Chuang-Stein and Tong (1995), compared with the normal
distribution, there is rather little research on binary data in this context.
We first consider how to use the methods of earlier chapters with binary data, using large-
sample approximations. The simplest approach is to apply the methods of earlier chapters
to the total number of successes on each treatment, assuming that the normal approxima-
tion to the binomial distribution will give acceptable results. This is an extension of the
simple test for comparing two proportions which is frequently presented in introductory
textbooks and courses, e.g. Armitage et al. (2002), p.125. This approach has been studied,
mainly as applied to Dunnett’s test, by for example Williams (1988), Chuang-Stein and
Tong (1995) and Koch and Hothorn (1999), as described in Section 5.2.
Another possibility we consider is to use univariate LRT statistics based on the observed
log odds ratios and assume that these have approximately normal distributions. This
is a direct extension of the asymptotic z-tests which are often used in two-arm trials
and in other contexts, e.g. through the use of generalized linear models with a logistic
link function - see, for example Armitage et al. (2002), p.127-128. This approach has been
studied, again mainly through the use of Dunnett’s test, by Williams (1988) and Piegorsch
(1990, 1991).
For small samples we will find that neither of these approaches gives acceptable results
and instead we develop an exact conditional test in the spirit of Fisher’s exact test, for
which see, for example, Armitage et al. (2002), p.134-137, and its extension to (I + 1)× 2
contingency tables (Mehta and Patel, 1983; Mehta, 1994). Just as the test statistic used
in Fisher’s test can be derived as the LRT statistic for testing equality against a two-
sided alternative for binomial data, so we derive the LRT statistic for our hypotheses.
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Then, just as in Fisher’s exact test, we condition on the marginal totals, the total number
of successes across all arms, and consider the distribution of the test statistic under all
possible contingency tables satisfying this condition. Other authors who have studied
exact conditional tests in similar contexts include Williams (1988) and Agresti and Coull
(1996).
There is some controversy in the literature about whether exact conditional tests or exact
unconditional tests should be used. The former condition on the total number of successes
across all arms, while the latter either condition on a fixed value of pi, such as pˆi, or take
a minimax approach to removing the dependence on pi, as in Barnard’s exact test for the
two-sided alternative to the null hypothesis of equality. Barnard’s test has been shown to
be more powerful for 2 × 2 tables, where Fisher’s test is very conservative. However, for
more arms the conservativeness of Fisher’s test reduces, due to the discrete distribution
having more points, while the conservativeness of Barnard’s test, which is due to the
minimax approach, as well as the discreteness, remains. Ultimately, there is no single
correct answer, but most authors have preferred the conditional tests and we also find this
to be the most natural approach. For some discussion of this topic, see Suissa and Shuster
(1985) and the references contained therein.
5.4 Large sample approximations
We consider two ways of using normal approximations. Since the binomial variance de-
pends on the mean, there are different ways of doing this. First, we use the original
proportions, with the normal approximation to the binomial distribution. Then, following
the suggestion in Chapter 2, we define the Zi using the log odds ratios and assume that
they are approximately normally distributed. We then use simulations to check the sizes
of the asymptotic tests for some particular sample sizes and values of pii.
5.4.1 Normal approximation to the binomial distribution
We apply the simple normal approximation to the binomial distribution and use the scaled
difference of two proportions from independent binomial samples as a univariate test statis-
tic. The normal approximation to the binomial distribution for our model gives
Zi =
pˆii − pˆi0√
pˆi(1− pˆi)( 1n0 + 1ni )
, (5.1)
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for i ∈ {1, . . . , I}, where pˆii = yi/ni and
pˆi =
∑I
i=0 yi∑I
i=0 ni
,
since
V ar(pˆii − pˆi0) = pi0(1− pi0)
n0
+
pii(1− pii)
ni
,
which, for the purposes of hypothesis testing, we approximate by
V̂ ar(pˆii − pˆi0) = pˆi(1− pˆi)
(
1
n0
+
1
ni
)
.
Note that we are using the total pooled variance, following the recommendation of Koch
and Hothorn (1999). Although it might seem more efficient to use
ˇV ar(pˆii − pˆi0) = pˆi0(1− pˆi0)
n0
+
pˆii(1− pˆii)
ni
,
Koch and Hothorn (1999) found that this was too conservative for a test statistic corre-
sponding to T∞. Note that V̂ ar(pˆii − pˆi0) ≥ ˇV ar(pˆii − pˆi0) by Jensen’s inequality.
It is immediately clear that V ar(Zi) ' 1 and, assuming equal numbers of subjects on each
experimental arm,
ρ = Cov(Zi, Zj) =
Cov(pˆii − pˆi0, pˆij − pˆi0)
pˆi(1− pˆi)
(
1
n0
+ 1n1
)
=
V ar(pˆi0)
pˆi(1− pˆi)
(
1
n0
+ 1n1
)
' n1
n0 + n1
=
δN
δN + (1− Iδ)N ,
where, as in earlier chapters, δ is the proportion of subjects on each experimental arm.
After simplification, we get
ρ ' δ
1− (I − 1)δ .
Hence when pi0 = pi1 = · · · = piI Z = [Z1, . . . , ZI ] is approximately multivariate normal,
with the same distribution as in Chapter 2.
5.4.2 Univariate likelihood ratio test statistics
Here we use the log odds ratios of the estimated proportions of successes in each arm
relative to the control. This is also a large sample approximation, but based on the
general asymptotic normality of LRT statistics. Let
ψi =
pii/(1− pii)
pi0/(1− pi0) ,
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i = 1, . . . , I, be the odds ratio of success on treatment i and control, where pii is the
probability of success on treatment i, i = 0, 1, . . . , I. For large N,
log ψˆi ∼ N(logψi, V ar(log ψˆi))
(Armitage et al., 2002, p.127), where
ψˆi =
pˆii/(1− pˆii)
pˆi0/(1− pˆi0) ,
and
V ar(log ψˆi) =
1
n0pi0(1− pi0) +
1
nipii(1− pii) .
In practice we use
V̂ ar(log ψˆi) =
1
n0pˆi0(1− pˆi0) +
1
nipˆii(1− pˆii) .
We scale the log odds ratios to get Zi with unit variance, so that
Zi =
log ψˆi√
V̂ ar(log ψˆi)
= log
(
pˆii/(1− pˆii)
pˆi0/(1− pˆi0)
)√
n0nipˆi0pˆii(1− pˆi0)(1− pˆii)
nipˆii(1− pˆii) + n0pˆi0(1− pˆi0) . (5.2)
From the general properties of LRT statistics, Zi ∼ N(0, 1).
To obtain the correlation, we note that, as ni →∞, √ni(Zi − ζi)→p 0, where
ζi = log ψˆi /
√
V ar(log ψˆi).
Hence, the asymptotic correlation of Zi and Zj is
ρ = Cov(ζi, ζj) = Cov
(
log ψˆi
se(log ψˆi)
,
log ψˆj
se(log ψˆj)
)
=
Cov(log ψˆi, log ψˆj)
V ar(log ψˆi)
,
since the standard errors are constant for equal numbers of subjects on each experimental
arm. Hence,
ρ =
n0n1pi(1− pi)
n0 + n1
[
Cov
{
log
(
pˆii
1− pˆii
)
, log
(
pˆij
1− pˆij
)}
−Cov
{
log
(
pˆi0
1− pˆi0
)
, log
(
pˆii
1− pˆii
)}
− Cov
{
log
(
pˆi0
1− pˆi0
)
, log
(
pˆij
1− pˆij
)}
+Cov
{
log
(
pˆi0
1− pˆi0
)
, log
(
pˆi0
1− pˆi0
)}]
=
n0n1pi(1− pi)
n0 + n1
V ar
{
log
(
pˆi0
1− pˆi0
)}
=
n0n1pi(1− pi)
n0 + n1
1
n0pi(1− pi)
=
δ
1− (I − 1)δ ,
CHAPTER 5. BINARY RESPONSE DATA 162
as before. Hence, the asymptotic distribution of Z is the same as in Chapter 2 and Section
5.4.1.
5.4.3 Simulations
Simulations of the null distribution were performed for the case I = 2. We generated
2,000,000 trials for three independent binomial samples for a given probability of success,
assumed to be the same in each arm, then for each simulation run calculated Z1 and
Z2, using each of the methods in Subsections 5.4.1 and 5.4.2. Then the values of T2 and
T∞ were calculated for each approximation. Note that the simulations allow the extreme
cases yi = 0 and yi = 1. In these cases the likelihoods were calculated directly to avoid
computational problems.
We present results for pi = 0.5 and pi = 0.1 to represent the case with smallest variance and
a case with reasonably large variance. Note that, since we are doing one-sided tests, the
results for pi = 0.1 cannot be assumed to apply for pi = 0.9. We present results with small,
moderate and fairly large sample sizes. In the case of equal allocation, we use the best
available critical values from Chapter 3, shown in Table 3.2, to check if each simulation
would reject H0 or not. This allows us to estimate the true size of each test.
5.4.4 Results for equal allocation
We first present the results for the simple approximation on the original scale. The esti-
mated sizes of the tests in the case of equal allocation are shown in Table 5.1 and plotted
in Figures 5.1 and 5.2. Generally, with moderate to large sample sizes, T2 seems liberal
when testing at 5% or 2.5%, but slightly conservative when testing at 1%. For a total
sample size of 600 or greater the sizes are very close to the nominal value. With a small
sample size of 30, the picture is much more confused, the test being severely conservative
or slightly liberal in different cases.
Note that the highly discrete nature of the true null distribution for such small sample
sizes mean that a slight change in the critical value could lead to a large change in the
size of the test. We could improve these results by using a randomized test, in which we
replace the large sample critical value, which is impossible to achieve with discrete data,
with the possible value immediately below it. If this value is obtained from our data, we
randomly reject or do not reject H0 in order to achieve a true size of exactly α. Such tests
are rarely used in practice and we will not pursue them here.
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Figure 5.1: Sizes of tests for T2 using normal approximation to binomial. The solid line
represents pi = 0.5 and the dashed line represents pi = 0.1. Black, red and blue represent
5%, 2.5% and 1% significance levels respectively.
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Figure 5.2: Sizes of tests for T∞ using normal approximation to binomial. The solid line
represents pi = 0.5 and the dashed line represents pi = 0.1. Black, red and blue represent
5%, 2.5% and 1% significance levels respectively.
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Table 5.1: Test sizes (%) using mean critical values for large sample approximation on the
original scale with δ = 1/3 for T2 and T∞
Estimated size of the test
N pi T2 T∞
5% 2.5% 1% 5% 2.5% 1%
30 .5 4.41 2.55 1.17 4.00 3.79 1.14
.1 3.96 0.70 0.38 3.97 2.29 0.38
90 .5 5.21 2.67 0.91 4.71 2.53 1.27
.1 5.48 2.58 0.66 5.59 2.56 0.98
300 .5 5.37 2.76 0.10 5.08 2.61 0.87
.1 5.15 2.59 0.93 5.06 2.58 0.97
600 .5 5.02 2.51 0.94 4.63 2.27 1.01
.1 5.14 2.49 0.96 5.19 2.55 1.00
1500 .5 5.17 2.55 0.98 4.85 2.70 0.99
.1 5.05 2.52 0.99 5.08 2.54 1.01
The results for T∞ are rather different, showing more variation between pi of 0.5 and 0.1.
For pi = 0.1, with moderate sample sizes it is generally liberal, whereas for pi = 0.5 it
can be conservative. For a sample size of 30, the results are similar to those for T2. For
T∞, the sizes are reasonably close to the nominal values for sample sizes of 300 or greater.
These results broadly agree with those presented by Chuang-Stein and Tong (1995) for a
two-sided alternative hypothesis.
The corresponding results for the large sample approximation based on log-odds ratios
with equal allocation are given in Table 5.2 and plotted in Figures 5.3 and 5.4. We find
that the sizes of the tests are not close to the nominal values unless the total sample size is
at least 600 and 1500 is better. For moderate sample sizes, T2 is generally slightly liberal
when pi = 0.5, except at the 1% level and somewhat conservative when pi = 0.1. For small
sample sizes, it can be quite extreme in either direction, the results for pi = 0.1 being
particularly far from the nominal sizes. Note that for N = 30 and pi = 0.1, H0 is rejected
if there are no successes on the control but at least one success on either of the other arms.
The probability of this is
P
(
{pˆi0 = 0}
⋂
{pˆi1 + pˆi2 > 0}
)
= 0.910
(
1− 0.920) = 0.3063,
which is very close to the tabulated size. This suggests that having no successes on the
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Table 5.2: Estimated test sizes (%) for the large sample approximation using log odds
ratios with δ = 1/3 for T2 and T∞
Size of the tests
N pi T2 T∞
5% 2.5% 1% 5% 2.5% 1%
30 .5 4.33 1.85 0.61 3.89 1.29 0.49
.1 30.65 30.64 30.64 30.65 30.64 30.64
90 .5 4.95 2.65 0.80 4.72 2.54 0.71
.1 5.13 4.34 4.24 5.32 4.32 4.24
300 .5 5.32 2.42 0.98 5.03 2.60 0.84
.1 4.22 1.87 0.54 4.10 1.83 0.52
600 .5 5.03 2.50 0.94 4.64 2.27 1.02
.1 4.71 2.20 0.80 4.60 2.15 0.76
1500 .5 5.18 2.53 0.96 4.86 2.52 0.98
.1 4.88 2.41 0.93 4.90 2.35 0.90
control accounts for almost all the probability of rejecting H0. The results for T∞ are
broadly similar.
The inaccuracy of the sizes of the tests achieved might alone be enough to make us hesitant
about using these asymptotic methods in small samples. However, in Section 5.6 we will
apply them to some examples, for one of which we carry out a small power study.
5.4.5 Results for unequal allocation
In Table 5.3, we show some results for a different treatment allocation, namely having
40% of subjects on the control, which we found in Chapter 4 was close to optimal. In
this case, since we do not have mean cutpoints for the unequal allocation, the critical
values are estimated from two million simulations. The results for equal allocation are
also shown, which are almost identical to those in Table 5.1, confirming that the critical
values are adequately estimated. The pattern of results is broadly similar for the different
allocations, but we can see that for unequal allocation some of the sizes are considerably
further from their nominal values than for equal allocation. The results for T∞ at 5% can
be compared with those of Koch and Hothorn (1999), although they used an even more
unequal allocation and different sample sizes. Our results are broadly similar to theirs, as
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Figure 5.3: Sizes of tests for T2 using normal approximation to log odds ratio. The solid
line represents pi = 0.5 and the dashed line represents pi = 0.1. Black, red and blue
represent 5%, 2.5% and 1% significance levels respectively.
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Figure 5.4: Sizes of tests for T∞ using normal approximation to log odds ratio. The solid
line represents pi = 0.5 and the dashed line represents pi = 0.1. Black, red and blue
represent 5%, 2.5% and 1% significance levels respectively.
50 100 200 500 1000
0.
00
0.
02
0.
04
0.
06
0.
08
0.
10
N (log scale)
Si
ze
CHAPTER 5. BINARY RESPONSE DATA 169
Table 5.3: Estimated test sizes (%) for T2 and T∞ for large sample approximation on
original scale with different treatment allocations.
Size of the tests
δ N pi T2 T∞
5% 2.5% 1% 5% 2.5% 1%
1/3 30 .5 4.41 2.55 1.17 4.00 3.79 1.14
.1 3.96 0.70 0.38 3.97 2.29 0.38
1/3 90 .5 5.19 2.66 0.91 4.68 2.52 1.27
.1 5.47 2.56 0.64 5.59 2.55 0.97
3/10 30 .5 5.74 2.63 0.89 5.35 2.69 0.88
.1 7.22 1.52 0.41 7.26 2.50 0.41
3/10 90 .5 4.96 2.50 1.02 5.03 2.51 0.96
.1 5.78 3.03 1.00 5.64 2.82 1.00
they also found that with small pi the test was liberal, although their results for pi = 0.5
are slightly on the other side of the nominal value from ours. Overall, tests based directly
on the normal approximation to the binomial distribution cannot be recommended for
fewer than 30 subjects on each arm.
For the approximation based on log-odds ratios with unequal allocation, the results are
given in Table 5.4. They show that in this case also, the sizes achieved are quite far from
the nominal sizes for small sample sizes. If pi is close to 0.5 the test is reasonably accurate
with 30 patients in each arm, but otherwise requires at least 100 in each arm.
5.5 An exact likelihood ratio test
For large samples, we can use the normal approximations. Perhaps a reasonable require-
ment would be that min(nipi0, ni(1− pi0)) is at least 30, 45 or 60 for testing at 5%, 2.5%
and 1% respectively. However, in the previous section we saw that for smaller samples
the approximation is unreliable and for very small samples, such as 10 in each arm, it is
essentially useless. Instead, we develop a test based directly on the binomial distribution.
We derive the likelihood ratio test statistic for the simple tree order for binomial data.
The null distribution of this is not known and, unlike in the normal case, a standardized
form of the binomial distribution cannot be obtained. Instead we develop a method to
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Table 5.4: Test sizes (%) for the large sample approximation using log odds ratios with
different allocations for T1 and T∞.
Size of the tests
δ N pi T2 T∞
5% 2.5% 1% 5% 2.5% 1%
1/3 30 .5 4.33 1.85 0.61 3.89 1.29 0.49
.1 30.65 30.64 30.64 30.65 30.64 30.64
1/3 90 .5 4.95 2.65 0.80 4.72 2.54 0.71
.1 5.13 4.34 4.24 5.32 4.32 4.24
3/10 30 .5 3.94 1.74 0.73 4.95 2.14 0.74
.1 24.09 24.02 24.01 24.08 24.02 24.01
3/10 90 .5 4.80 2.36 0.90 4.96 2.46 0.92
.1 4.20 2.66 2.26 3.79 2.68 2.30
calculate the exact conditional p-value for a given marginal total number of successes.
Because of the lack of a standardised form, the general properties of this cannot easily be
studied, but we give some examples to show how they can be considered in specific cases.
5.5.1 Likelihood ratio test statistic
As in Chapter 2, we derive the likelihood ratio test statistic in the usual way by obtaining
the restricted and unrestricted maximum likelihood estimators (MLEs) and plugging them
into the log-likelihood. Let Yi ∼ Bin(ni, pii), where i = 0, ..., I and assume that Yi (i =
0, ..., I) are independent. Then the unrestricted MLEs are, as usual, pˆii = yi/ni, i =
0, 1, . . . , I.
The restricted MLEs are those from a model using the simple tree order pii ≤ pi0, i =
1, . . . , I. Barlow et al. (1972), p.93, showed that the MLEs for a simple tree order restric-
tion for any one-parameter exponential family, which includes the binomial, distribution
are given by the isotonic regression estimators. Robertson et al. (1988), p.8-11, showed
that the pool adjacent violators algorithm (PAVA) gives the isotonic regression estimators
- see also Barlow et al. (1972), p.102. We now apply this result to obtain our restricted
MLEs. Note that these are essentially the same as the estimators mentioned by Williams
(1988), although he suggested using them to test different hypotheses and did not give the
form of the LRT statistic. Silvapulle and Sen (2005) also give several tests which use these
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and similar estimators, although they also did not derive the form of the LRT statistic.
The joint likelihood is given by
L (pi0, . . . , piI | y) =
I∏
i=0
(
ni
yi
)
piyii (1− pii)ni−yi .
Assuming that none of the piis are 0 or 1, the log-likelihood is
logL (pi0, . . . , piI | y) =
I∑
i=0
{
log
(
ni
yi
)
+ yi log pii + (ni − yi) log (1− pii)
}
.
However, in what follows, we will need to consider the boundary cases, so we define
log+
A
B
=
 1 if A = 0 or B = 0;log AB otherwise.
and we write
logL (pi0, . . . , piI | y) =
I∑
i=0
[
log
(
ni
yi
)
+ yi log+ (pii) + (ni − yi) log+ (1− pii)
]
. (5.3)
Let p˜i denote the restricted MLEs under H0. We calculate p˜i using the PAVA algorithm.
Assume that the unrestricted MLEs of the experimental arms are in the order pˆi1 ≥ pˆi2 ≥
· · · ≥ pˆiI , where as usual other orders follow by symmetry. We must consider I+1 different
possibilities which we describe as the following cases.
Case 0: If pˆi1 ≤ pˆi0, then p˜ii = pˆii i = 0, . . . , I.
Case 1: If pˆi1 > pˆi0, pool with the control to get p˜i
(1)
0 =
y0+y1
n0+n1
. If pˆi2 ≤ p˜i(1)0 , then
p˜i0 = p˜i1 = p˜i
(1)
0 and p˜ii = pˆii for i = 2, . . . , I.
Case 2: If pˆi2 > p˜i
(1)
0 , then let p˜i
(2)
0 =
y0+y1+y2
n0+n1+n2
. If pˆi3 ≤ p˜i(2)0 , then p˜i0 = p˜i1 = p˜i2 = p˜i(2)0 and
p˜ii = pˆii for i = 3, . . . , I.
...
Case J : If pˆiJ > p˜i
(J−1)
0 then pool to get p˜i
(J)
0 =
y0+y1+···+yJ
n0+n1+···+nJ =
∑J
j=0 yj∑J
j=0 nj
. If pˆiJ+1 ≤ p˜i(J)0 ,
then p˜i0 = p˜i1 = · · · = p˜iJ = p˜i(J)0 and p˜ii = pˆii, for i = J + 1, . . . , I.
...
Case I: If pˆiI > p˜i
(I−1)
0 then pool to get p˜i0 = p˜i1 = · · · = p˜iI = y0+y1+···+yIn0+n1+···+nI =
∑I
j=0 yj∑I
j=0 nj
.
We will briefly consider the form of p˜i for boundary values of pˆi:
• pˆi0 = 0 but pˆi1 > 0 ⇒ Case 0 is not true. Hence, the control will be pooled with
other groups and p˜i0 6= 0.
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• pˆi0 = pˆi1 = · · · = pˆiI = 0⇒ p˜i = pˆi = 0 and so the log-likelihood ratio is 0.
• pˆi0 = 1⇒ pˆi1 ≤ pˆi0 and we have Case 0, p˜i = pˆi.
Now assume 0 < pˆi0 < 1.
• pˆi1 = 0⇒ pˆi2 = · · · = pˆiI = 0. Then we have Case 0, p˜i = pˆi.
• pˆi1 = 1⇒ we do not have Case 0, so we will pool treatment 1 (and any others with
pˆij = 1), so that 0 < p˜ii < 1 ∀i = 0, 1, . . . , I.
• pˆiI = 0⇒ we do not have Case I, so we will not pool treatment I ⇒ p˜iI = pˆiI = 0.
• pˆiI = 1⇒ pˆi1 = · · · = pˆiI−1 = 1⇒ everything is pooled, so that p˜i = pˆi.
Thus, p˜ii can be equal to zero or one only if p˜ii = pˆii. Hence, we will see that the following
results cover the boundary cases as well as the more general cases.
From (5.3), twice log-likelihood ratio is given by
λ = 2
I∑
i=0
{
yi log+
(
pˆii
p˜ii
)
+ (ni − yi) log+
(
1− pˆii
1− p˜ii
)}
. (5.4)
For Case J , i.e. pˆiJ > p˜i
(J−1)
0 , we substitute the values of p˜ij and pˆij to get
λ = 2
J∑
i=0
[
yi
{
log+
(
yi
ni
)
− log+
(∑J
j=0 yj∑J
j=0 nj
)}
+(ni − yi)
{
log+
(
1− yi
ni
)
− log+
(
1−
∑J
j=0 yj∑J
j=0 nj
)}]
.
Hence,
λ = 2
J∑
i=0
[
yi log+
(
yi
ni
∑J
j=0 nj∑J
j=0 yj
)
+ (ni − yi) log+
{
ni − yi
ni
∑J
j=0 nj∑J
j=0(nj − yj)
}]
= 2
J∑
i=0
yi log+ yi − yi log ni + yi log
 J∑
j=0
nj
− yi log+
 J∑
j=0
yj

+ (ni − yi) log+ (ni − yi)− (ni − yi) log ni + (ni − yi) log
 J∑
j=0
nj

− (ni − yi) log+

J∑
j=0
(nj − yj)

 .
After simplifying,
λ = 2
J∑
i=0
yi log+ yi − yi log+
 J∑
j=0
yj
+ (ni − yi) log+ (ni − yi)− ni log ni
+ni log
 J∑
j=0
nj
− (ni − yi) log+

J∑
j=0
(nj − yj)

 .
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Separating the terms in the summation,
λ = 2
 J∑
i=0
yi log+ yi −
J∑
i=0
yi log+
 J∑
j=0
yj
+ J∑
i=0
(ni − yi) log+ (ni − yi)−
J∑
i=0
ni log ni
+
J∑
i=0
ni log
 J∑
j=0
nj
− J∑
i=0
(ni − yi) log+

J∑
j=0
(nj − yj)

 .
Finally, taking common factors and rearranging, we obtain the general form of the LRT
statistic as
λ = 2
[
J∑
i=0
yi log+
(
yi∑J
j=0 yj
)
+
J∑
i=0
(ni − yi) log+
{
ni − yi∑J
j=0 (nj − yj)
}
−
J∑
i=0
ni log
(
ni∑J
j=0 nj
)]
. (5.5)
As in Chapter 3, λ does not meet the conditions for the null distribution to have an
asymptotically χ2 distribution, even ignoring the boundary values, due to the restricted
MLEs possibly being on the boundary of the parameter space. Its distribution is asymp-
totically a mixture of χ2 distributions with unknown mixing probabilities (Barlow et al.,
1972; Robertson et al., 1988; Silvapulle and Sen, 2005). As in Chapter 3, we prefer to try
to find the exact distribution by numerical methods.
5.5.2 Conditional null distribution of the likelihood ratio test statistic
The null distribution of the LRT statistic λ depends on the unknown values of the piis
and so there is no way it can be obtained in general. Instead, we will follow the usual
practice in such circumstances and condition on
∑I
i=0 Yi =
∑I
i=0 yi. We also condition on
the sample sizes n0, n1, . . . , nI , i.e. we will fix the marginal totals in the contingency table
of the observed data. There are a finite number of tables of dimension (I + 1) × 2 with
these fixed marginal totals. We will calculate the exact p-value assuming pi0 = pi1 = · · ·piI ,
conditional on these margins. The probability of a type I error is maximised when all piis
are equal.
This general structure is illustrated for three arms in Table 5.5. The probability of observed
cell frequencies being r0, r1, . . . , rI , conditional on the observed marginal totals
∑I
i=0 Yi =∑I
i=0 yi = Y and n0, n1, . . . , nI , is given by
P (Y0 = r0, Y1 = r1, . . . , YI = rI) = P (Y0 = r0)P (Y1 = r1 | Y0 = r0) · · ·
P (YI = rI | Y0 = r0, Y1 = r1, . . . , YI−1 = rI−1),
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Table 5.5: Structure of frequency table for three arms
Success Failure Total
Control r0 n0 − r0 n0
Treatment 1 r1 n1 − r1 n1
Treatment 2 r2 n2 − r2 n2
Total Y N − Y N
where
r0 ∈ {max(0, Y −N + n0), ...,min(n0, Y )}
r1 ∈ {max(0, Y −N + n0 + n1), ...,min(n1, Y − r0)}
...
rI = Y −
I−1∑
i=0
ri.
Then it is clear that, if pi0 = pi1 = · · · = piI ,
P (Y0 = r0, Y1 = r1, . . . , YI = rI) =
(
Y
r0
)(
N−Y
n0−r0
)(
N
n0
) × (Y−r0r1 )(N−Y−n0+r0n1−r1 )(
N−n0
n1
) × · · · × 1
=
(
n0
r0
)(
n1
r1
) · · · (nIrI )(
N
Y
) . (5.6)
These probabilities, which form what is sometimes known as the multivariate hyperge-
ometric distribution, are the same as those used by Mehta and Patel (1983), Williams
(1988), Silvapulle and Sen (2005) and other authors who calculate exact distributions for
other test statistics. As noted by Koch and Hothorn (1999), these probabilities remain the
same for any test statistic, but generate different distributions for different test statistics.
These probabilities and the corresponding values of λ, can be evaluated for each possible
set of values of r0, r1, . . . , rI . The p-value is obtained exactly as the sum of probabilities
of values of λ which are greater than or equal to the observed value. Note that if any
pii < pi0, the probabilities will change, but those for large values of λ will be smaller, so
that the p-value reported is the maximum probability, under H0, of observing a value of
λ at least as large as that observed. Hence, it is a matter of convention whether or not
we should refer to this test as exact, but we will continue to do so.
Because this is an exact test, there is no need to calculate the size, which can be made
exactly α by the use of a randomised test. Although this gives the exact test some advan-
tage over the large-sample tests, whose size is not exactly α, it would also be interesting
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Table 5.6: A frequency table for three arms
Survival Death Total
Control 5 25 30
Treatment 1 16 14 30
Treatment 2 18 12 30
Total 39 51 90
to compare the powers of the different methods. This, however, is not as simple as for
the normal case studied in Chapter 3. The power depends not just on the true differences
between treatments, but on the specific values of pi0, pi1, . . . , piI and on the sample sizes
n0, n1, . . . , nI , so it is not possible to be comprehensive. Further, the exact conditional
test is computationally intensive, so applying it to each of a large number of simulated
data sets takes up very large amounts of computer time. It is noticeable that most of the
literature on exact tests, e.g. Williams (1988), Piegorsch (1990), Chuang-Stein and Tong
(1995) and Koch and Hothorn (1999), focus on comparisons of size and not power. Instead
of attempting to study the power in detail, in the next section we present a few examples,
with a small power comparison for one of them.
5.6 Examples
5.6.1 Example 1
We use a simple fictitious example to demonstrate the calculation and use of the null
distribution of λ. Let there be 39 successes in total in a three arm trial, including a
control arm, with 30 subjects in each arm. The observed proportions of successes in the
control and treatment arms were 5/30, 16/30 and 18/30 respectively, as shown in Table 5.6.
If we test the simple null hypothesis H∗0 : pi0 = pi1 = pi2 against the two-sided alternative,
the χ2 test gives a p-value of 0.00129, whereas Fisher’s exact test gives 0.00105.
We apply our exact one-sided test as follows. After ordering, pˆi0 = 5/30, pˆi1 = 18/30
and pˆi2 = 16/30. We get the restricted MLEs by pooling as follows. pˆi1 > pˆi0, so pool to
get p˜i
(1)
0 = 23/60. pˆi2 > p˜i
(1)
0 , so pool to get p˜i0 = p˜i1 = p˜i2 = 13/30. Here there are two
violations, so that J = 2. Then, from equation (5.5), calculate the observed value of λ for
CHAPTER 5. BINARY RESPONSE DATA 176
Table 5.7: Frequency tables conditional on marginal totals with 39 successes.
0 30 30 0 30 30 · · · 30 0 30
9 21 30 10 20 30 · · · 9 21 30
30 0 30 29 1 30 · · · 0 30 30
39 51 90 39 51 90 · · · 39 51 90
this data set as
λ = 2
(
5 log
5
39
+ 16 log
16
39
+ 18 log
18
39
+ 25 log
25
51
+ 14 log
14
51
+ 12 log
12
51
− 30 log 30
90
− 30 log 30
90
− 30 log 30
90
)
= 14.2919.
We now consider all possible allocations of 39 successes to the 3 treatments, as illustrated
in Table 5.7. The total number of tables can be calculated as follows. Clearly, the number
of successes on the control arm can be anything from 0 to 30. If there are no successes on
the control, the number of successes on treatment 1 must be at least 9 (since there are 39
in total) and can be no more than 30; if there is one success on the control, the number
on treatment 1 can be from 8 to 30; · · · ; if there are nine successes on the control, the
number on treatment 1 can be from 0 to 30; if there are 10 successes on the control, the
number on treatment 1 can be from 0 to 29; · · · ; if there are 30 successes on the control,
the number on treatment 1 can be from 0 to 9. Since the number of successes on treatment
2 is determined by the numbers on treatments 0 and 1, we find the number of possible
contingency tables to be (22 + 23 + · · ·+ 31) + (30 + · · ·+ 10) = 685.
The probabilities corresponding to each value of λ are calculated from equation (5.6).
From these we can construct the exact conditional probability mass function of λ when
pi0 = pi1 = · · · = piI and a histogram of this is shown in Figure 5.5. The probability that
λ = 0 is 0.3906 and the largest possible value of λ is 73.8. We can see that the distribution
is highly skewed to the right. By adding the probabilities for contingency tables which
give λ ≥ 14.2919, we find the p-value is 0.000265.
We also use this example to show how to calculate T2 and, from the simulations of the null
distribution done in Chapter 3, we find out the p-values from the large sample approxi-
mations to compare them with those from the exact test for the binomial distribution. Of
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course, similar calculations could be done for any other test statistic reported in Chapter
3.
We had pˆi0 = 5/30, pˆi1 = 16/30 and pˆi2 = 18/30. Then pˆi =
5+16+18
30+30+30 =
39
90 . For the simple
normal approximation to the binomial distribution, from (5.1) we calculate
Z1 =
16/30− 5/30√
39/90(1− 39/90)( 130 + 130)
= 2.8658
and
Z2 =
18/30− 5/30√
39/90(1− 39/90)( 130 + 130)
= 3.3868.
Then
T2 =
√
3.3868+2 +
(2.8658− 0.5× 3.3868)+2
1− 0.52 = 3.6474.
From the normal distribution simulation we use
no. of simulations with (T2 > 3.6474)
total no. of simulations
to get the p-value, which turns out to be 0.000352. This is somewhat different from the
p-value from the exact test, although the qualitative conclusions do not change.
Similarly in the normal approximation to the log odds ratio we have, from (5.2),
Z1 = log
(
16/14
5/25
)√
(16× 5× 14× 25) / (30× 30)
(16× 14/30) + (5× 25/30) = 2.8503
and
Z2 = log
(
18/12
5/25
)√
18× 5× 12× 25/30× 30
18× 12/30 + 5× 25/30 = 3.2734.
Then
T2 =
√
3.2734+2 +
(2.8503− 0.5× 3.2734)+2
1− 0.52 = 3.5608.
From the normal distribution simulation we use
no. of simulations with (T2 > 3.5608)/total no. of simulations
to get the p-value, which turns out to be 0.0004785.
Example 2: just one arm better than control
Here we consider another frequency table where, as in Example 1, the total number of
success is 39, but only one experimental arm has more successes than the control. Let the
observed proportion of successes in the control and treatments be 12/30, 20/30 and 7/30
respectively. As before we order them as pˆi0 = 12/30, pˆi1 = 20/30 and pˆi2 = 7/30. To get
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the restricted MLEs by pooling we have pˆi1 > pˆi0, so pool to get p˜i
(1)
0 = 32/60. However
pˆi2 < p˜i
(1)
0 , so no more pooling is needed, p˜i2 = pˆi2 = 7/30 and J = 1. Then, from equation
(5.5), we calculate the observed value of λ for this data set as
λ = 2
(
12 log
12
39
+ 20 log
20
39
+ 18 log
18
51
+ 10 log
10
51
+ −30 log 30
90
− 30 log 30
90
)
= 4.3392.
Note that since one arm is worse than the control it is not used in λ, i.e. in equation (5.5)
the summation is only up to J . The exact p-value in this case is 0.0455.
As before, for the simple normal approximation to the binomial distribution, from (5.1)
we calculate
Z1 =
20/30− 12/30√
39/90(1− 39/90)( 130 + 130)
= 2.0842
and
Z2 =
7/30− 12/30√
39/90(1− 39/90)( 130 + 130)
= −1.3026.
Obviously Z2 does not contribute, T2 =
√
2.08422 = 2.0842 and from the null distribution
simulation we obtain the p-value of 0.0376. This is rather more optimistic than the exact
p-value.
Similarly in the normal approximation to the log odds ratio we have, from (5.2),
Z1 = log
(
20/10
12/18
)√
20× 12× 10× 18/30× 30
20× 10/30 + 12× 18/30 = 2.0440
and
Z1 = log
(
7/23
12/18
)√
(7× 12× 23× 18) / (30× 30)
(7× 23/30) + (12× 18/30) = −0.5971,
which does not contribute to T2, so that T2 = Z1 = 2.0440 for which the p-value is 0.0412.
This is also optimistic but slightly closer to the exact p-value.
5.6.2 Example 3: smaller total success rate
Consider another example with N = 90 where the success rate is smaller. Let the observed
proportions be pˆi0 = 3/30, pˆi1 = 8/30 and pˆi2 = 10/30, respectively. Then pˆi = (3 + 8 +
10)/(30 + 30 + 30) = 21/90. Conditioning on the total number of successes being equal
to 21, the LRT statistic gives λ = 5.2984 and the corresponding exact p-value is 0.0286.
Calculating Z1 = 1.5262 and Z2 = 2.1366 for the normal approximation to the binomial
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Table 5.8: Power when pi0 = 0.1, pi1 = 4/15, pi2 = 1/3 and N = 90 with δ = 1/3 for the
large sample approximations for T2 and T∞ and for the exact conditional test.
Power (%)
T2 T∞
Scale 5% 2.5% 1% 5% 2.5% 1%
Probability 71.358 58.954 41.245 70.270 57.502 40.160
log OR 70.034 54.483 31.324 68.246 50.698 25.871
λ
Exact test 69.519 57.877 40.909
distribution, from (5.1), then T2 = 2.2011 and in this case the second best treatment
contributes very little and the p-value is 0.0349. Similarly the normal approximation to
log ORs, Z1 = 1.6122 and Z2 = 2.0850 from (5.2), and we have T2 = 2.1028 which gives
a p-value of 0.0361. In this case, the approximate p-values are far enough from the exact
p-value to cause some concern.
For T∞ = 2.1366 the p-value for the above example for the direct normal approximation
is 0.0301 and, with the log OR, T∞ = 2.0850 and the p-value is 0.0341.
5.6.3 Power study for Example 3
We can study the power of the approximate tests for any given values of the piis and nis.
Here we consider the case where the piis are all equal to their estimates in Example 3.
100,000 values were simulated from each of Y0 ∼ Bin(30, 1/10), Y1 ∼ Bin(30, 4/15) and
Y2 ∼ Bin(30, 1/3) and the proportion which rejected H0 according to the two asymptotic
tests, using the critical values from Chapter 3, and the exact test was counted. The results
are shown in Table 5.8.
The results in Section 5.4, shown in Tables 5.3 and 5.4, suggested that both tests were
slightly liberal for this sample size, so it is perhaps surprising that the test on the original
scale is substantially more powerful than the tests on the log odds scale. We also see
that T2 is more powerful than T∞. Given that the approximate tests are liberal, we
would expect them to have higher power than the exact test. In this sense, the exact test
performs remarkably well. Although more experience is needed, this example suggests
that the exact test is very promising.
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5.6.4 Example 4: four-arm trial
We obtain the exact distribution of λ for 4 arms using the example from Chuang-Stein
and Tong (1995). The trial has low, medium and high doses of a new drug, comparing
each with placebo. The sample size in each group is 200. For the placebo, pˆi0 = 50/200,
for the low dose, pˆi1 = 45/200, for the medium dose, pˆi2 = 52/200 and, for the high dose,
pˆi3 = 72/200. The LRT statistic has observed value λ = 5.7318 and, after considerable
computing, we find the p-value is 0.0274. From their unconditional exact test, based on
T∞, Chuang-Stein and Tong (1995) rejected H0 at the 5% level of significance, but did
not give a p-value.
For this 4-arm example we calculate the large sample approximation both on the original
scale and on the log odds scale. For the simple normal approximation to the binomial
distribution, pˆi = (50 + 45 + 52 + 72)/(4 × 200) = 219/800. As before we calculate
Z1 = −0.5607 (as the observed low dose is worse than the placebo), Z2 = 0.2243 and
Z3 = 2.4670. There is no contribution to the test statistic from the medium or low doses.
Then the test statistic is based on the high dose, i.e. T2 = Z3. From the normal distribution
simulations we use
no. of simulations with (T2 ≥ 2.4670)
total no. of simulations
to get the p-value, which turns out to be 0.0229. T∞ gives a p-value of 0.0184, agreeing
with the conclusion of Chuang-Stein and Tong (1995) that H0 is rejected at the 5% level
of significance.
Similarly, using the log OR approximation we have Z1 = −0.5873, Z2 = 0.2294 and
Z3 = 2.3512. Then T2 = 2.3512 and the p-value is 0.0305. Meanwhile T∞ gives a p-value
of 0.0249.
We can see in this case, with a large sample size, that the p-values are fairly close for all
three methods which use the LRT methods and that methods based on the maximum give
smaller p-values.
5.7 Discussion
We have explored a variety of methods for analysing binary data in this chapter. We find
that the asymptotic methods work reasonably well with total sample sizes as small as 90,
if the success probabilities are close to 0.5. If the success probabilities are 0.1, they are
appropriate for large sample sizes, with at least 600 subjects in total. Perhaps surprisingly,
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the methods based on univariate likelihood ratio test statistics seem less good than those
based on the direct normal approximation to the binomial distribution.
We have developed a conditional exact test and would recommend it for small and mod-
erate sized samples. In fact, if the success probabilities are considerably smaller than
those we have studied, this will be necessary even for much larger samples. It is probably
advisable to use the exact test as long as the computing power available is able to cope
with it. Even if it is not, it might be advisable to use a random-permutation test, in
which we calculate λ for a large random sample of the possible contingency tables if nipii
or ni(1 − pii) is less than 60. This is a trivial modification of the method described in
Section 5.5. Example 4 is at, or slightly beyond, the limit of the size of data set for which
it is possible to do the full set of permutations in a sensible amount of computing time.
Chapter 6
Two-stage adaptive designs
Sequential design of clinical trials is widely acknowledged to be beneficial, when it is possi-
ble, due to the possibility of saving resources and exposing fewer patients to experimental
treatments, by allowing for possible early stopping. Adaptive design, in which the alloca-
tion of treatments to patients can also be changed in the light of data collected at early
stages, has recently received much attention in the pharmaceutical industry. As with fixed
designs, most of the literature on sequential and adaptive designs concerns two-arm trials,
e.g. most of the contents of the books by Whitehead (1997) and Jennison and Turnbull
(2000), although multi-arm trials have received attention in the recent literature. Some
of this is concerned with all pairwise comparisons, while some deals with many-to-one
comparisons with a control, as in this thesis.
The idea of most adaptive designs is to use the information from interim analyses to
change the allocation of patients to treatments so that improved estimates or tests can be
obtained. Trials comparing several experimental treatments with a control, as considered
in this thesis, seem to be a good candidate for adaptive design, since inferior treatments
can be dropped at an early stage, in order to get better comparisons of the good treatments
with the control. They are usually only viable, however, for responses which are available
very soon after treatment.
Adaptive designs for comparing several treatments with a control are considered in this
chapter. Attention will be restricted to two-stage procedures, in which a decision about
which treatment(s) to drop is made after analysing the data from stage 1. Results will be
given for two experimental arms, but the methods are general for any number of arms.
We consider equal allocation at each stage, since this is likely to be common in practice,
but also briefly study some different pre-assigned allocations. We concentrate mainly on
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the case where the two stages use equal numbers of patients, but also briefly explore using
fewer patients in the first stage. The results are compared, in terms of power and expected
loss, with those from fixed trials.
Another possible application of the adaptive designs which allow treatments to be dropped,
as considered here, is in seamless phase-II/III trials, which have received some attention
recently. In these, rather than running a phase-II trial to select the best experimental
treatment (e.g. the optimal dose or formulation), followed by a phase-III trial to establish
improved efficacy compared with a control, a single two- (or more-)stage trial is run to
simultaneously find the optimal dose and compare it with the control. If this is done using
an adaptive two-stage design, stage 1 essentially plays the exploratory role of the phase-II
trial in selecting the best treatment or treatments and checking that they are reasonable
candidates, while stage 2 plays the confirmatory role of the phase-III trial in comparing
them with the control. The benefit is that the comparison can be done using data from
both stages, so that overall there is a considerable saving in resources.
In terms of the methodology described in this chapter, a seamless phase-II/III trial and
an adaptively designed phase-III trial do not differ. All of the methodology described
here can be appropriate to either type of trial. The crucial aspect, as usual, is that the
hypotheses we discuss are relevant to the research questions of interest. This chapter only
begins the exploration of adaptive designs for the hypothesis H0 : ∆i ≤ 0 ∀i, there being
much more scope for research in this area.
The extension of our notation to deal with adaptive designs is described in Section 6.1 and
the relevant literature is reviewed in Section 6.2. Several adaptive designs are studied and
compared in Section 6.3 in the context of equal allocation to all treatments and stages of
equal sizes. A brief study of some designs with unequal stage sizes is described in Section
6.4. Finally, some conclusions are drawn in Section 6.5.
6.1 Notation
The model and notations we defined in Chapter 2 are now reintroduced and extended to
two-stage designs. Let N be the total number of patients in all arms in a fixed trial, with
ni = δN patients on each experimental arm and n0 = (1 − Iδ)N patients on the control
arm. We assume that we have Zi, for i = 1, . . . , I, which is a normalised statistic comparing
treatment arm i with the control. Since we have large samples, Z = (Z1, . . . , ZI)
′ is
multivariate normal with E(Zi) = ∆i/σ, V ar(Zi) = 1 and ρ = Cov(Zi, Zj) = δ/{1− (I −
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1)δ}, i 6= j, where σ2 = {1 − (I − 1)δ}/{δ(1 − Iδ)}. The Zis are correlated due to their
dependence on a common control arm. For I = 2, Z1
Z2
 ∼ N
 ∆1/σ
∆2/σ
 ,
 1 ρ
ρ 1
 .
With equal allocation, i.e. δ = 1/3, the correlation is ρ = 1/2. This could be derived by
defining Yij to be the (scaled) response from patient j on treatment i = 0, 1, . . . , I, where
i = 0 is the control arm. After rescaling to get unit variance, we have Y0j ∼ N(µ0, 1)
and Yij ∼ N(µi, 1), i = 1, . . . , I. All observations are assumed to be independent. Then
∆i =
√
N(µi − µ0) and Zi =
√
N{(Y¯i − Y¯0)/σ}. Although such assumptions are not
necessary, they make the derivation of the appropriate test statistics in an adaptive design
simpler.
For a two-stage adaptive design, let Zi.k be a normalised univariate test statistic for
comparing treatment i with the control obtained from the data in stage k and assume
that responses are instantly available. For example, for normally distributed responses,
let Yij.k be the response from the jth patient on the ith treatment i = 0, 1, . . . , I in the
kth stage, k = 1, 2. Let there be N.k patients in the kth stage and ni.k = δ.kN.k patients
on each experimental arm in stage k. Let I.k be the number of experimental arms studied
at stage k. Then n0.k = (1− I.kδ.k)N.k and
Zi.k =
√
N.k{(Y¯i.k − Y¯0.k)/σ.k}, (6.1)
where
σ2.k = {1− (I.k − 1)δ.k}/{δ.k(1− I.kδ.k)}. (6.2)
As before, it is not necessary to derive Zi.k from the normal case. The following methods
apply asymptotically to any normalised univariate test statistics. Note, however, that the
asymptotic results now require large samples in every stage.
When combining data from different stages we will define global normalised univariate
test statistics Zi, which will be based on sufficient statistics. They will be obtained from
Zi.k in such a way as to ensure that V ar(Zi) = 1. To find the optimal way to combine
stages, it is simplest to work with Y¯i.k − Y¯0.k, although the results generalise as usual.
As in the rest of this thesis, assume that the aim of the trial is to test the null hypothesis
H0 : ∆i ≤ 0, ∀i ∈ {1, . . . , I} against H1 : ∆i > 0 for at least one i and, if H0 is rejected, to
recommend the best treatment, or at least a good treatment. We will also sometimes refer
to the simple null hypothesis H∗0 : ∆ = 0 and the univariate null hypotheses H0i : ∆i ≤ 0
and H∗0i : ∆i = 0.
CHAPTER 6. TWO-STAGE ADAPTIVE DESIGNS 186
As noted in earlier chapters, since selection of the best treatment is important, it is
possible to correctly reject H0, but to select an inferior treatment. If H0 is rejected and
the treatment selected is no better than the control, we say that a type-III error has
been made. If H0 is rejected and the treatment selected is better than the control, but
suboptimal, we say that a type-IV error has been made. These concepts continue to be
important in adaptive designs, but with the additional point that selection of the best
treatment might be done before the end of the trial, so that a suboptimal treatment might
be the only one studied in the second stage of the adaptive procedure.
6.2 Literature review
Although the general area of adaptive design has received a lot of attention, two-stage
sequential adaptive design for comparing two or more experimental arms with a control
has become an area of interest only relatively recently. Here we focus on that work which
is most closely related to the work presented in this chapter.
Thall et al. (1988) suggested an adaptive procedure for binary response data, in which
they used the angular transformation to achieve approximate normality. They allocate
equal numbers to each arm in stage 1 and, if in stage 1 max(Zi.1) < c1, for some stopping
cutpoint c1, then they stop the trial and accept H
∗
0 : ∆i = 0, ∀ i. If max(Zi.1) ≥ c1, then
they select the active arm i∗ = arg max(Zi.1) to be carried forward to stage 2. In stage 2,
they allocate equal numbers of patients to control and treatment i∗. After stage 2, they
do a Z-test based on data from treatment i∗ and the control from both stages. The critical
value of this test has to be adjusted to take account of the selection of the active arm with
the largest estimate and also to take account of the fact that some trials stopped early.
The adjustment is made to achieve size α. The stopping boundary c1 is chosen in order
to minimise the expected sample size for some pre-specified values of the true treatment
effects ∆1 and ∆2. Clearly, the same procedure can be applied for any of the univariate
test statistics Zi discussed in this thesis.
Schaid et al. (1990) suggested using two-stage adaptive designs for survival data. They
tested each active treatment against the control at stage 1 and, for each H0i, they either
accepted, rejected or failed to make a decision. They stopped if any treatment were found
to be better than the control, or if all H0i were accepted. Otherwise, they continued with
all treatments i for which H0i had been neither accepted nor rejected. Unlike most other
work in this area, Schaid et al. did not adjust for the multiple comparisons.
CHAPTER 6. TWO-STAGE ADAPTIVE DESIGNS 187
Royston et al. (2003) developed a more realistic two-stage approach for survival data, in
which the decision to stop or drop treatments after stage 1 is based on a surrogate outcome
variable, which is assumed to be available more quickly than the survival outcome and also
to be less variable. At stage 1 a one-sided test is carried out for each arm against the control
and only those treatments which are significantly better than control are taken to stage
2. After stage 2 a one-sided test of each arm against the control is based on the primary
survival outcome. Equal allocation is used at each stage and no adjustment is made for
multiple comparisons, although Royston et al. (2003) suggest how such an adjustment can
be made if required. The emphasis in this work is on the individual hypotheses H0i. The
major technical difficulty dealt with in this paper is the unknown correlation between the
primary outcome and the surrogate outcome. This is an important practical consideration
for survival data which could be explored further for the designs developed in this chapter.
Hughes (1993) was one of the first to take the approach of sequentially applying multiple
comparison procedures in the context of clinical trials with several treatments against a
control. However, unlike the work reported in this thesis, his procedure was based on tests
of all pairwise comparisons, with adjustments to preserve the global size. At each stage
experimental treatment i is dropped either if it is significantly worse than the control, or
if it is significantly worse than another experimental treatment j, where the significance
levels for testing against the control and against treatment j need not be the same.
Follmann et al. (1994) developed a procedure which, for multiple comparisons with a
control, is based on sequentially testing each H∗0i against the two-sided alternative. If
H∗0i is rejected in favour of the control, then treatment i is dropped. As soon as any H
∗
0i
is rejected in favour of the active treatment, the trial is stopped and that treatment is
selected. If all H∗0i are accepted, or all active arms are dropped then the trial is stopped
in favour of the control. Proschan et al. (1994) compared different methods of adjusting
for multiple comparisons, which take account of the multiple arms as well as the repeated
testing, when using this procedure.
Betensky (1996) developed a fully sequential procedure, i.e. with continuous monitoring of
immediately available responses, to compare three treatments, including the case when one
was a control, for normally distributed responses. A sequential test of each H∗0i against
H1i is carried out for i = 1, 2, with Bonferroni adjustment of the significance levels.
When H∗0i is accepted or rejected for any i ∈ {1, 2}, then treatment i or the control,
respectively, is dropped and the procedure continues with a sequential test of the two
remaining treatments. Betensky (1997) extended this method to deal with survival data.
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In the work reported later in this chapter, we do not allow the control to be dropped and
this simplifies matters to some extent due to the fact that less testing is needed.
Hellmich (2001) described group sequential adaptive procedures, to compare several treat-
ments with a control, in which early stopping was allowed with either acceptance or rejec-
tion of the null hypothesis, i.e. due to either efficacy or futility, and arms could be dropped
due to inferiority. His aim was different from that in this thesis, being to test each indi-
vidual hypothesis H∗0i, while controlling the overall error rate. This leads to considerable
technical difficulties which do not arise in the work reported in this chapter, but Hellmich
made considerable progress by using closed testing procedures of the type described in
Chapter 1.
Vincent et al. (2002) describe a more flexible multi-stage approach for comparing two
experimental arms with a control. In keeping with the approach of Whitehead (1997),
they set up any number of interim analyses at pre-specified (not necessarily equally-spaced)
expected values of the Fisher information. At the kth interim analysis, each Zi (calculated
from the data collected so far) is used to test each H∗0i : ∆i = 0, against the one-sided
alternative and also to decide whether to continue to use treatment i. When some H∗0i are
rejected, we stop and conclude that experimental treatment i is better than the control.
If two or more arms are found to be better than the control, the best is chosen on the
basis of some point estimate, e.g. the corresponding Zi. If all experimental arms are
dropped, we stop and accept H∗0 . Vincent et al. developed the methodology to work out
the stopping boundaries for each interim analysis, in order to control the global size of
the test and the power. They worked with the adjusted power, as defined in Chapter
3, and used it to calculate expected sample sizes. This work is more ambitious in scope
than what is attempted in this chapter, especially due to the need for testing H0 at each
interim analysis. In keeping with the spirit of this thesis, we avoid multiple testing issues
by only carrying out a single hypothesis test and this means that we can avoid some of
the complications of Vincent et al.’s work. However, their paper is very close to the work
in this thesis in the recognition it gives to the selection of the best treatment, as well as
the global hypothesis test. In this chapter, we consider some other test statistics which
might be more appropriate than that used by Vincent et al.
The work of Thall et al. (1988) was generalised by Stallard and Todd (2003) to any
normally distributed test statistics based on the efficient score, following the methodology
of Whitehead (1997), which covers most of our cases. They also allowed any number of
experimental arms and any number of interim analyses, although after stage 1, they always
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select the best treatment and continue with that treatment and the control.
Kelly et al. (2005) extended this work to the more general procedure in which any number
of experimental treatments can be dropped at any stage. Testing at each stage is based
on Dunnett-type tests. If any H0i is rejected at any stage, the trial is stopped in favour of
treatment i, while the decision to drop treatment i at any stage is based on the accumulated
Zi up to that stage being below some boundary.
The methodology in the papers of Vincent et al. (2002), Stallard and Todd (2003) and Kelly
et al. (2005) is essentially that of sequential designs for two-arms applied to each pairwise
comparison, with adjustment of the significance levels for multiple comparisons with the
control based on Dunnett’s procedure. Some authors therefore refer to this as sequential
design, reserving the name adaptive design for procedures which allow unplanned changes
to the design at interim analyses.
There is another large body of literature on unplanned adaptations to designs, such as
sample-size recalculation, at interim analyses. This work, following Bauer (1989) and
many other papers by Bauer and his coworkers, was reviewed by Hellmich and Hommel
(2004) and by Posch et al. (2005). The important idea is that the stages are first analysed
separately and then the p-values combined. A slightly different approach is the conditional
error function method of Mu¨ller and Scha¨fer (2001). Jennison and Turnbull (2003) showed
that these methods, and any unplanned redesign that maintains the overall type-I error
rate whenever the design is modified, must preserve the conditional type-I error rate and
hence all such procedures are closely related even though they are described differently.
The topic of unplanned adaptations which preserve the type-I error rate was recently re-
viewed by Jennison and Turnbull (2006), who showed that, because these methods require
the use of nonsufficient statistics, they are inefficient. Jennison and Turnbull recommended
that such procedures should only be used as a last resort, when crucial assumptions are
clearly contradicted at the interim analysis. We will not consider such methods here, al-
though clearly the trial could be redesigned after stage 1 of the procedures described in
this chapter.
Koenig et al. (2008) also used the conditional error function approach and showed, in some
limited situations, that an adaptive Dunnett test using this principle could perform well.
One of the specific procedures they assessed was to use equal numbers of patients in each
of two stages. In stage 1, equal numbers are allocated to two active treatments and a
control. In stage 2, equal numbers of patients are allocated to the treatment with the best
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Table 6.1: Summary of adaptive design strategies.
Procedure At end of stage 1
1 Drop all experimental arms except most promising
2 Stop for futility?
Drop all experimental arms except most promising
3 Drop between 0 and I experimental arms depending on results
0 = nothing dropped, I = stop for futility
I − 1 = continue with one experimental arm and control
estimate at the interim analysis and the control. Finally, Dunnett’s test is carried out,
with suitable adjustment of the nominal significance level, using data from both stages on
the arms carried forward to stage 2. We will study a similar procedure below.
Most of the above literature assumes that the null hypothesis will be H∗0 and avoids the
issue of this implying a model which does not allow experimental treatments to be worse
than the control. The adaptive procedures described in this chapter, like the rest of the
work in this thesis, will be based on testing H0 directly. In the next section, we compare
several rules for two-stage designs where treatments can be dropped after the first stage,
but H0 can only be rejected after the second stage.
6.3 Comparisons of adaptive procedures
We consider several different rules for deciding which arms to carry forward to stage 2.
We will consider only procedures in which the control treatment is used in each stage
and no new treatments are introduced at stage 2. First we consider always forwarding
one experimental arm to stage 2, which allows us to assess the benefit of dropping arms.
Second, we either stop or forward one experimental arm, so that we can see the possible
costs of reducing the expected sample size. Third, we stop or forward a number of arms
determined by the results from stage 1, which potentially allows us to obtain the benefits
of early stopping or early selection, while also maintaining the possibility of using the
advantages of our test statistic T2 when more than one experimental arm seems promising.
As before, we assume that the objective is to test the null hypothesis H0 : ∆i ≤ 0, ∀i,
against the alternative H1 : ∆i > 0, for at least one i, and, if H0 is rejected, to select the
best experimental treatment. The three procedures considered are summarised in Table
6.1.
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In the first procedure considered, selection is always carried out after stage 1 and the test
after stage 2. In the second procedure, H0 might be accepted after stage 1 or accepted or
rejected after stage 2, while selection is carried out after stage 1. In the third procedure, H0
might be accepted after stage 1, or accepted or rejected after stage 2, while selection might
be carried out after either stage 1 or stage 2. The details of the procedures are described
in the relevant subsections. We emphasise that, unlike much of the work reviewed in the
previous section, we do not allow early stopping with rejection of H0. Also note that arms
are dropped not only because there is evidence that they are inferior to the control, but
rather because the other active arm seems like a better bet for establishing superiority
over the control.
Within each of the next three subsections, we first describe the proposed procedure as
it might apply in general and then study the properties of some specific special cases
through simulation. The simulation studies are restricted to two experimental arms, equal
allocation at each stage and a few values of the decision boundaries. Although these results
are not comprehensive, they are enough to compare methods and evaluate how attractive
they are for practical use.
In fact, we can define a more general procedure as follows.
Stage 1: Allocate δ.1N.1 patients to each experimental arm and (1−Iδ.1)N arms to the control,
where 0 < δ.1 < 1/I . If, for some 1 ≤ I.2 ≤ I,
X1.1 > c1, X2.1 > c2ρX1.1, . . . , XI.2.1 > cI.2
ρ
1 + (I.2 − 2)ρ
I.2−1∑
j=1
Xj.1,
but
X(I.2+1).1 ≤ cI.2+1
ρ
1 + (I.2 − 1)ρ
I.2∑
j=1
Xj.1,
where Xj.1 is the jth largest of Z1.1, . . . , ZI.1 and c1, . . . , cI are known constants, then
carry forward the I.2 experimental arms corresponding to X1.1, . . . , XI.2.1, along with
the control.
Stage 2: Allocate a further δ.2N.2 patients to each remaining experimental arm and (1 −
I.2δ.2)N.2 to the control arm, where 0 < δ.2 < 1/I2 and N.1 + N.2 = N . Test
using the statistic Tk, for some k, defined in chapter 2 (based on the control plus I.2
treatments used at this stage) with a critical value adjusted to take account of the
bias induced by the adaptive design.
Recall that k is an index defining which member of a family of test statistics is to be used.
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As k is increased, Tk makes less use of the information on the treatments other than that
which is estimated to be best.
In this section, we consider the following procedures:
• Procedure 1: N.1 = N/2, δ.1 = 1/(I+1), c1 → −∞, cj →∞, j = 2, . . . , I , δ.2 = 1/2
and Tk (which is the same for any k in this case) is used;
• Procedure 2: N.1 = N/2, δ.1 = 1/(I + 1), cj →∞, j = 2, . . . , I, δ.2 = 1/2 and Tk is
used, with various values of c1;
• Procedure 3: N.1 = N/2, δ.1 = 1/(I + 1), δ.2 = 1/(I.2 + 1) and T1, T2 or T∞ are
used, with various values of c1 and cj , for j = 2, . . . , I.
In Section 6.4, we will consider:
• Procedure 3 with I = 2 as above, but with N.1 = N/4, with various values of c1 and
c2.
6.3.1 Procedure 1: always forward one experimental treatment
We begin with the simplest adaptive design, which is one of those studied by Koenig
et al. (2008). Allocate half of the patients to each of stage 1 and stage 2 and allocate
N
2(I+1) patients to each arm in stage 1. We always carry forward the one experimental arm
which gives the best results in stage 1, along with the control, to stage 2 and allocate N4
patients to each. Thus the interim analysis is used for selection but not for testing the
null hypothesis. After stage 2, the data on the selected experimental treatment and the
control from both stages are combined in order to carry out a test similar to a Z-test to
accept or reject H0, but with the critical value chosen to ensure the correct size in the
adaptive design.
We now use the defined notation for Zi.k from Section 6.1 and show how the data from
the two stages should be combined in this case.
At stage 1, we allocate N2(I+1) patients to each arm. Then n.1 = δ.1N.1 = N/{2(I +
1)} and I.1 = I, so that σ2.1 = 1−1/(I+1)1/(I+1)(1−I/(I+1)) = 2(I + 1) and Zi.1 =
√
N/2{(Y¯i.1 −
Y¯0.1)/
√
2(I + 1)} = √N(Y¯i.1 − Y¯0.1)/{2
√
I + 1}.
At stage 2, n.2 = δ.2N.2 =
1
2
N
2 = N/4 and I.2 = 1, so that σ
2
.2 =
1
1/2(1−1/2) = 4 and
Zi∗.2 =
√
N/2{(Y¯i∗.2− Y¯0.2)/
√
4} = √N(Y¯i∗.2− Y¯0.2)/
√
8, where treatment i∗ was selected
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after stage 1.
We will combine the estimated differences between the selected experimental treatment
and the control from stage 1 and stage 2 as Zi∗ = γ1Zi∗.1 + γ2Zi∗.2, for constants γ1 and
γ2 chosen to give equal weight to each patient such that V ar(Zi∗) = 1. In calculating
these constants, we ignore the selection of treatment i∗ at stage 1. In fact, V ar(Zi∗.1) < 1,
since a particular treatment is unlikely to be selected when the corresponding Zi.1 turns
out to be in the lower tail of its distribution. If, for example, we select treatment 1,
we actually work with the distribution of Z1, whereas strictly speaking we should work
with the conditional distribution of Z1|Z1.1 > Zj.1 ∀j = 2, . . . , I. We will ignore this
complication in the rest of this chapter.
With equal allocation, it is clear that we can write Zi∗ as a constant multiple of Y¯i∗ − Y¯0.
Then writing Y¯i in terms of Y¯i.k for i = 0, i
∗, for some constant K, we have
Zi∗ = K
(
Y¯i∗ − Y¯0
)
= K
[
N
2(I+1) Y¯i∗.1 +
N
4 Y¯i∗.2
N
2(I+1) +
N
4
−
N
2(I+1) Y¯0.1 +
N
4 Y¯0.2
N
2(I+1) +
N
4
]
=
K
I + 3
[
2
(
Y¯i∗.1 − Y¯0.1
)
+ (I + 1)
(
Y¯i∗.2 − Y¯0.2
)]
.
Substituting
(
Y¯i∗.1 − Y¯0.1
)
= 2
√
I+1Zi∗.1√
N
and
(
Y¯i∗.2 − Y¯0.2
)
=
√
8Zi∗.2√
N
, we have
Zi∗ =
K
I + 3
[
2
2
√
I + 1Zi∗.1√
N
+ (I + 1)
√
8Zi∗.2√
N
]
=
2K
(I + 3)
√
N
[
2
√
I + 1Zi∗.1 + (I + 1)
√
2Zi∗.2
]
∴ Zi∗ = K2
(
2
√
I + 1Zi∗.1 + (I + 1)
√
2Zi∗.2
)
,
for some constant K2.
Now, in order to ensure that V ar (Zi∗) = 1, we require
V ar
[
K2
{
2
√
I + 1Zi∗.1 + (I + 1)
√
2Zi∗.2
}]
= 1.
Note that Zi∗.1 and Zi∗.2 are independent, since patients in stages 1 and 2 are different
and V ar (Zi∗.k) = 1. Hence,
K22
[
V ar
(
2
√
I + 1Zi∗.1
)
+ V ar
{
(I + 1)
√
2Zi∗.2
}]
= 1
=⇒ K22
{
4(I + 1)V ar (Zi∗.1) + 2(I + 1)
2V ar (Zi∗.2)
}
= 1
∴ K2 =
1√
2(I + 1)(I + 3)
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Table 6.2: Cutpoints of the rejection region for Procedure 1
5% 2.5% 1%
1.8460 2.1515 2.5049
and, therefore,
Zi∗ =
1√
2(I + 1)(I + 3)
(
2
√
I + 1Zi∗.1 +
√
2(I + 1)Zi∗.2
)
=
1√
I + 3
(√
2Zi∗.1 +
√
I + 1Zi∗.2
)
.
Then the test statistic used is
Tk = max (0, Zi∗) ,
which is the same for any k, since only one arm was forwarded.
For three-arm trials, I = 2, σ2.1 = 6 and
Zi∗ =
1√
5
(√
2Zi∗.1 +
√
3Zi∗.2
)
. (6.3)
Simulation and results
The null distributions for I = 2 were approximated as follows. As in the fixed design, it is
clear from Theorem 13 in Chapter 3 that P (Reject H0|H0 true) is maximised when ∆ = 0.
Therefore, to determine the boundary of the rejection region for the test for significance
level α, we can simulate under ∆ = 0. For stage 1, we simulated two million values of
Z1.1 and Z2.1 from a bivariate normal distribution with expectations zero, unit variances
and correlation ρ = 0.5 (i.e. equal allocation). Then, for stage 2, we simulated two million
values of Zi∗.2 from a univariate standard normal distribution. The stages were combined
to give two million simulated values of Zi∗ , from which critical values were calculated
for 5%, 2.5% and 1% by ensuring that the appropriate proportion of simulations l led to
rejection after stage 2. Note that, since our critical values are based on simulations, we
expect them to be more accurate than those of Koenig et al. (2008) who used conservative
methods.
The cutpoints, as shown in Table 6.2, are smaller than the corresponding critical values
for fixed trials, due to the selection bias induced by the adaptive design and also probably
because, as noted above, the true variance of Zi∗ is less than one.
As in the fixed trial, the power is calculated as the proportion of 100,000 simulations which
rejected H0 using different values of the scaled mean differences between experimental
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treatments and the control, d1 and d2, and expected loss is calculated in a similar way.
The same simulation errors were used for all values of d1 and d2. Note, however, that from
a particular simulation different arms can be forwarded for different values of d1 and d2,
depending on the results from stage 1.
Similar to the results obtained in fixed designs with different allocations, care is needed in
choosing the appropriate scaling of d1 and d2 for the adaptive designs. In particular, the
standardisations used for Zi.1 and Zi.2 are different, so we cannot simply use the obvious
dis for each stage. Instead, we fix the scalings of di to be those suitable for the fixed design
with equal allocation, and rescale them internally to get di.1 and di.2 corresponding to Zi.1
and Zi.2, as follows.
For the fixed design with equal allocation in Chapter 3, we had Zi =
√
N
(
Y¯i − Y¯0
)
/σ and
E(Zi) = ∆i/σ where ∆i =
√
N (µi − µ0) and we defined di = ∆i/σ =
√
N (µi − µ0) /
√
6.
For the adaptive design, we define
di.1 =
√
N/2 (µi − µ0) /σ.1 =
√
N
12
(µi − µ0) = di√
2
and
di.2 =
√
N/2 (µi − µ0) /σ.2 =
√
N
8
(µi − µ0) =
√
3di
2
,
where σ.1 =
√
6 and σ.2 = 2 as above.
The estimated powers are shown in Table 6.3, along with the corresponding results for
fixed trials, with equal allocation, using T2 and T∞. Comparing these, there is an overall
power gain from using the adaptive design. However, when ∆2 = 0 the gain is relatively
higher than when ∆2 = 0.5∆1 and the gain is least when ∆2 = ∆1 . This is not surprising,
since the one of the benefits of the adaptive design is that, by allowing early selection,
it improves the comparison of the best treatment with the control. However, when the
treatments are equally good, this benefit is lost.
The expected losses for the same situations are shown in Table 6.4, along with the corre-
sponding results from the fixed design. When ∆2 = 0 the expected loss is smaller than
with the fixed trial. When ∆2 = 0.5∆1 most losses continue to be smaller in a two-stage
design although to a lesser extent. There still seems to be some difference between the
fixed and two-stage designs when ∆1 = ∆2, although if we refer back to Chapter 3, we find
that with T1, the fixed design is just as good. Since the treatment selection is based on
only half the number of patients as in the fixed design, there are more type-III/IV errors
when the adaptive design is used. On the other hand, when a correct selection is made,
more effort goes into comparing the best treatment with the control, so that fewer type-II
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Table 6.3: Power of Procedure 1 and the fixed design at 5, 2.5 and 1%.
5% 2.5% 1%
Adapt. Fixed Adapt. Fixed Adapt. Fixed
d1 d2 T2 T∞ T2 T∞ T2 T∞
2.5 0 80.902 71.169 72.242 72.323 59.915 61.565 60.081 45.959 47.891
3 0 92.328 85.477 86.330 87.511 77.348 78.625 79.357 65.451 67.313
3.5 0 97.596 93.956 94.398 95.616 89.460 90.294 91.583 81.522 82.960
2.5 1.25 79.082 74.586 74.349 70.103 63.821 63.574 57.729 49.731 49.513
3 1.5 90.229 87.579 87.490 84.656 79.988 79.871 76.129 68.576 68.493
3.5 1.75 96.022 94.926 94.909 93.343 90.888 90.916 88.542 83.525 83.644
2 2 74.499 71.518 70.028 63.332 60.075 58.011 49.180 45.572 43.020
2.5 2.5 89.215 87.151 85.937 82.188 79.358 77.255 71.014 67.465 64.408
3 3 96.568 95.565 94.877 93.357 91.699 90.340 87.195 84.595 82.177
errors will be made. When ∆2 = 0, type-III/IV errors are very rare anyway, so this is the
situation in which we get most benefit from using this adaptive design. When ∆1 and ∆2
have similar values, this adaptive procedure might be undesirable, since it always drops a
potentially good treatment at stage 1.
6.3.2 Procedure 2: Stop or forward one experimental treatment
This procedure is similar to Procedure 1, except that we now allow for early stopping if
neither of the experimental arms shows sufficient evidence of being better than the control
after stage 1. In this case, we will accept H0 without carrying out stage 2. This has the
benefit that, on average, fewer patients will be used in cases where H0 is accepted. Of
course, the corresponding disadvantage is that we will lose power, since we will stop in
some cases in which we would have continued and rejected H0. For this procedure, it is
necessary to define the boundary value for deciding whether or not to stop after stage 1.
We choose a constant c1 so that we stop and accept H0 if max(Zi.1) < c1. This procedure
is essentially that of Thall et al. (1988), except that they considered only the angular
transformation for binary responses, or equivalently it is a special case of the procedure
of Stallard and Todd (2003), with no early rejection of H0. Note that as c1 → −∞, this
procedure converges to Procedure 1 and as c1 increases we are more likely to stop.
If we stop early, then Tk = 0 and no further calculation is needed. If stage 2 is run, then
the data from the stages are combined in exactly the same way as for Procedure 1.
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Table 6.4: Expected loss of Procedure 1 and the fixed design at 5, 2.5 and 1%.
5% 2.5% 1%
Adapt. Fixed Adapt. Fixed Adapt. Fixed
d1 d2 T2 T∞ T2 T∞ T2 T∞
2.5 0 0.4872 0.7260 0.6985 0.6973 1.0044 0.9639 1.0004 1.3533 1.3042
3 0 0.2361 0.4374 0.4116 0.3782 0.6808 0.6423 0.6210 1.0374 0.9812
3.5 0 0.0875 0.2119 0.1964 0.1554 0.3692 0.3400 0.2955 0.6470 0.5966
2.5 1.25 0.6398 0.7170 0.7186 0.8357 0.9705 0.9706 1.1140 1.3041 1.3027
3 1.5 0.4306 0.4490 0.4485 0.5699 0.6664 0.6652 0.7949 0.9955 0.9911
3.5 1.75 0.2815 0.2384 0.2371 0.3544 0.3743 0.3706 0.4943 0.6240 0.6157
2 2 0.5100 0.5696 0.5994 0.7334 0.7985 0.8398 1.0164 1.4841 1.4094
2.5 2.5 0.2696 0.3212 0.3516 0.4453 0.5161 0.5686 0.7247 0.8134 0.8898
3 3 0.1030 0.1330 0.1537 0.1993 0.2490 0.2898 0.3842 0.4622 0.5347
Simulation and results
This procedure was evaluated using the simulation results for Procedure 1, described
above. For each simulation run, both for the null distribution and the different values of
d1 and d2, we checked whether the trial would have been stopped early by comparing Zi∗.1
with each value of c1. If the trial would have stopped, the final value of Zi∗ calculated was
replaced by zero.
The cutpoints are shown in Table 6.5, again calculated so that the correct proportion
of trials is rejected under H0 using the adaptive procedure. As expected, these become
smaller as c1 increases, i.e. as stopping becomes easier, since some cases in which H0 would
have been rejected are now not forwarded to stage 2. As noted above, as c1 → −∞, this
procedure converges to Procedure 1 and we see that with c1 = −1.5 it is almost identical.
The percentages of trials stopping early are shown in Table 6.6. We see that if H0 is true,
then we stop early only about 1.8% of the time when c1 = −1.5, while with c1 = 0.5
we stop early more than half of the time. Ideally, we would choose a value of c1 which
makes early stopping likely when H0 is true, but unlikely when H0 is false, especially when
d1 is such that the power of a fixed design is large, say greater than 60%. Of course a
compromise is necessary and, from Table 6.6, values of c1 equal to −0.5 or 0 seem like a
reasonable compromise. The former stops early almost 1/6 of the time when H0 is true
and no more than 1% of the time for the other values of d1 and d2 shown, while the latter
stops early 1/3 of the time (theoretically, the value in the table being an estimate) when
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Table 6.5: Cutpoints of the rejection region for Procedure 2 with different stopping cut-
points.
c1 5% 2.5% 1%
-1.5 1.8460 2.1515 2.5049
-1 1.8458 2.1514 2.5048
-.5 1.8442 2.1509 2.5045
0 1.8350 2.1464 2.5023
.5 1.7993 2.1258 2.4919
1 1.6882 2.0590 2.4536
H0 is true and no more than 4% of the time for the other values of d1 and d2.
Note that in this adaptive design the sample size is a random variable, taking value N/2
with probability estimated by the values in Table 6.6 and value N otherwise. Hence we
can calculated the expected sample sizes under H0 in each case and these are shown in
Table 6.7 as a proportion of the fixed sample size. For example, with c1 = −0.5, the
expected sample size is N2 0.1631 + N(1 − 0.1631) = 0.9185N . Note that, for c1 = 0, the
theoretical value is 5/6 = 0.8333, so the simulations seem very accurate.
The powers are shown in Tables 6.8-6.10. The power falls as c1 is increased, indicating
that the increase in the probability of rejection implied by the lower cutpoints is less than
the decrease in the probability of rejection caused by stopping early in some cases in which
we would have gone on to reject H0. Comparing with the fixed design, shown in Table
6.3, this rule gives higher power when ∆2 = 0 except for c1 = 1. Because we are allowed
to stop early in Procedure 2, and despite the lower cutpoints, the power is smaller than
in Procedure 1 and decreases as c1 increases, since in this case we stop early more often.
However, we see that the loss of power is negligible up to c1 = −0.5 and very small for
c1 = 0. For positive values of c1, the power decreases more quickly, but is still not very
large and such values could be used if there is particular pressure to reduce the expected
sample size.
The corresponding expected losses are shown in Tables 6.11-6.13. Again, we see that the
expected loss increases with c1, but that the increase is very small up to c1 = 0. In some
cases, however, we see that the expected loss is much greater for positive values of c1. This
is because the trial has been stopped in too many cases where we would have gone on to
reject H0 had it been continued.
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Table 6.6: Percentages of trials stopping early for Procedure 2 with different stopping
cutpoints and values of d1 and d2.
c1
d1 d2 -1.5 -1 -.5 0 .5 1
0 0 1.819 6.229 16.314 33.319 54.624 74.517
2.5 0 0.026 0.174 0.933 3.485 9.727 21.542
3 0 0.007 0.060 0.356 1.534 5.101 12.930
3.5 0 0.001 0.015 0.122 0.607 2.374 6.997
2.5 1.25 0.011 0.083 0.533 2.305 7.315 17.996
3 1.5 0.001 0.026 0.196 0.964 3.701 10.624
3.5 1.75 0.000 0.005 0.063 0.356 1.683 5.631
2 2 0.010 0.084 0.531 2.291 7.647 18.851
2.5 2.5 0.001 0.020 0.160 0.890 3.349 10.150
3 3 0.000 0.002 0.037 0.264 1.331 4.790
Table 6.7: Expected sample sizes under H0 for Procedure 2 with different stopping cut-
points relative to fixed sample size.
c1
-1.5 -1 -.5 0 .5 1
0.9909 0.9680 0.9185 0.8334 0.7269 0.6274
Table 6.8: Power for Procedure 2 at 5% with different stopping cutpoints.
c1
d1 d2 -1.5 -1 -.5 0 .5 1
2.5 0 80.901 80.892 80.773 80.210 77.990 71.927
3 0 92.328 92.312 92.228 91.762 89.898 84.456
3.5 0 97.596 97.592 97.550 97.278 96.022 92.163
2.5 1.25 79.082 79.084 79.044 78.815 77.559 73.273
3 1.5 90.229 90.222 90.196 90.004 88.917 85.035
3.5 1.75 96.022 96.021 96.003 95.905 95.152 92.441
2 2 74.499 74.499 74.503 74.450 73.605 70.315
2.5 2.5 89.215 89.215 89.206 89.121 88.431 85.246
3 3 96.568 96.566 96.567 96.518 96.063 93.711
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Table 6.9: Power for Procedure 2 at 2.5% with different stopping cutpoints.
c1
d1 d2 -1.5 -1 -.5 0 .5 1
2.5 0 72.323 72.317 72.248 71.886 70.419 66.164
3 0 87.511 87.503 87.446 87.111 85.688 81.366
3.5 0 95.616 95.612 95.581 95.368 94.365 90.967
2.5 1.25 70.103 70.099 70.080 69.939 69.139 66.321
3 1.5 84.656 84.653 84.641 84.499 83.716 80.844
3.5 1.75 93.343 93.341 93.334 93.253 92.693 90.347
2 2 63.332 63.333 63.329 63.301 62.900 61.045
2.5 2.5 82.188 82.189 82.185 82.168 81.782 79.691
3 3 93.357 93.356 93.359 93.330 92.990 91.303
Table 6.10: Power for Procedure 2 at 1% with different stopping cutpoints.
c1
d1 d2 -1.5 -1 -.5 0 .5 1
2.5 0 60.081 60.080 60.065 59.889 59.106 56.554
3 0 79.357 79.355 79.337 79.147 78.259 75.225
3.5 0 91.583 91.582 91.561 91.403 90.681 88.058
2.5 1.25 57.729 57.728 57.735 57.678 57.273 55.644
3 1.5 76.129 76.128 76.126 76.057 75.585 73.633
3.5 1.75 88.542 88.541 88.534 88.472 88.076 86.360
2 2 49.180 49.180 49.188 49.191 49.059 48.189
2.5 2.5 71.014 71.014 71.022 71.023 70.886 69.765
3 3 87.195 87.195 87.204 87.194 87.013 85.928
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Table 6.11: Expected Loss for Procedure 2 at 5% with different stopping cutpoints.
c1
d1 d2 -1.5 -1 -.5 0 .5 1
2.5 0 0.4873 0.4875 0.4905 0.5047 0.5606 0.7138
3 0 0.2361 0.2366 0.2392 0.2533 0.3095 0.4740
3.5 0 0.0875 0.0876 0.0892 0.0988 0.1430 0.2787
2.5 1.25 0.6398 0.6398 0.6408 0.6469 0.6791 0.7854
3 1.5 0.4307 0.4309 0.4317 0.4380 0.4708 0.5859
3.5 1.75 0.2815 0.2815 0.2822 0.2861 0.3124 0.4064
2 2 0.5100 0.5100 0.5099 0.5110 0.5279 0.5937
2.5 2.5 0.2696 0.2696 0.2699 0.2720 0.2892 0.3689
3 3 0.1030 0.1030 0.1030 0.1045 0.1181 0.1887
Table 6.12: Expected Loss for Procedure 2 at 2.5% with different stopping cutpoints.
c1
d1 d2 -1.5 -1 -.5 0 .5 1
2.5 0 0.6973 0.6975 0.6992 0.7082 0.7450 0.8521
3 0 0.3782 0.3784 0.3801 0.3901 0.4329 0.5632
3.5 0 0.1554 0.1556 0.1567 0.1641 0.1993 0.3186
2.5 1.25 0.8357 0.8358 0.8363 0.8400 0.8606 0.9309
3 1.5 0.5699 0.5700 0.5704 0.5748 0.5991 0.6858
3.5 1.75 0.3545 0.3545 0.3548 0.3580 0.3780 0.4599
2 2 0.7334 0.7333 0.7334 0.7340 0.7420 0.7791
2.5 2.5 0.4453 0.4453 0.4454 0.4458 0.4555 0.5077
3 3 0.1993 0.1993 0.1992 0.2001 0.2103 0.2609
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Table 6.13: Expected Loss for Procedure 2 at 1% with different stopping cutpoints.
c1
d1 d2 -1.5 -1 -.5 0 .5 1
2.5 0 1.0004 1.0004 1.0008 1.0052 1.0248 1.0888
3 0 0.6210 0.6210 0.6216 0.6273 0.6540 0.7451
3.5 0 0.2955 0.2956 0.2963 0.3018 0.3271 0.4190
2.5 1.25 1.1140 1.1140 1.1139 1.1155 1.1258 1.1668
3 1.5 0.7949 0.7949 0.7950 0.7973 0.8118 0.8714
3.5 1.75 0.4943 0.4943 0.4946 0.4968 0.5111 0.5718
2 2 1.0164 1.0164 1.0162 1.0162 1.0188 1.0362
2.5 2.5 0.7247 0.7247 0.7245 0.7244 0.7279 0.7559
3 3 0.3842 0.3842 0.3839 0.3842 0.3896 0.4222
6.3.3 Procedure 3: Stop or forward one or more experimental treat-
ments
In this procedure, we modify Procedure 2 by allowing more than one experimental arm
to be forwarded to stage 2 if it is unclear which is best. If, after stage 1, more than one
of the experimental treatments seems to be possibly better than the control and if their
estimated effects do not differ by much, then it should be beneficial to forward all of these
experimental arms in order to make a better selection after stage 2. We can describe the
procedure as follows:
Stage 1: Allocate N2(I+1) patients to each arm. Carry forward the experimental treatment
with the best results in stage 1 if X1.1 > c1; also carry forward the treatment with the
second best results if X2.1 > c2ρX1.1; . . .. We also carry forward the control. Stage 2:
Allocate N2(I.2+1) patients to each remaining arm. Test using T1, T2 or T∞ (based on I.2
treatments) with a critical value adjusted to take account of the bias in the test statistics
caused by the adaptive design.
This procedure is similar to that of Kelly et al. (2005), except that we do not allow early
rejection of H0 and they considered only the test statistic T∞.
If we stop early, then Tk = 0 for k = 1, 2,∞ and no further calculation is needed. If we
continue with one experimental arm, then the data from the two stages are combined in
exactly the same way as for Procedure 1. If we continue with both experimental arms, then
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Zi = (Zi.1 +Zi.2)/
√
2, i.e. Zi is calculated in the same way as from the fixed design. Note
also, that when one arm is forwarded, di.2 is calculated in the same way as for Procedure
1, whereas when two arms are forwarded di.2 = di.1.
Simulation and results
The null distributions of the test statistics were approximated using a new set of sim-
ulations. We chose not to reuse the earlier simulations because, depending on whether
one or two arms is forwarded to stage 2, there are different numbers of patients on each
arm. For stage 1, we simulated two million values of Z1.1 and Z2.1 from a bivariate normal
distribution with correlation ρ = 0.5 (i.e. equal allocation), as for Procedure 1. It was
noted whether the values of Z1.1 and Z2.1 led to stopping (Case 0), forwarding one arm
(Case 1) or forwarding both arms (Case 2). Then, for stage 2, a loop was created so that
for those simulations which led to Case 1 we simulated values of Zi∗.2 from a univariate
normal distribution, while for those simulations which led to Case 2, we simulated values
of Z1.2 and Z2.2 from a bivariate normal distribution with correlation ρ = 0.5. The stages
were combined to give two million simulated values of T1, T2 and T∞, from which critical
values were calculated at 5%, 2.5% and 1% levels of significance corresponding to the
appropriate proportion being rejected. Again, we could have simulated bivariate normal
random variables in each case and only used those which were needed. However, we chose
not to, since the responses from treatment 1 at stage 2, for example, seem conceptually
different if there are different numbers of subjects in different cases, so that reusing the
same simulated values would create non-interpretable correlations among the simulation
results.
On the basis of the results from Procedure 2, we decided to use only the values −0.5 and 0
for the stopping boundary c1 and considered four different values of c2, which determines
whether we forward one or two arms to stage 2. The cutpoints, as shown in Table 6.14,
indicate that changing c2 has a clear impact, especially for T1 and T2. The difference
between the two values of c1 given is very small.
The probabilities of stopping, forwarding one treatment and forwarding two treatments
under the null hypothesis are estimated in Table 6.15. Since the stopping rule is identical
to that for Procedure 2, i.e. we stop if X1.1 ≤ c1, the expected sample sizes under H0 are
the same as those in Table 6.7, apart from simulation error. The probability of forwarding
both arms, when H0 is true, is always smaller than the probability of forwarding one arm,
but varies considerably with c2, where we forward two arms if X2.1 >
c2
2 X1.1.
CHAPTER 6. TWO-STAGE ADAPTIVE DESIGNS 204
Table 6.14: Cutpoints for T1, T2 and T∞ for c1 and c2 at 5, 2.5 and 1%.
5% 2.5% 1%
c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
0 1.5 1.9467 1.8837 1.8690 2.2994 2.1985 2.1790 2.7311 2.5640 2.5381
0 1 2.0491 1.9254 1.8977 2.4257 2.2378 2.2034 2.8873 2.5959 2.5538
0 .75 2.0836 1.9367 1.9058 2.4635 2.2457 2.2076 2.9255 2.6065 2.5574
0 .5 2.1069 1.9441 1.9113 2.4905 2.2555 2.2149 2.9572 2.6165 2.5648
-0.5 1.5 1.9565 1.8939 1.8794 2.3029 2.2036 2.1845 2.7311 2.5643 2.5382
-0.5 1 2.0551 1.9321 1.9064 2.4286 2.2424 2.2086 2.8893 2.5993 2.5560
-0.5 .75 2.0893 1.9432 1.9127 2.4717 2.2524 2.2130 2.9377 2.6106 2.5607
-0.5 0.5 2.1146 1.9528 1.9203 2.4946 2.2583 2.2178 2.9576 2.6131 2.5645
Table 6.15: Percentages of Cases 0, 1 and 2 under H0 for Procedure 3
Case
c1 c2 0 1 2
0 1.5 33.318 58.968 7.714
0 1 33.386 49.973 16.641
0 .75 33.269 45.439 21.292
0 .5 33.249 41.158 25.594
-.5 1.5 16.321 75.950 7.729
-.5 1 16.363 66.962 16.675
-.5 .75 16.367 62.435 21.198
-.5 .5 16.341 58.038 25.622
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As before, the power and expected loss are calculated as the proportion of 100,000 simu-
lations which rejected H0 using different values of d1 and d2. Since different numbers of
arms can be forwarded for different values of d1 and d2, depending on the results from
stage 1, we chose to simulate a new set of errors for each value of d1 and d2. Hence, when
comparing the estimated powers or expected losses from different values of d1 and d2 for
this procedure, the variance is larger than for the other simulations presented in this the-
sis. However, the variance of each single power or expected loss is approximately the same
as for any of the other procedures, since it is based on the same number of simulations.
The percentages of trials which stopped early, carried forward one treatment and carried
forward two treatments under the alternative hypothesis are shown in Table 6.16. The
percentages of trials which stop early are the same as with Procedure 2, the observed
differences being due to simulation variance. On the other hand, we see that the number
of arms carried forward is very sensitive to the value of d2, as it should be. When d2 = 0 it
is rare to forward both arms, but when d2 = d1 it is very common to forward both arms.
The value of c2, which gives the decision about how many treatments to forward, is also
quite influential, with the smaller values forwarding two treatments too often. From this
table, a procedure with c1 = 0 and c2 = 1 or 1.5 looks quite attractive in that it forwards
two arms rarely when ∆2 = 0, but often when ∆2 = ∆1.
Table 6.17 shows the power for all three tests for various values of d1 when d2 = 0. As we
saw in Table 6.16, in this case it is quite rare to forward both arms, except for small c2. As
in the fixed design, T∞ has the highest power for these configurations, T2 is only slightly
less powerful, but T1 is worse. The effect of sometimes forwarding two treatments is a loss
of power compared with Procedure 2 (cf. Tables 6.8-6.10). We see that c2 = 1.5 always
gives the highest power for these configurations and, of course, as c2 →∞, this procedure
converges to Procedure 2, i.e. we never forward both arms. These results are as expected,
since when only one treatment is better than the control, it is clearly wasteful of resources
to forward two treatments, since the likelihood of forwarding the inferior treatment if only
one is selected is small whenever the power is reasonably high. The power is slightly lower
with c1 = 0 than with c1 = −0.5, although of course the expected sample size is smaller.
Table 6.18 shows the power when d2 = 0.5d1. Again, as in the fixed design, T2 gives the
highest power for this configuration, with T∞ being slightly less powerful and T1 slightly
less again. The power with c1 = −0.5 is only very slightly higher than with c1 = 0. The
best value of c2 is clearly 1.5 and, in this case, this procedure outperforms Procedure 2.
In a few cases, it even has higher power than Procedure 1, despite using fewer patients.
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Table 6.16: Percentages of Cases 0, 1 and 2 for Procedure 3 for different values of d1 and
d2
d2 = 0 d2 = .5d1 d2 = d1
Case Case Case
d1 c1 c2 0 1 2 0 1 2 0 1 2
2 0 1.5 6.630 86.376 6.994 4.776 76.115 19.109 2.307 66.785 30.908
2 0 1 6.666 75.564 17.770 4.732 54.691 40.577 2.285 38.311 59.404
2 0 .75 6.678 68.673 24.649 4.699 44.391 50.910 2.320 27.552 70.128
2 0 .5 6.683 60.468 32.849 4.642 35.298 60.060 2.258 19.843 77.899
2 -.5 1.5 2.155 90.907 6.938 1.346 79.363 19.291 0.523 68.602 30.875
2 -.5 1 2.134 80.332 17.534 1.356 57.911 40.733 0.537 39.935 59.528
2 -.5 .75 2.083 72.931 24.986 1.292 47.968 50.740 0.535 29.454 70.011
2 -.5 .5 2.155 64.853 32.992 1.254 39.098 59.648 0.561 21.879 77.560
2.5 0 1.5 3.397 91.730 4.873 2.349 77.144 20.507 0.829 61.701 37.470
2.5 0 1 3.448 82.362 14.190 2.349 53.353 44.298 0.876 29.668 69.456
2.5 0 .75 3.471 75.134 21.395 2.267 41.494 56.239 0.857 19.218 79.925
2.5 0 .5 3.418 66.185 30.397 2.261 31.831 34.092 0.874 12.661 86.465
2.5 -.5 1.5 0.953 94.165 4.882 0.575 78.868 20.557 0.167 62.333 37.500
2.5 -.5 1 0.957 84.992 14.051 0.537 55.159 44.304 0.151 30.444 69.405
2.5 -.5 .75 0.933 77.699 21.368 0.578 43.556 55.866 0.151 19.959 79.890
2.5 -.5 .5 0.944 68.459 30.597 0.492 33.451 66.057 0.160 13.185 86.655
3 0 1.5 1.545 95.466 2.989 0.995 78.237 20.768 0.260 55.499 44.241
3 0 1 1.531 87.883 10.586 1.011 51.852 47.137 0.271 21.582 78.147
3 0 .75 1.596 80.701 17.339 0.960 38.956 60.084 0.293 12.643 87.064
3 0 .5 1.503 70.954 27.543 0.926 28.191 70.883 0.276 7.314 92.410
3 -.5 1.5 0.395 96.566 3.039 0.209 79.120 20.671 0.048 55.598 44.354
3 -.5 1 0.382 88.878 10.740 0.192 52.751 47.057 0.041 21.642 78.317
3 -.5 .75 0.368 81.609 18.023 0.193 39.686 60.121 0.039 12.718 87.243
3 -.5 .5 0.360 72.002 27.638 0.175 29.111 70.714 0.035 7.668 92.297
3.5 0 1.5 0.613 97.719 1.668 0.407 79.247 20.346 0.072 49.295 50.633
3.5 0 1 0.628 91.732 7.640 0.396 51.198 48.406 0.070 15.251 84.679
3.5 0 .75 0.606 85.212 14.182 0.380 36.723 62.897 0.084 7.729 92.187
3.5 0 .5 0.611 74.858 24.531 0.379 24.670 74.951 0.088 3.834 96.078
3.5 -.5 1.5 0.137 98.164 1.699 0.056 79.428 20.516 0.015 49.135 50.850
3.5 -.5 1 0.115 92.371 7.514 0.063 51.214 48.723 0.005 15.420 84.575
3.5 -.5 .75 0.121 85.634 14.245 0.068 36.852 63.080 0.002 7.705 92.293
3.5 -.5 .5 0.136 75.479 24.385 0.083 25.143 74.774 0.013 3.949 96.038
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Table 6.17: Power of the tests using Procedure 3 with ∆2 = 0.
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2.5 0 1.5 78.243 79.664 79.979 67.673 70.753 71.320 51.912 57.839 58.793
2.5 0 1 75.301 78.448 79.056 62.805 68.845 69.935 45.198 55.897 57.349
2.5 0 .75 73.993 77.849 78.524 61.107 68.239 69.373 43.084 54.959 56.749
2.5 0 .5 72.869 77.346 78.108 59.305 67.223 68.451 40.996 53.611 55.466
2.5 -.5 1.5 78.954 80.460 80.784 68.136 71.218 71.798 52.133 58.309 59.230
2.5 -.5 1 75.875 79.053 79.650 63.179 69.298 70.320 45.397 56.252 57.737
2.5 -.5 .75 74.394 78.412 79.177 60.991 68.391 69.645 42.972 54.913 56.670
2.5 -.5 .5 73.343 77.949 78.796 59.724 67.839 69.089 41.268 54.186 55.948
3 0 1.5 90.863 91.639 91.816 84.369 86.535 86.92 72.668 77.550 78.248
3 0 1 89.166 91.003 91.336 81.175 85.409 86.104 66.912 76.206 77.331
3 0 .75 88.315 90.545 90.969 79.598 84.830 85.660 64.650 75.073 76.516
3 0 .5 87.600 90.335 90.817 78.405 84.258 85.143 62.703 74.204 75.821
3 -.5 1.5 91.229 92.066 92.238 84.733 86.828 87.157 72.814 77.903 78.618
3 -.5 1 89.289 91.168 91.536 81.096 85.446 86.157 66.494 75.927 77.121
3 -.5 .75 88.609 90.954 91.391 79.591 84.940 85.819 64.212 75.010 76.462
3 -.5 .5 87.835 90.620 91.118 78.530 84.546 85.382 62.693 74.590 76.065
3.5 0 1.5 96.843 97.167 97.251 94.094 95.043 95.199 87.570 90.576 90.965
3.5 0 1 96.320 97.030 97.184 92.454 94.681 95.009 84.028 89.828 90.443
3.5 0 .75 95.857 96.846 97.031 91.627 94.338 94.717 82.266 89.221 90.036
3.5 0 .5 95.513 96.697 96.892 90.894 93.987 94.430 80.850 88.614 89.525
3.5 -.5 1.5 97.131 97.450 97.525 94.231 95.194 95.375 87.842 90.777 91.145
3.5 -.5 1 96.503 97.317 97.469 92.592 94.761 95.094 84.138 89.955 90.671
3.5 -.5 .75 96.207 97.177 97.361 91.898 94.630 95.011 82.253 89.498 90.356
3.5 -.5 .5 95.671 96.916 97.119 90.977 94.078 94.542 80.881 88.768 89.676
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Table 6.18: Power of the tests using Procedure 3 when ∆2 = .5∆1.
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2.5 0 1.5 78.585 79.062 78.957 68.362 69.672 69.544 53.544 56.644 56.663
2.5 0 1 77.733 78.583 78.353 66.772 68.827 68.500 50.650 55.446 55.257
2.5 0 .75 77.008 78.039 77.886 65.392 67.943 67.669 49.108 53.930 53.727
2.5 0 .5 76.164 77.295 77.048 64.294 66.946 66.670 48.058 52.798 52.707
2.5 -.5 1.5 78.973 79.437 79.374 68.950 70.206 70.091 53.930 57.116 57.017
2.5 -.5 1 77.904 78.711 78.479 66.704 68.781 68.561 50.710 55.357 55.182
2.5 -.5 .75 77.361 78.365 78.171 65.336 68.161 68.028 48.967 54.011 54.039
2.5 -.5 .5 76.578 77.698 77.490 64.515 67.249 67.065 48.091 53.211 52.997
3 0 1.5 90.371 90.660 90.624 84.140 85.036 84.963 73.095 75.843 75.781
3 0 1 89.722 90.165 90.064 82.526 84.156 84.017 69.837 74.358 74.103
3 0 .75 89.116 89.749 89.625 81.435 83.451 83.231 67.998 72.950 72.823
3 0 .5 88.793 89.543 89.363 80.688 82.831 82.629 66.799 72.059 71.954
3 -.5 1.5 90.556 90.827 90.749 84.414 85.290 85.156 73.448 76.077 76.064
3 -.5 1 89.976 90.482 90.314 82.458 84.227 84.119 69.652 74.073 73.940
3 -.5 .75 89.703 90.387 90.246 81.836 84.015 83.752 68.457 73.481 73.301
3 -.5 .5 88.800 89.623 89.457 80.476 82.871 82.648 66.784 72.070 71.873
3.5 0 1.5 96.471 96.567 96.535 93.457 93.981 93.899 87.288 88.920 88.762
3.5 0 1 96.158 96.374 96.321 92.499 93.393 93.243 84.806 87.748 87.552
3.5 0 .75 95.967 96.261 96.150 92.036 93.117 93.016 83.661 87.124 87.030
3.5 0 .5 95.604 96.024 95.941 91.233 92.611 92.440 82.018 85.984 85.935
3.5 -.5 1.5 96.380 96.501 96.468 93.428 93.893 93.798 87.159 88.815 88.729
3.5 -.5 1 96.190 96.432 96.346 92.520 93.362 93.196 84.715 87.652 87.479
3.5 -.5 .75 95.992 96.328 96.250 91.882 93.133 92.989 83.092 86.929 86.799
3.5 -.5 .5 95.711 96.074 95.960 91.302 92.761 92.643 82.097 86.284 86.123
It is interesting to note that the powers in this table are often lower than when d2 = 0,
which was never the case with the fixed design. There are probably two contributing
factors. First, as can be seen from Table 6.16, when d2 = 0.5d1, both experimental arms
are forwarded to stage 2 considerably more often, and this reduces the number of patients
used for comparing treatment 1 with the control. Second, if one treatment is forwarded,
it is more likely to be the inferior treatment when d2 = 0.5d1 than when d2 = 0; when
this happens it is likely that we will fail to reject H0.
Table 6.19 shows the power when d2 = d1. As in the fixed design, T∞ has the least
power in this case. In the fixed design, T1 was clearly more powerful than T2, but the
difference seems to be very small here. In some cases at 1%, T2 is more powerful, though
this might be due only to simulation variation. However, there seems to be no practical
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Table 6.19: Power of the tests using Procedure 3 when ∆2 = ∆1
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2 0 1.5 74.929 74.791 74.319 63.479 63.672 62.992 48.245 48.992 48.006
2 0 1 74.621 73.885 73.032 63.445 62.567 61.083 48.850 48.161 46.085
2 0 .75 74.579 73.302 72.147 63.559 62.078 60.259 49.180 47.469 45.274
2 0 .5 74.663 73.045 71.762 63.454 61.532 59.645 48.883 46.672 44.334
2 -.5 1.5 74.901 74.820 74.404 63.497 63.621 62.829 48.421 49.152 48.040
2 -.5 1 75.047 74.127 73.131 63.678 62.827 61.403 48.853 48.172 46.207
2 -.5 .75 74.759 73.572 72.428 63.515 62.103 60.462 48.885 47.436 45.316
2 -.5 .5 74.728 73.327 72.058 63.691 61.707 59.794 48.904 47.016 44.458
2.5 0 1.5 89.364 89.215 88.833 82.168 82.179 81.508 70.247 70.941 69.672
2.5 0 1 89.426 88.622 87.939 82.369 81.398 79.893 70.981 69.992 67.309
2.5 0 .75 89.264 88.413 87.526 82.395 80.996 79.328 71.236 69.335 66.738
2.5 0 .5 89.172 88.075 87.147 82.236 80.516 78.695 70.988 68.591 65.764
2.5 -.5 1.5 89.493 89.349 88.984 82.441 82.389 81.685 70.483 71.273 70.067
2.5 -.5 1 89.406 88.673 87.848 82.381 81.325 79.920 70.756 69.809 67.475
2.5 -.5 .75 89.492 88.593 87.642 82.361 80.992 79.329 70.910 69.201 66.661
2.5 -.5 .5 89.379 88.237 87.240 82.221 80.632 78.708 71.035 68.715 65.732
3 0 1.5 96.655 96.635 96.430 93.540 93.451 92.941 86.908 87.273 86.213
3 0 1 96.647 96.306 95.887 93.573 92.971 92.032 87.334 86.476 84.363
3 0 .75 96.492 95.994 95.501 93.233 92.374 91.278 86.956 85.558 83.388
3 0 .5 96.472 95.938 95.367 93.366 92.242 91.046 87.012 85.203 82.875
3 -.5 1.5 96.690 96.608 96.385 93.514 93.407 92.918 86.839 87.236 86.106
3 -.5 1 96.760 96.379 95.905 93.621 92.891 91.940 87.291 86.485 84.464
3 -.5 .75 96.658 96.180 95.646 93.516 92.509 91.457 87.136 85.765 83.626
3 -.5 .5 96.658 96.111 95.526 93.451 92.417 91.222 87.020 85.430 83.097
difference in power between the two tests. In this case, c1 = 0 can even give higher power
than c1 = −0.5, even though it leads to more early stopping, although this might be just
due to simulation variance. Again c2 = 1.5 seems to be the best value and again this
procedure is better than Procedure 2, although only very slightly. Again, it also gives
a more powerful test than Procedure 1, despite using fewer patients. As expected, the
powers when d2 = d1 are considerably higher than when d2 = 0.5d1, because whichever
arm or arms are forwarded to stage 2, we are still likely to reject H0.
Tables 6.20-6.22 show the expected loss when d2 = 0, d2 = d1/2 and d2 = d1 respectively.
The results are broadly consistent with those for the power. T∞ is best when d2 = 0,
but T2 is better in the other cases, being very similar to T1 when d2 = d1. As with the
power, there is very little difference between the values of c1, with c1 = 0 even giving
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smaller expected loss than c1 = −0.5 when d1 and d2 are both large. A value of 1.5 for
c2 is clearly the best of those studied. When d2 = 0, the expected loss is slightly higher
than for Procedure 2, since we sometimes forward two experimental treatments, but end
up only using one to calculate the test statistic, and so we lose power due to the wasted
patients on the second treatment. In the other two configurations it is somewhat lower
than in Procedure 2, because we more often forward the best treatment and so reduce the
probability of a type-III/IV error. In many cases, including all of those with ∆2 = ∆1/2,
the expected loss is even clearly better than for Procedure 1, which on average uses more
patients.
The flexibility of Procedure 3 in allowing a more powerful test when it is clear which
experimental treatment is better after stage 1, but allowing better optimal treatment
selection when it is not clear which is best, seems to lead to fewer type-III/IV errors and
hence to a lower expected losses.
6.3.4 Discussion
To summarise the results from this section, a powerful design from each procedure, includ-
ing the fixed design, is compared in Table 6.23, using the test statistic T2 at the 5% level of
significance. A design which always drops one treatment after stage 1 (Procedure 1) shows
improved performance over the fixed design with the same sample size, due to the extra
information gained on the important pairwise comparison. A design which additionally
allows early stopping for futility (Procedure 2) leads to some savings in expected sample
size, up to about N/6, without much loss of performance. A design which additionally
allows two arms to be forwarded if it is unclear which is best (Procedure 3), although
the most complex to manage, allows identical savings in terms of expected numbers of
patients to Procedure 2, while achieving power and expected loss, which are as good as
Procedure 1.
Overall, the message from the simulations reported in this chapter is very clear. When
feasible, an adaptive design should be used in preference to the fixed design. The best
adaptive design studied seems to be Procedure 3, with c2 = 1.5 and c1 = 0. This design
saves, on average, at least 1/6 of the patients if H0 is true, but, if H1 is true, achieves a
similar power to Procedure 1, which has a fixed sample size and which, in turn, has higher
power than the fixed design. Note also that the increase in power over the fixed design can
be as much as 6%, whereas the optimal allocation for the fixed design found in Chapter 4
increased the power over equal allocation by no more than 3%.
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Table 6.20: Expected loss of the tests using Procedure 3 when ∆2 = 0
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2.5 0 1.5 0.5501 0.5145 0.5065 0.8118 0.7347 0.7204 1.2048 1.0557 1.0315
2.5 0 1 0.6230 0.5440 0.5283 0.9340 0.7820 0.7545 1.3730 1.1047 1.0680
2.5 0 .75 0.6557 0.5584 0.5410 0.9766 0.7971 0.7684 1.4257 1.1279 1.0829
2.5 0 .5 0.6839 0.5712 0.5514 1.0217 0.8222 0.7912 1.4775 1.1612 1.1145
2.5 -.5 1.5 0.5329 0.4951 0.4867 0.8010 0.7235 0.7089 1.1993 1.0445 1.0212
2.5 -.5 1 0.6087 0.5284 0.5130 0.9244 0.7705 0.7446 1.3677 1.0954 1.0579
2.5 -.5 .75 0.6463 0.5452 0.5256 0.9801 0.7940 0.7620 1.4290 1.1295 1.0850
2.5 -.5 .5 0.6732 0.5566 0.5349 1.0119 0.8077 0.7758 1.4714 1.1473 1.1025
3 0 1.5 0.2767 0.2533 0.2480 0.4706 0.4056 0.3940 0.8208 0.6745 0.6535
3 0 1 0.3297 0.2744 0.2634 0.5668 0.4436 0.4222 0.9961 0.7167 0.6800
3 0 .75 0.3526 0.2855 0.2727 0.6138 0.4565 0.4314 1.0618 0.7487 0.7051
3 0 .5 0.3739 0.2915 0.2769 0.6493 0.4733 0.4466 1.1199 0.7745 0.7259
3 -.5 1.5 0.2659 0.2410 0.2358 0.4597 0.3968 0.3869 0.8166 0.6638 0.6422
3 -.5 1 0.3230 0.2666 0.2555 0.5684 0.4376 0.4162 1.0060 0.7228 0.6868
3 -.5 .75 0.3440 0.2735 0.2601 0.6141 0.4532 0.4266 1.0750 0.7506 0.7069
3 -.5 .5 0.3671 0.2834 0.2683 0.6458 0.4651 0.4398 1.1207 0.7633 0.7187
3.5 0 1.5 0.1111 0.0998 0.0969 0.2071 0.1740 0.1685 0.4353 0.3301 0.3164
3.5 0 1 0.1294 0.1046 0.0991 0.2646 0.1866 0.1751 0.5594 0.3562 0.3347
3.5 0 .75 0.1454 0.1108 0.1043 0.2934 0.1985 0.1852 0.6210 0.3774 0.3489
3.5 0 .5 0.1575 0.1160 0.1091 0.3191 0.2108 0.1952 0.6705 0.3987 0.3669
3.5 -.5 1.5 0.1015 0.0903 0.0877 0.2025 0.1689 0.1626 0.4259 0.3232 0.3102
3.5 -.5 1 0.1231 0.0946 0.0892 0.2597 0.1839 0.1722 0.5555 0.3518 0.3267
3.5 -.5 .75 0.1334 0.0994 0.0930 0.2841 0.1884 0.1750 0.6215 0.3678 0.3377
3.5 -.5 .5 0.1519 0.1084 0.1013 0.3161 0.2077 0.1914 0.6695 0.3933 0.3616
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Table 6.21: Expected loss of the tests using Procedure 3 when ∆2 = .5∆1
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2.5 0 1.5 0.6296 0.6172 0.6188 0.8638 0.8304 0.8317 1.2122 1.1328 1.1295
2.5 0 1 0.6476 0.6223 0.6252 0.9060 0.8477 0.8514 1.2899 1.1629 1.1628
2.5 0 .75 0.6639 0.6331 0.6338 0.9401 0.8691 0.8708 1.3296 1.1993 1.1985
2.5 0 .5 0.6856 0.6508 0.6535 0.9677 0.8931 0.8949 1.3561 1.2273 1.2239
2.5 -.5 1.5 0.6194 0.6075 0.6084 0.8492 0.8170 0.8182 1.2024 1.1215 1.1214
2.5 -.5 1 0.6417 0.6181 0.6214 0.9058 0.8486 0.8500 1.2880 1.1642 1.1630
2.5 -.5 .75 0.6542 0.6238 0.6255 0.9402 0.8621 0.8606 1.3319 1.1965 1.1902
2.5 -.5 .5 0.6757 0.6411 0.6425 0.9622 0.8856 0.8852 1.3557 1.2179 1.2172
3 0 1.5 0.3841 0.3762 0.3767 0.5542 0.5279 0.5289 0.8660 0.7836 0.7828
3 0 1 0.3922 0.3774 0.3787 0.5974 0.5454 0.5467 0.9649 0.8238 0.8263
3 0 .75 0.4081 0.3858 0.3869 0.6293 0.5637 0.5659 1.0202 0.8631 0.8616
3 0 .5 0.4196 0.3931 0.3955 0.6542 0.5831 0.5844 1.0583 0.8913 0.8889
3 -.5 1.5 0.3745 0.3671 0.3686 0.5423 0.5164 0.5191 0.8528 0.7733 0.7715
3 -.5 1 0.3827 0.3657 0.3687 0.5976 0.5412 0.5414 0.9690 0.8305 0.8296
3 -.5 .75 0.3905 0.3671 0.3694 0.6173 0.5468 0.5508 1.0068 0.8484 0.8487
3 -.5 .5 0.4185 0.3901 0.3925 0.6591 0.5813 0.5841 1.0578 0.8918 0.8919
3.5 0 1.5 0.2061 0.2034 0.2043 0.3007 0.2834 0.2858 0.5027 0.4469 0.4503
3.5 0 1 0.2011 0.1933 0.1944 0.3235 0.2911 0.2943 0.5851 0.4789 0.4823
3.5 0 .75 0.2044 0.1929 0.1956 0.3378 0.2970 0.2980 0.6243 0.4984 0.4977
3.5 0 .5 0.2193 0.2027 0.2038 0.3677 0.3156 0.3186 0.6831 0.5391 0.5369
3.5 -.5 1.5 0.2098 0.2062 0.2072 0.3019 0.2871 0.2895 0.5062 0.4498 0.4513
3.5 -.5 1 0.1995 0.1905 0.1925 0.3220 0.2907 0.2947 0.5874 0.4813 0.4832
3.5 -.5 .75 0.2040 0.1909 0.1925 0.3427 0.2965 0.2992 0.6436 0.5054 0.5059
3.5 -.5 .5 0.2129 0.1984 0.2008 0.3630 0.3087 0.3100 0.6787 0.5274 0.5288
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Table 6.22: Expected loss of the tests using Procedure 3 when ∆2 = ∆1
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2 0 1.5 0.5014 0.5042 0.5136 0.7304 0.7266 0.7402 1.0351 1.0202 1.0399
2 0 1 0.5076 0.5223 0.5394 0.7311 0.7487 0.7783 1.0230 1.0368 1.0783
2 0 .75 0.5084 0.5340 0.5571 0.7288 0.7584 0.7948 1.0164 1.0506 1.0945
2 0 .5 0.5067 0.5391 0.5648 0.7309 0.7694 0.8071 1.0223 1.0666 1.1133
2 -.5 1.5 0.5020 0.5036 0.5119 0.7301 0.7276 0.7434 1.0316 1.0170 1.0392
2 -.5 1 0.4991 0.5175 0.5374 0.7264 0.7435 0.7719 1.0229 1.0366 1.0759
2 -.5 .75 0.5048 0.5286 0.5514 0.7297 0.7579 0.7908 1.0223 1.0513 1.0937
2 -.5 .5 0.5054 0.5335 0.5588 0.7262 0.7659 0.8041 1.0219 1.0597 1.1108
2.5 0 1.5 0.2659 0.2696 0.2792 0.4458 0.4455 0.4623 0.7438 0.7265 0.7582
2.5 0 1 0.2644 0.2845 0.3015 0.4408 0.4651 0.5027 0.7255 0.7502 0.8173
2.5 0 .75 0.2684 0.2897 0.3119 0.4401 0.4751 0.5168 0.7191 0.7666 0.8316
2.5 0 .5 0.2707 0.2981 0.3213 0.4441 0.4871 0.5326 0.7253 0.7852 0.8559
2.5 -.5 1.5 0.2627 0.2663 0.2754 0.4390 0.4403 0.4579 0.7379 0.7182 0.7483
2.5 -.5 1 0.2649 0.2832 0.3038 0.4405 0.4669 0.5020 0.7311 0.7548 0.8131
2.5 -.5 .75 0.2627 0.2852 0.3090 0.4410 0.4752 0.5168 0.7273 0.7700 0.8335
2.5 -.5 .5 0.2655 0.2941 0.3190 0.4445 0.4842 0.5323 0.7241 0.7821 0.8567
3 0 1.5 0.1004 0.1010 0.1071 0.1938 0.1965 0.2118 0.3928 0.3818 0.4136
3 0 1 0.1006 0.1108 0.1234 0.1928 0.2109 0.2390 0.3800 0.4057 0.4691
3 0 .75 0.1052 0.1202 0.1350 0.2030 0.2288 0.2617 0.3913 0.4333 0.4984
3 0 .5 0.1058 0.1219 0.1390 0.1990 0.2327 0.2686 0.3896 0.4439 0.5138
3 -.5 1.5 0.0993 0.1018 0.1085 0.1946 0.1978 0.2125 0.3948 0.3829 0.4168
3 -.5 1 0.0972 0.1086 0.1229 0.1914 0.2133 0.2418 0.3813 0.4055 0.4661
3 -.5 .75 0.1003 0.1146 0.1306 0.1945 0.2247 0.2563 0.3859 0.4271 0.4912
3 -.5 .5 0.1003 0.1167 0.1342 0.1965 0.2275 0.2633 0.3894 0.4371 0.5071
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Table 6.23: Summary of properties of different procedures using T2 at the 5% level of
significance.
Procedure
Fixed 1 2 (c1 = 0) 3 (c1 = 0, c2 = 1.5)
Expected no. patients ×100/N 100 100 83.33 83.33
Power (d1 = 3, d2 = 0) 85.477 92.328 91.762 91.639
Power (d1 = 3, d2 = 1.5) 87.579 90.229 90.004 90.660
Power (d1 = 2.5, d2 = 2.5) 87.151 89.215 89.121 89.215
E(Loss) (d1 = 3, d2 = 0) 0.4374 0.2361 0.2533 0.2533
E(Loss) (d1 = 3, d2 = 1.5) 0.4490 0.4306 0.4380 0.3762
E(Loss) (d1 = 2.5, d2 = 2.5) 0.3212 0.2696 0.2720 0.2696
Further refinement of these values could be used to find an optimum design for specific
situations, but the criterion of optimality would have to balance costs against benefits.
Because the main benefit of Procedure 3 is its ability to forward a different number of
treatments depending on the results from stage 1, the benefits will be even greater if more
arms are used. For example, with a large number of experimental treatments, this design
will forward a larger or smaller number depending on the results of stage 1, thus allowing
resources to be concentrated on comparing a few treatments against the control if only a
few are beneficial, or using the information from many treatments if many are beneficial.
6.4 Procedure 3 with unequal stage sizes
So far we have considered only stages of equal sizes. For any of the procedures, it might be
better to use fewer patients in stage 1, but this is particularly true for Procedure 3, since it
has the flexibility to drop a clearly inferior arm, but continue with all arms which remain
good candidates. There is little advice in the literature on how to choose the stage sizes
in adaptive multi-arm trials, though Stallard and Todd (2003) showed that in a four-arm
trial with their procedure, it was optimal to use slightly fewer than N/5 patients in stage
1. Here we consider Procedure 3 with a total of N/4 patients in stage 1 and 3N/4 patients
in stage 2, keeping balanced allocation within stages. Again, this is just a preliminary
study and no attempt is made to optimise the size of the stages.
The possible advantage of this method is that, when a clearly inferior treatment is dropped
after stage 1, only N/12 patients have been used for it, whereas with equal stage sizes N/6
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patients would have been used. As well as possible ethical benefits, this should lead to
more efficient comparisons of the best treatment with the control. When both treatments
are good and we continue to use them in stage 2, the total numbers allocated to each
treatment are the same in this design as in the design with equal stage sizes. A possible
disadvantage of this procedure is that, with less information available at stage 1, a bad
decision, either to drop a promising treatment, or to continue with a poor treatment, is
more likely to be made.
As with equal stage sizes, we need to combine the univariate test statistics from the two
stages in the appropriate way. As before, this depends on whether one (Case 1) or two
(Case 2) treatments are forwarded to the second stage. From stage 1, σ2.1 = 6, so that
Zi.1 =
√
N
4
(
Y¯i.1 − Y¯0.1
)
/
√
6
⇒ Y¯i.1 − Y¯0.1 = Zi.1
√
24√
N
.
In Case 1, there are only two treatments at stage 2, so that σ2.2 = 4 and
Zi.2 =
√
3N
4
(
Y¯i.2 − Y¯0.2
)
/
√
4
⇒ Y¯i.2 − Y¯0.2 = Zi.2
√
16√
3N
.
Combining stages, we have
Y¯i =
2Y¯i.1 + 9Y¯i.2
11
and
Y¯0 =
2Y¯0.1 + 9Y¯0.2
11
,
so that, writing Zi = k1
(
Y¯i − Y¯0
)
, for a constant k1 chosen to ensure unit variance, and
rewriting in terms of Zi.k, we obtain
Zi =
1√
11
(√
2Zi.1 + 3Zi.2
)
.
In Case 2, there are three treatments at stage 2, so that σ2.2 = 6 and
Zi.2 =
√
3N
4
(
Y¯i.2 − Y¯0.2
)
/
√
6
⇒ Y¯i.2 − Y¯0.2 = Zi.2
√
8√
N
.
Combining stages, we have
Y¯i =
Y¯i.1 + 3Y¯i.2
4
and
Y¯0 =
Y¯0.1 + 3Y¯0.2
4
,
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Table 6.24: Cutpoints for T1, T2 and T∞ for Procedure 3 with unequal stage sizes.
5% 2.5% 1%
c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
0 1.5 1.8478 1.8048 1.7942 2.2009 2.1315 2.1173 2.6206 2.5022 2.4829
0 1 1.9418 1.8523 1.8324 2.3199 2.1786 2.1515 2.7775 2.5516 2.5173
-0.5 1.5 1.8714 1.8303 1.8214 2.2157 2.1481 2.1347 2.6316 2.5191 2.5007
-0.5 1 1.9641 1.8778 1.8587 2.3305 2.1939 2.1688 2.7790 2.5577 2.5245
so that, writing Zi = k2
(
Y¯i − Y¯0
)
, for a constant k2 chosen to ensure unit variance, and
rewriting in terms of Zi.k, we obtain
Zi =
1
2
(
Zi.1 +
√
3Zi.2
)
.
The relationships between di.k and di are also worked out in the same way as before. We
obtain di.1 = di/2. In Case 1, di.2 = 3di/2
√
2 and, in Case 2, di.2 =
√
3di/2.
6.4.1 Simulations and results
The simulations were carried out in the same way as in Section 6.3.3, but only for the
stopping rules c1 = 0,−0.5 and for the rules to carry forward two arms c2 = 1.5, 1. Note,
however, that these values are not directly comparable with the values of c1 and c2 for
equal stage sizes, since scaling of Zi.1 is different. The percentages of trials stopping early
(Case 0), carrying forward one arm (Case 1) and carrying forward two arms (Case 2) are
the same as those shown in Table 6.15, except for simulation variance. However, because
the first stage uses fewer patients, the expected sample sizes are smaller, being 0.75N when
c1 = 0 and approximately 0.163N/4 + 0.837N = 0.878N when c1 = −0.5. Therefore, in
terms of the expected sample size under H0, the results here with c1 = −0.5 are roughly
comparable with those for c1 = 0 when the stage sizes are equal.
The cutpoints for rejecting H0 using T1, T2 and T∞ are shown in Table 6.24. These are
smaller than the corresponding results with equal stage sizes, indicating that the tails of
the null distributions are less extreme. This might be expected to lead to more powerful
tests.
The simulations under H1 were carried out, as before, with new errors simulated for
different values of d1, d2, c1 and c2. Table 6.25 shows the percentages stopping early and
forwarding one or two arms to stage 2 under H1. The trial stops early here more often
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Table 6.25: Percentages of Cases 0, 1 and 2 for Procedure 3 with unequal stage sizes for
different values of d1 and d2
d2 = 0 d2 = .5d1 d2 = d1
Case Case Case
d1 c1 c2 0 1 2 0 1 2 0 1 2
2 0 1.5 12.690 78.283 9.027 9.640 73.707 16.653 6.220 70.633 23.147
2 0 1 12.727 66.608 20.665 9.831 55.317 34.852 6.136 47.324 46.540
2 -.5 1.5 4.676 86.312 9.012 3.226 80.378 16.396 1.774 75.049 23.177
2 -.5 1 4.744 74.677 20.579 3.224 61.844 34.932 1.789 52.134 46.077
2.5 0 1.5 8.669 83.327 8.004 6.398 75.114 18.488 3.456 68.774 27.770
2.5 0 1 8.779 72.048 19.173 6.251 55.195 38.554 3.446 41.922 54.632
2.5 -.5 1.5 2.988 89.142 7.870 1.858 79.848 18.294 0.912 71.244 27.844
2.5 -.5 1 2.986 77.950 19.082 1.894 59.500 38.606 0.892 44.767 54.341
3 0 1.5 5.717 87.830 6.453 4.045 76.157 19.798 1.821 65.396 32.783
3 0 1 5.769 77.295 16.945 4.020 54.235 41.745 1.840 36.074 62.086
3 -.5 1.5 1.749 91.753 6.498 1.018 79.377 19.605 0.415 66.998 32.587
3 -.5 1 1.775 81.580 16.645 1.064 57.049 41.887 0.384 37.647 61.969
3.5 0 1.5 3.550 91.499 4.951 2.388 77.108 20.504 0.882 62.020 37.098
3.5 0 1 3.511 82.043 14.446 2.296 53.322 44.382 0.895 29.975 69.130
3.5 -.5 1.5 0.965 93.934 5.101 0.585 78.912 20.503 0.185 62.279 37.536
3.5 -.5 1 0.976 84.714 14.310 0.530 55.057 44.413 0.154 30.818 69.028
than with equal stage sizes, due to the high variance in stage 1. When d2 = 0 this design
seems to forward both experimental arms to the second stage more often than the design
with equal stage sizes, since with higher variance it is more difficult to decide which is
best. When d2 = 0.5d1 and when d2 = d1, it seems to forward one arm more than the
other case. All of these features are undesirable and might counteract the narrower tails
in the null distribution to make this design less powerful.
The powers for various configurations are shown in Tables 6.26-6.28 and the corresponding
expected losses are in Tables 6.29-6.31. The first thing to note is that it is much less clear
than with equal allocation which value of c2 is best. When ∆1 is not so large, c2 = 1.5
gives higher power and lower expected loss, but as ∆1 increases, c2 = 1 becomes better.
Overall, perhaps we would recommend c2 = 1, as the difference can become quite large,
e.g. more than 1% difference in power for d1 = 3.5 and d2 = 1.75.
As noted earlier, the design described here with c1 = −0.5 is roughly equivalent, in terms
of expected sample size under H0, to the design described earlier with c1 = 0. Comparing
CHAPTER 6. TWO-STAGE ADAPTIVE DESIGNS 218
Table 6.26: Power of the tests using Procedure 3 with unequal stage sizes when ∆2 = 0.
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2 0 1.5 58.224 59.144 59.366 47.655 49.519 49.862 34.136 37.515 38.057
2 0 1 56.314 58.391 58.826 44.409 48.237 48.935 29.166 35.711 36.706
2 -0.5 1.5 60.544 61.545 61.757 49.266 51.329 51.715 34.937 38.289 38.850
2 -0.5 1 58.524 60.783 61.224 45.792 49.977 50.708 30.032 36.785 37.795
2.5 0 1.5 75.760 76.408 76.561 68.021 69.551 69.848 55.759 59.383 59.949
2.5 0 1 74.676 76.259 76.601 64.940 68.646 69.308 49.812 57.203 58.187
2.5 -0.5 1.5 78.498 79.225 79.397 70.155 71.877 72.204 57.057 60.586 61.178
2.5 -0.5 1 77.041 78.773 79.144 66.860 70.622 71.324 51.456 58.944 59.987
3 0 1.5 87.204 87.518 87.604 83.027 83.952 84.141 74.839 77.407 77.782
3 0 1 86.836 87.706 87.870 81.392 83.663 84.054 70.653 76.380 77.143
3 -0.5 1.5 89.895 90.267 90.336 85.421 86.346 86.548 76.829 79.451 79.837
3 -0.5 1 89.580 90.484 90.707 83.762 86.152 86.566 72.529 78.413 79.194
3.5 0 1.5 93.518 93.659 93.691 91.942 92.309 92.399 88.329 89.540 89.731
3.5 0 1. 93.903 94.209 94.278 91.615 92.633 92.806 85.970 89.219 89.597
3.5 -0.5 1.5 95.762 95.904 95.917 94.043 94.455 94.528 90.113 91.351 91.559
3.5 -0.5 1 95.829 96.206 96.289 93.311 94.460 94.641 87.359 90.782 91.224
Table 6.27: Power of the tests using Procedure 3 with unequal stage sizes when ∆2 = .5∆1.
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2 0 1.5 59.111 59.459 59.433 48.238 49.000 48.945 34.900 36.633 36.607
2 0 1 58.810 59.395 59.254 47.226 48.560 48.393 32.790 35.648 35.534
2 -0.5 1.5 60.607 60.933 60.850 49.429 50.317 50.263 35.465 37.177 37.197
2 -0.5 1 60.041 60.679 60.599 48.018 49.548 49.349 33.297 36.317 36.288
2.5 0 1.5 74.965 75.283 75.224 66.522 67.253 67.208 54.503 56.230 56.237
2.5 0 1 75.388 75.889 75.715 66.034 67.413 67.271 52.107 55.616 55.461
2.5 -0.5 1.5 76.802 77.105 77.033 68.079 68.807 68.772 55.337 57.143 57.056
2.5 -0.5 1 77.263 77.778 77.676 67.673 69.082 68.821 53.195 56.777 56.716
3 0 1.5 85.678 85.843 85.828 80.542 81.057 81.003 71.960 73.336 73.233
3 0 1 86.818 87.138 87.063 81.084 82.072 81.921 70.537 73.473 73.339
3 -0.5 1.5 87.684 87.864 87.839 82.298 82.838 82.771 73.306 74.749 74.709
3 -0.5 1 88.297 88.593 88.511 82.239 83.246 83.056 71.588 74.356 74.313
3.5 0 1.5 92.214 92.385 92.380 89.443 89.753 89.716 84.538 85.394 85.358
3.5 0 1 93.267 93.445 93.398 90.271 90.833 90.701 84.313 86.037 85.875
3.5 -0.5 1.5 93.367 93.495 93.465 90.439 90.750 90.711 85.414 86.217 86.130
3.5 -0.5 1 94.519 94.715 94.657 91.406 91.988 91.903 85.011 87.006 86.833
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Table 6.28: Power of the tests using Procedure 3 with unequal stage sizes when ∆2 = ∆1
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2 0 1.5 70.373 70.545 70.346 59.311 59.597 59.241 44.872 45.749 45.163
2 0 1 70.960 70.637 70.095 59.912 59.693 58.849 45.731 45.862 44.516
2 -0.5 1.5 71.246 71.349 71.059 59.871 60.101 59.709 45.145 45.806 45.198
2 -0.5 1 72.112 71.870 71.273 60.742 60.651 59.744 46.332 46.400 45.070
2.5 0 1.5 85.284 85.375 85.255 77.873 78.132 77.830 65.975 67.067 66.414
2.5 0 1 85.759 85.736 85.363 78.608 78.615 77.837 67.058 67.573 66.093
2.5 -0.5 1.5 86.360 86.470 86.236 78.542 78.829 78.471 66.235 67.045 66.321
2.5 -0.5 1 86.837 86.786 86.366 79.176 79.235 78.308 67.351 67.796 66.306
3 0 1.5 93.818 93.929 93.876 89.805 90.143 89.933 82.286 83.191 82.655
3 0 1 94.262 94.226 94.005 90.653 90.728 90.240 83.477 84.091 82.909
3 -0.5 1.5 94.682 94.771 94.692 90.552 90.849 90.614 82.818 83.733 83.232
3 -0.5 1 95.096 95.128 94.920 91.278 91.427 90.926 84.017 84.698 83.532
3.5 0 1.5 97.752 97.813 97.782 96.098 96.287 96.198 92.528 93.129 92.897
3.5 0 1 97.957 97.962 97.887 96.515 96.657 96.416 93.132 93.601 92.912
3.5 -0.5 1.5 98.311 98.369 98.339 96.613 96.801 96.705 92.822 93.473 93.186
3.5 -0.5 1 98.551 98.577 98.478 97.022 97.142 96.917 93.661 94.067 93.384
Table 6.29: Expected loss of the tests using Procedure 3 with unequal stage sizes when
∆2 = 0
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2 0 1.5 0.8513 0.8332 0.8286 1.0558 1.0183 1.0112 1.3214 1.2536 1.2425
2 0 1 0.8874 0.8452 0.8361 1.1197 1.0421 1.0277 1.4212 1.2892 1.2690
2 -0.5 1.5 0.8050 0.7849 0.7805 1.0235 0.9820 0.9739 1.3054 1.2379 1.2265
2 -0.5 1 0.8428 0.7967 0.7873 1.0923 1.0073 0.9922 1.4039 1.2676 1.2469
2.5 0 1.5 0.6185 0.6026 0.5990 0.8057 0.7674 0.7599 1.1085 1.0180 1.0039
2.5 0 1 0.6408 0.6013 0.5929 0.8809 0.7883 0.7717 1.2570 1.0722 1.0473
2.5 -0.5 1.5 0.5491 0.5314 0.5272 0.7522 0.7095 0.7013 1.0766 0.9883 0.9734
2.5 -0.5 1 0.5818 0.5387 0.5294 0.8333 0.7390 0.7214 1.2163 1.0288 1.0024
3 0 1.5 0.3922 0.3834 0.3810 0.5130 0.4859 0.4804 0.7564 0.6797 0.6685
3 0 1 0.3995 0.3740 0.3689 0.5609 0.4928 0.4810 0.8818 0.7098 0.6868
3 -0.5 1.5 0.3113 0.3006 0.2987 0.4414 0.4138 0.4079 0.6965 0.6182 0.6068
3 -0.5 1 0.3163 0.2894 0.2828 0.4894 0.4178 0.4053 0.8255 0.6488 0.6252
3.5 0 1.5 0.2317 0.2273 0.2263 0.2844 0.2719 0.2688 0.4095 0.3673 0.3607
3.5 0 1 0.2154 0.2051 0.2029 0.2943 0.2590 0.2530 0.4914 0.3779 0.3647
3.5 -0.5 1.5 0.1537 0.1492 0.1488 0.2116 0.1974 0.1950 0.3472 0.3041 0.2968
3.5 -0.5 1 0.1481 0.1352 0.1323 0.2350 0.1953 0.1890 0.4428 0.3230 0.3077
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Table 6.30: Expected loss of the tests using Procedure 3 with unequal stage sizes when
∆2 = .5∆1
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2 0 1.5 0.8985 0.8915 0.8916 1.0910 1.0754 1.0755 1.3358 1.3003 1.2994
2 0 1 0.8994 0.8863 0.8877 1.1116 1.0818 1.0828 1.3814 1.3195 1.3185
2 -0.5 1.5 0.8670 0.8605 0.8617 1.0664 1.0481 1.0481 1.3241 1.2891 1.2875
2 -0.5 1 0.8770 0.8624 0.8624 1.0971 1.0629 1.0642 1.3725 1.3074 1.3052
2.5 0 1.5 0.7289 0.7226 0.72389 0.9113 0.8943 0.8948 1.1852 1.1426 1.1411
2.5 0 1 0.7062 0.6934 0.6963 0.9191 0.8830 0.8844 1.2473 1.1563 1.1573
2.5 -0.5 1.5 0.6832 0.6771 0.6784 0.8731 0.8561 0.8562 1.1643 1.1200 1.1209
2.5 -0.5 1 0.6610 0.6480 0.6494 0.8793 0.8432 0.8472 1.2207 1.1283 1.1268
3 0 1.5 0.5493 0.5466 0.5472 0.6736 0.6616 0.6629 0.9021 0.8636 0.8655
3 0 1 0.4858 0.4775 0.4792 0.6397 0.6110 0.6141 0.9375 0.8489 0.8502
3 -0.5 1.5 0.4901 0.4869 0.4878 0.6222 0.6094 0.61088 0.8612 0.8214 0.8219
3 -0.5 1 0.4457 0.4383 0.4404 0.6082 0.5798 0.5836 0.9090 0.8250 0.8237
3.5 0 1.5 0.3946 0.3914 0.3920 0.4650 0.4578 0.4591 0.6072 0.5823 0.5839
3.5 0 1 0.3207 0.3166 0.3183 0.4102 0.3940 0.3978 0.6025 0.5444 0.5484
3.5 -0.5 1.5 0.3556 0.3536 0.3548 0.4313 0.4246 0.4260 0.5779 0.5543 0.5570
3.5 -0.5 1 0.2797 0.2751 0.2767 0.3728 0.3551 0.3579 0.5792 0.5125 0.5169
the results here with those in Section 6.3.3, Tables 6.17-6.22, we find that this design does
not succeed in improving the properties under H1. Although the power and expected
loss are similar, they are mostly slightly inferior and the expected sample size under H0,
although also similar, is slightly higher.
6.5 Conclusions
In this chapter, we have shown that a two-stage adaptive design is very promising for
three-arm trials with a control. In particular, Procedure 3 seems to give power and
expected loss which are better than the fixed design, but with a smaller expected sample
size. The results obtained here are from balanced designs, with equal allocation to each
treatment. These are the only adaptive designs used in practice and commonly described
in the literature, although a few authors, such as Koenig et al. (2008) have suggested that
unbalanced designs might be beneficial.
We have only looked at two-stage designs, with a single interim analysis. However, method-
ologically, there is no restriction to the number of interim analyses which can be performed.
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Table 6.31: Expected loss of the tests using Procedure 3 with unequal stage sizes when
∆2 = ∆1
5% 2.5% 1%
d1 c1 c2 T1 T2 T∞ T1 T2 T∞ T1 T2 T∞
2 0 1.5 0.5925 0.5891 0.5931 0.8138 0.8081 0.8152 1.1026 1.0850 1.0967
2 0 1 0.5808 0.5873 0.5981 0.8018 0.8061 0.8230 1.0854 1.0828 1.1097
2 -0.5 1.5 0.5751 0.5730 0.5788 0.8026 0.7980 0.8058 1.0971 1.0839 1.0960
2 -0.5 1 0.5578 0.5626 0.5745 0.7852 0.7870 0.8051 1.0734 1.0720 1.0986
2.5 0 1.5 0.3679 0.3656 0.3686 0.5532 0.5467 0.5543 0.8506 0.8233 0.8397
2.5 0 1 0.3560 0.3566 0.3659 0.5348 0.5346 0.5541 0.8236 0.8107 0.8477
2.5 -0.5 1.5 0.3410 0.3383 0.3441 0.5365 0.5293 0.5382 0.8441 0.8239 0.8420
2.5 -0.5 1 0.3291 0.3304 0.3409 0.5206 0.5191 0.5423 0.8162 0.8051 0.8424
3 0 1.5 0.1855 0.1821 0.1837 0.3059 0.2957 0.3020 0.5314 0.5043 0.5203
3 0 1 0.1721 0.1732 0.1799 0.2804 0.2782 0.2928 0.4957 0.4773 0.5127
3 -0.5 1.5 0.1595 0.1569 0.1592 0.2834 0.2745 0.2816 0.5155 0.4880 0.5030
3 -0.5 1 0.1471 0.1462 0.1524 0.2617 0.2572 0.2722 0.4795 0.4591 0.4940
3.5 0 1.5 0.0787 0.0765 0.0776 0.1366 0.1230 0.1331 0.2615 0.2405 0.2486
3.5 0 1 0.0715 0.0713 0.0740 0.1220 0.1170 0.1254 0.2404 0.2240 0.2481
3.5 -0.5 1.5 0.0591 0.05709 0.0581 0.1185 0.1120 0.1153 0.2512 0.2284 0.2385
3.5 -0.5 1 0.0507 0.0498 0.0533 0.1042 0.1000 0.1079 0.2219 0.2077 0.2316
If Procedure 3 is used with several interim analyses, one could start with a small value of
c2 and increase it through the analyses, so that it is very likely that one treatment would
eventually be dropped, but only after sufficient information had been gained to make a
good treatment selection. The benefits of this should be even greater with more than two
experimental treatments. However, one of the commonly cited benefits of having many
interim analyses is that they allow sequential hypothesis testing with early rejection of H0.
Although it has been avoided in this chapter, early rejection based on the test statistic T2
is another area of research which remains to be explored.
Of course, there are many practical situations in which the use of adaptive designs is
not possible, e.g. because it takes too long to obtain responses from the patients, but,
when they can be used, they seem to have clear benefits, both in terms of the expected
numbers of patients used and in terms of the amount of information obtained. We hope
that opportunities for their application will arise in the near future.
Chapter 7
Conclusions and Further Work
7.1 Conclusions
This thesis has considered clinical trials for comparing several treatments with a control,
in which the aim is to establish evidence for efficacy of at least one experimental treat-
ment and, if it is established, to select a treatment to be recommended for practical use.
Most important is to find a treatment which is better than the control and of secondary
importance is to find the best such treatment. Efficacy is established by testing the null
hypothesis H0 : ∆i ≤ 0 ∀i ∈ {1, . . . , I} against the alternative H1 : ∆i > 0, for at least one
i ∈ {1, . . . , I}. If H0 is rejected, then the experimental treatment with the best estimated
response is selected.
The most important conclusion from this work is that, if this is the aim of the trial, then
a test which is suitable for this hypothesis must be used. Many methods available in the
literature for similar, but not identical, hypotheses have been used, but these can have
undesirable, and even very poor, properties. This conclusion is not original, but it is not
widely recognised, at least in applications to clinical trials, that with multiple treatments,
when the alternative hypothesis is one-sided, the distinction between a null hypothesis of
equality and one of inequality is of vital importance.
The emphasis in this thesis has been on developing likelihood ratio tests (LRTs) and
studying their properties. In doing so, we have had to give a new definition of the size of
a test, to take account of the probability of type-III errors, although this seems to have
little impact in practice. For the common large-sample case, we conclude that the test
statistic based on the LRT, T2, has good properties, but so do the test statistic based on
Dunnett’s procedure, T∞, and that based on Hochberg’s procedure. If equal numbers of
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patients are allocated to each arm, it is difficult to convincingly recommend any one of
these procedures for three-arm trials. Hochberg’s procedure is a little more awkward to
use than the others and does not seem to offer any particular advantages, so the choice
seems to be between T2 and T∞. For more than three arms, the differences are somewhat
greater and there are many configurations for which T2 is somewhat better than T∞.
Several authors have considered the so-called least favourable configuration (mainly for
choosing a design) and on this basis, T∞ would be preferred. However, this argument is not
completely convincing, since it implies that it is more important to detect a difference of
the type (∆∗, 0, . . . , 0) than one of the type (∆∗−ε, . . . ,∆∗−ε) for a small value of ε. It also
takes a minimax approach to the choice of statistic. Over a broad range of configurations,
T2 performs slightly better than T∞, especially when the number of experimental arms
is large. Also, in trials in which the experimental treatments are similar, e.g. different
doses of the same drug, two drugs for the same target, or one drug either alone or in
combination with another, then we would often expect a priori that either H0 is true or
∆1 and ∆2 are both positive. Using T2 is also consistent with using the χ
2 statistic for
two-sided tests, rather than combining the results from I z-tests, which gives it a certain
logic. On balance, it is justified to recommend T2 as the most appropriate test statistic
for this problem, but we recognise that T∞ is also reasonably acceptable.
If these results were the strongest argument for T2, the conclusions from this thesis might
be rather disappointing. However, when different allocations of patients to treatments
are possible, the benefit of T2 becomes greater. With T∞, other authors have shown that
the so-called square root allocation, which for two experimental arms gives slightly more
than 40% of patients to the control, maximises the power of the test. We have shown
that with T2 the optimal proportion allocated to the control is similar, but slightly higher,
and that similar conclusions hold for the expected loss we have used, as well as power.
When close to optimal allocations are used, T2 has a slight, but clear, benefit over T∞ in
terms of power and expected loss. Given these results, it does not seem to be sensible to
recommend different test statistics for different allocations, so our overall recommendation
must be for T2.
The large sample results developed will be adequate for many clinical trials but sometimes,
especially with binary response data, they will be insufficiently precise. In this case,
we recommend that the normal approximation be abandoned and a conditional exact
test, using the LRT statistic for the binomial distribution, should be used. As far as
its properties have been studied in this thesis, this test appears to show great promise,
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although its power has not been thoroughly studied, and its use is consistent with that of
Fisher’s exact test in the case of two-sided alternative hypotheses.
If a two-stage adaptive design can be used, it is possible to simultaneously achieve higher
power if H1 is true and a smaller expected sample size if H0 is true, by allowing inferior
treatments to be dropped after the first stage. A design which allows early stopping for
futility and allows either one or two experimental arms to be forwarded to the second
stage, along with the control, shows considerable advantages over the fixed design. In this
situation, T2 performs somewhat better than T∞.
In conclusion, the likelihood ratio tests used and developed in this thesis have been shown
to have good properties and can be recommended for use in practice whenever the aims
of the trial dictate that the null hypothesis to be tested is H0 : ∆i ≤ 0 ∀i, there are no
restrictions on the model and no prior information is to be used in the analysis. These
methods now await practical use in clinical trials.
7.2 Further work
As well as requiring successful applications, before the methods presented here will be
widely accepted, there are many further methodological developments that could be made.
Some of these have been mentioned in passing throughout the thesis, but here we sum-
marise a few ideas for further research.
The implementations describe here have been largely simulation based. This is probably
the best that can be done and the general idea was strongly recommended in order re-
stricted inference by Silvapulle and Sen (2005), in place of the approximations used in
the older texts of Barlow et al. (1972) and Robertson et al. (1988). However, there might
be a place for further approximations to be developed and compared with the simulation
results. These would be particularly useful for further theoretical studies of the properties
of the tests, where simulation takes a considerable time.
After defining the corrected size of a test to take account of the probability of a type-III, we
found that this had no consequences for the usual significance levels. However, we have not
dealt with how to make a similar adjustment to calculated p-values. Conceptually, there is
no difficulty. The corrected p-value is the smallest α† such that H0 is rejected at corrected
significance level α†. However computing this from the simulations presented here is
rather tedious, since we would have to consider, in the three arm case, the probability of
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rejecting H0 in favour of treatment 2 over a range of values of d1 with d2 = 0. It would be
particularly useful to try to derive expressions giving the value of d1 which maximises the
probability of a type-III error, or at least bounds on this value. A separate, but related
problem, is to work out a suitable correction for the p-value in the exact test for binary
responses.
The emphasis in this thesis has been on large-sample normal approximations. Although
these will be used in many applications, there will be some trials in which they cannot
be relied upon. The exact conditional test for binary responses, developed in Chapter
5, could be extended to ordered (or unordered) categorical responses. Silvapulle and
Sen (2005) developed an exact conditional test for the null hypothesis of equality in an
order restricted model, which was a direct extension of the corresponding test for binary
responses. We would expect that a direct extension of our exact conditional test could
be developed, although we would require either an assumption of proportional odds, or a
further refinement of the null hypothesis.
Small-sample tests for continuous data are a more difficult case to consider. If normality
can be assumed, it will be straightforward to modify the testing procedure for unknown,
but equal, variances and indeed Robertson et al. (1988) and Silvapulle and Sen (2005) show
how the LRT statistic can be obtained. An open question is whether this test statistic
can be expressed in a neat form similar to T2.
If it is not reasonable to assume normality, an obvious form of test is a permutation test.
However, a straightforward permutation test fails, because under H0, the responses from
different treatments are not necessarily exchangeable (the means from each treatment need
not be equal). One possibility would be to adjust for the restricted maximum likelihood
estimates under H0 and use permutations of the residuals. Similarly, the residuals could
be bootstrapped. The difference between these two methods is that the former samples
from the residuals without replacement, while the latter samples with replacement. The
permutation test relies less on large sample approximations, but the results of bootstrap-
ping, if valid, are applicable to the population of patients and not just those in the trial.
These methods deserve further investigation.
As noted in Chapter 6, this thesis has only just scratched the surface of adaptive and
sequential designs for multi-arm trials. An enormous amount of work remains to be done
in this area and it is quite possible that this will become a topic of major interest in the
near future. The first priority in this area is probably a more detailed study of the sizes
of stages and the balance between treatments within stages, to optimise the properties of
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two-stage designs. Given that no improvement was obtained from the designs with unequal
stage sizes studied, further exploration of this might not lead to great improvements. It
might, therefore, be more beneficial to consider designs with more than two stages.
The topic of estimation has not been discussed in this thesis, although it will almost always
be needed in clinical trials, even if only as a secondary analysis after testing. When H0
is rejected and a treatment selected, the simple estimator of the difference between that
treatment and the control is positively biased, due to the effect of selection. This is
most obvious in the case of ∆1 = ∆2, where the larger of two estimates will be used.
The development of corrections to the estimator to make it approximately unbiased is an
essential area of future work and could be a major area of research in itself. We would
expect such corrections would make use of the estimates of other treatment differences.
If the selected treatment is estimated to be considerably better than any of the other
treatments, the bias will be trivially small, whereas if there are several nearly equally
good treatments, it will be more substantial. In adaptive designs, there is an additional
selection bias caused by the selection of treatments after stage 1 and the decision to
continue to stage 2.
In conclusion, we hope that research in the use of order restricted inference in clinical
trials will continue and that it will prove beneficial in their design and analysis.
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